Details of Disease

General Information of Disease (ID: DISLQ7E2)

• Disease Name: Osteosarcoma
• Synonyms: bone tissue neoplasm; osteoid sarcoma; osteosarcoma, malignant; osteosarcoma; osteosarcoma (disease); sarcoma of osteoid; osteogenic sarcoma
• Disease Class: 2B51: Osteosarcoma
• Definition: A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.
• Disease Hierarchy:
  DISZDG3U: Sarcoma
  DISLQ7E2: Osteosarcoma
• ICD Code:
  ICD-11: ICD-11: 2B51
  ICD-9: ICD-9: 170
  Expand ICD-11: 'XH1XF3
  Expand ICD-9: 170
• Disease Identifiers:
  MONDO ID: MONDO_0009807
  MESH ID: D012516
  UMLS CUI: C0029463
  OMIM ID: 259500
  MedGen ID: 10501
  HPO ID: HP:0002669
  SNOMED CT ID: 1163405004

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 2 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cisplatin	DMRHGI9	Approved	Small molecular drug	[1]
Naxitamab	DMXB7V8	Approved	NA	[1]

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Hu3F8 mAb	DM9MKQ5	Phase 2	NA	[2]
Saracatinib	DMBLHGP	Phase 2	Small molecular drug	[3]
Tideglusib	DME4LA1	Phase 2	Small molecular drug	[4]
ALMB-0168	DMB0LSF	Phase 1/2	Small molecule	[5]
AU101	DMLAKPI	Phase 1/2	NA	[6]
Anti-GD2-CAR engineered T cells	DMCNFZG	Phase 1	CAR T Cell Therapy	[7]
GD2 T cells	DM9TD2N	Phase 1	CAR T Cell Therapy	[8]
[153Sm]CycloSam	DM20XUQ	Phase 1	Radiopharmaceutical therapy agent	[9]

This Disease is Treated as An Indication in 1 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Robatumumab	DMOEQO1	Discontinued in Phase 2	Monoclonal antibody	[10]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
DG-8	DMRAGOW	Investigative	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 761 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
WRN	OT81JS6K	Moderate	Autosomal recessive	[12]
ACTL6A	OT0EC5BQ	Limited	Biomarker	[481]
ACYP2	OTRB4S6X	Limited	Genetic Variation	[482]
ADAMTS17	OTCFITM9	Limited	Genetic Variation	[483]
ADAMTS6	OTSZE6L4	Limited	Genetic Variation	[483]
APCDD1	OTV9AD0L	Limited	Altered Expression	[484]
ASPSCR1	OTXTOD10	Limited	Biomarker	[485]
ATG12	OTJRO09Y	Limited	Biomarker	[486]
ATG16L1	OTEOYC5D	Limited	Altered Expression	[487]
ATRNL1	OTY5JUX2	Limited	Biomarker	[21]
BCL9	OTRBIPR4	Limited	Altered Expression	[488]
BEST1	OTWHE1ZC	Limited	Biomarker	[489]
BHLHE22	OTZUQY5L	Limited	Altered Expression	[490]
BRMS1	OTV5A6LL	Limited	Biomarker	[491]
BRMS1L	OTJIW47U	Limited	Biomarker	[491]
BTG3	OT9ANHVT	Limited	Genetic Variation	[492]
BZW2	OTBT0A1B	Limited	Biomarker	[493]
CA8	OT9Y8GA8	Limited	Altered Expression	[494]
CANX	OTYP1F6J	Limited	Altered Expression	[495]
CAP1	OTYM8A2N	Limited	Biomarker	[71]
CCL24	OT9LGHV0	Limited	Altered Expression	[496]
CCL27	OTUZYC61	Limited	Biomarker	[21]
CD247	OT45FGUX	Limited	Biomarker	[497]
CDH15	OTJ1TO02	Limited	Biomarker	[32]
CDH18	OTC06P9H	Limited	Biomarker	[498]
CEP72	OTVYNPNL	Limited	Biomarker	[499]
CILP2	OTAFSWG1	Limited	Genetic Variation	[500]
CKAP2	OTCLTC0J	Limited	Biomarker	[501]
CLDN2	OTRF3D6Y	Limited	Biomarker	[502]
CLSTN2	OT2PJYHX	Limited	Biomarker	[503]
CNMD	OTHND8EL	Limited	Biomarker	[504]
CORO1A	OTVAZOHC	Limited	Altered Expression	[505]
CORO1C	OTXDF9T3	Limited	Biomarker	[506]
COX2	OTTMVBJJ	Limited	Altered Expression	[507]
CPNE1	OTH5YKSL	Limited	Biomarker	[508]
CRISP2	OT8HLTV5	Limited	Altered Expression	[509]
CTHRC1	OTV88X2G	Limited	Biomarker	[510]
CTNND1	OTUMPSHR	Limited	Altered Expression	[511]
CUL1	OTXPE1UZ	Limited	Biomarker	[512]
CXADR	OT9ZP02A	Limited	Biomarker	[353]
CXCL5	OTZOUPCA	Limited	Altered Expression	[513]
CYGB	OTX153DQ	Limited	Biomarker	[514]
DAB2	OTRMQTMZ	Limited	Biomarker	[515]
DAB2IP	OTF456VC	Limited	Biomarker	[515]
DDX46	OTB2X9TO	Limited	Biomarker	[516]
DHX9	OT5AAOQI	Limited	Biomarker	[517]
EFEMP2	OT0I2B4J	Limited	Biomarker	[518]
EIF3B	OTF67VPH	Limited	Biomarker	[519]
EIF4A3	OTYYFE7K	Limited	Biomarker	[520]
ELF2	OTEI347F	Limited	Altered Expression	[521]
ERCC2	OT1C8HQ4	Limited	Genetic Variation	[522]
EXT1	OTRPALJK	Limited	Genetic Variation	[523]
FBXO39	OTPRR6SK	Limited	Biomarker	[524]
FERMT1	OT626PBA	Limited	Biomarker	[525]
FERMT3	OTFQOT3C	Limited	Altered Expression	[525]
FGD1	OTV3T64P	Limited	Biomarker	[526]
FGFRL1	OT8HZ3ZL	Limited	Biomarker	[527]
FHL2	OT0OAYWT	Limited	Altered Expression	[528]
FLT3LG	OTU0YGC4	Limited	Altered Expression	[529]
FOXD1	OT80PRHS	Limited	Biomarker	[530]
FOXO3	OTHXQG4P	Limited	Altered Expression	[531]
FSTL1	OT6KEZUD	Limited	Biomarker	[532]
FZD8	OTZ9IRFL	Limited	Altered Expression	[533]
FZD9	OTTZ9MKK	Limited	Biomarker	[534]
GFER	OTVK43OK	Limited	Biomarker	[535]
GIT1	OTHO92S5	Limited	Altered Expression	[536]
GLCCI1	OTU0R1CU	Limited	Genetic Variation	[506]
HACD1	OTEC7EP7	Limited	Biomarker	[71]
HAS2	OTTD3PAL	Limited	Altered Expression	[537]
HAT1	OT307KEN	Limited	Altered Expression	[538]
HELLS	OTVVV668	Limited	Biomarker	[256]
HES4	OTCGMQDT	Limited	Biomarker	[539]
HIPK3	OT4WYQM2	Limited	Biomarker	[540]
ICMT	OT8CNKBO	Limited	Biomarker	[541]
IFITM5	OTLP5QEJ	Limited	Biomarker	[542]
IKZF1	OTCW1FKL	Limited	Biomarker	[543]
INPP4B	OTLROA7G	Limited	Altered Expression	[544]
IRF2	OTAZRUW3	Limited	Altered Expression	[545]
KDM4B	OT5P1UPY	Limited	Biomarker	[546]
KHSRP	OTDHZARB	Limited	Altered Expression	[547]
KIRREL1	OTOA7ON7	Limited	Altered Expression	[499]
LAMA1	OTQZMP86	Limited	Biomarker	[498]
LDOC1	OTWZH4O9	Limited	Biomarker	[548]
LEF1	OTWS5I5H	Limited	Altered Expression	[549]
MARCHF1	OTI2EYO6	Limited	Biomarker	[550]
MCM2	OTGGORIQ	Limited	Biomarker	[517]
MICA	OTPEIEAR	Limited	Biomarker	[551]
MOCOS	OT0TL3Q5	Limited	Biomarker	[552]
MSN	OTZJ4J6G	Limited	Biomarker	[553]
MTBP	OTWLCW9C	Limited	Altered Expression	[554]
NAA10	OTYB9R6I	Limited	Altered Expression	[555]
NFIC	OTLMCUIB	Limited	Biomarker	[556]
NKD2	OTCYT3I6	Limited	Biomarker	[557]
NKX2-2	OTDCOYNG	Limited	Biomarker	[558]
NR2C2	OTDZWVOJ	Limited	Biomarker	[559]
NSD3	OT3677ZG	Limited	Biomarker	[560]
PAX7	OTDMQRPO	Limited	Biomarker	[561]
PDK4	OTCMHMBZ	Limited	Altered Expression	[562]
PDLIM3	OTVXQC81	Limited	Biomarker	[21]
PHEX	OTG7N3J7	Limited	Altered Expression	[563]
PIAS3	OT3TWH9R	Limited	Biomarker	[564]
PIEZO1	OTBG1FU4	Limited	Biomarker	[565]
PIGF	OTJKE6VW	Limited	Biomarker	[566]
PLAAT3	OTVXXJ5K	Limited	Altered Expression	[567]
PLAC8	OT3SYRUJ	Limited	Altered Expression	[568]
PLEKHO1	OTMVUQ9W	Limited	Biomarker	[569]
POLD1	OTWO4UCJ	Limited	Altered Expression	[570]
PPIG	OTZ8BTTM	Limited	Altered Expression	[571]
PRMT9	OT6OBK3K	Limited	Altered Expression	[572]
PRSS55	OTXXWI5Y	Limited	Altered Expression	[509]
PTGES3	OTPPQWI0	Limited	Biomarker	[573]
PUM2	OT2H7NXV	Limited	Biomarker	[574]
PVR	OT3N91T7	Limited	Biomarker	[575]
RAB11B	OT6GI23M	Limited	Altered Expression	[576]
RAB23	OTBAKFBR	Limited	Altered Expression	[577]
RAB27B	OTPF9D0K	Limited	Biomarker	[106]
RAB8A	OTPB54Y3	Limited	Genetic Variation	[578]
RABL6	OTJLVIQ1	Limited	Biomarker	[579]
RANBP9	OTM8COM5	Limited	Altered Expression	[580]
RASAL1	OTAHUNN7	Limited	Biomarker	[581]
RASSF4	OT7YLOFH	Limited	Biomarker	[582]
RFC1	OT3L5PK3	Limited	Biomarker	[136]
RMC1	OT7K8MTJ	Limited	Altered Expression	[583]
RNH1	OT6EC79B	Limited	Biomarker	[584]
RPL34	OT0U9VMQ	Limited	Biomarker	[585]
RPS9	OTPV69Q0	Limited	Altered Expression	[586]
RRP12	OTQQAEH4	Limited	Biomarker	[587]
RTKN2	OTV2AXQM	Limited	Biomarker	[588]
RUBCNL	OTMQIDOI	Limited	Biomarker	[589]
SCARA5	OTOVA96E	Limited	Altered Expression	[590]
SDHA	OTOJ8QFF	Limited	Biomarker	[591]
SENP2	OTPQJXIR	Limited	Biomarker	[592]
SERPINB6	OT7G55IK	Limited	Biomarker	[71]
SGK3	OTQ6QO99	Limited	Biomarker	[593]
SIVA1	OTDT0XZK	Limited	Biomarker	[594]
SIX3	OTP5E3VU	Limited	Altered Expression	[595]
SMCP	OTXKY794	Limited	Biomarker	[552]
SORBS1	OTWH8762	Limited	Biomarker	[71]
SPC24	OT1HVYV4	Limited	Biomarker	[596]
SPZ1	OTQH8HJ5	Limited	Altered Expression	[509]
SRSF1	OTF61HOV	Limited	Altered Expression	[597]
STARD13	OTB4U1HY	Limited	Biomarker	[574]
SUZ12	OT655XF8	Limited	Biomarker	[543]
TCF12	OTZVONNU	Limited	Altered Expression	[598]
TEAD1	OTK6971C	Limited	Biomarker	[599]
TFG	OT2KJENI	Limited	Altered Expression	[600]
TGFB1I1	OTIK337D	Limited	Biomarker	[601]
TGFBR3	OTQOOUC4	Limited	Altered Expression	[503]
TGIF2	OTMKKE3W	Limited	Altered Expression	[602]
TIMP2	OT8S1RRP	Limited	Biomarker	[603]
TMEM119	OT0HFEIC	Limited	Biomarker	[604]
TMEM45B	OTVQCO8N	Limited	Biomarker	[605]
TMIGD3	OT4MJUWB	Limited	Altered Expression	[14]
TNFAIP8	OT1G9297	Limited	Biomarker	[606]
TNFAIP8L2	OTII0RM0	Limited	Biomarker	[607]
TNFRSF11A	OT1FISGN	Limited	Autosomal dominant	[111]
TNFSF9	OTV9L89D	Limited	Altered Expression	[608]
TNMD	OTHLVA9G	Limited	Biomarker	[609]
TOPBP1	OT6UPZPD	Limited	Biomarker	[610]
TOX4	OTSOXQFN	Limited	Biomarker	[611]
TPM1	OTD73X6R	Limited	Altered Expression	[612]
TRAF3	OT5TQBGV	Limited	Altered Expression	[613]
TRIM2	OT0V1YVC	Limited	Biomarker	[614]
TRIM29	OT2DNESG	Limited	Altered Expression	[615]
TSPAN1	OTZQPIYK	Limited	Biomarker	[616]
TSPAN13	OTCS9BZY	Limited	Altered Expression	[617]
BGLAP	OTK1YLWQ	Disputed	Altered Expression	[126]
CEP55	OTGSG2PA	Disputed	Biomarker	[618]
DPT	OTINRFC7	Disputed	Biomarker	[619]
GAB2	OTBFN705	Disputed	Altered Expression	[620]
GRAP2	OTS5NIZ3	Disputed	Biomarker	[40]
KLF9	OTBFEJRQ	Disputed	Biomarker	[621]
MED27	OT40PZ9R	Disputed	Biomarker	[622]
NCOA5	OTOGWTWB	Disputed	Altered Expression	[623]
NMU	OTW9X7BQ	Disputed	Biomarker	[132]
NUDT1	OTZSES3W	Disputed	Altered Expression	[624]
POLDIP2	OT8SZSJ6	Disputed	Biomarker	[40]
RAP2B	OTD2NDQP	Disputed	Biomarker	[625]
RASSF6	OT25GVWY	Disputed	Altered Expression	[626]
RNF19A	OTKWCV80	Disputed	Biomarker	[40]
S100A11	OTI57KDN	Disputed	Altered Expression	[627]
SOCS6	OT2O5ZBK	Disputed	Biomarker	[628]
SOX6	OTT0W0LE	Disputed	Biomarker	[629]
SPARCL1	OT74DWMV	Disputed	Biomarker	[630]
ACTR2	OT3C8U5T	moderate	Biomarker	[631]
ALX1	OTZVARA5	moderate	Altered Expression	[632]
ARMC8	OTNAXGM7	moderate	Biomarker	[633]
ATG14	OTPZDKI0	moderate	Biomarker	[634]
ATP6V1C2	OTSM7ML1	moderate	Altered Expression	[635]
BLM	OTEJOAJX	Moderate	Autosomal recessive	[12]
CBFA2T3	OTOJ10S1	moderate	Biomarker	[636]
CCNDBP1	OTBWG1M0	moderate	Biomarker	[637]
CDC27	OTDT45XJ	moderate	Biomarker	[638]
CETN1	OTGQ8JOZ	moderate	Biomarker	[639]
CIP2A	OTVS2GXA	moderate	Biomarker	[640]
CMTM8	OTG28GH2	moderate	Biomarker	[641]
COL4A3	OT6SB8X5	moderate	Biomarker	[642]
COLGALT1	OTVG0P58	moderate	Biomarker	[469]
CPQ	OTTNZNLD	moderate	Biomarker	[195]
CTAG1B	OTIQGW6U	moderate	Biomarker	[145]
CXCL14	OTM189TA	moderate	Altered Expression	[643]
CXCL16	OTD49T9R	moderate	Altered Expression	[644]
DDX3X	OTDO4TRX	moderate	Altered Expression	[645]
DIRAS3	OT3XHLQA	moderate	Altered Expression	[646]
DKC1	OTX7DJR6	moderate	Biomarker	[647]
DSPP	OT1TYNDN	moderate	Altered Expression	[648]
EIF2S1	OTM0GDTP	moderate	Altered Expression	[649]
ETV5	OTE2OBM4	moderate	Altered Expression	[650]
EXT2	OT8IR5QN	moderate	Genetic Variation	[523]
FOXL1	OT89XFPN	moderate	Altered Expression	[651]
GAS1	OTKJXG52	moderate	Altered Expression	[652]
GSTM3	OTLA2WJT	moderate	Genetic Variation	[653]
HAVCR2	OTOL603T	moderate	Altered Expression	[654]
HEY1	OTJQL0I3	moderate	Biomarker	[655]
HMGN1	OTSMGH99	moderate	Biomarker	[656]
HMGN2	OTN20MEF	moderate	Altered Expression	[656]
HOXC8	OTJUYU8J	moderate	Biomarker	[657]
HSPA4	OT5HR0AR	moderate	Biomarker	[166]
HUWE1	OTFH6BJS	moderate	Biomarker	[658]
IPO8	OTBHGNKT	moderate	Altered Expression	[659]
IRX1	OT0ZN9EJ	moderate	Biomarker	[660]
ITGA3	OTBCH21D	moderate	Genetic Variation	[661]
LMLN	OTQF0JPY	moderate	Biomarker	[662]
LZTS1	OTXXL864	moderate	Altered Expression	[663]
MAGT1	OTQSAV5C	moderate	Biomarker	[139]
MCAT	OTH07FIW	moderate	Biomarker	[144]
MCTS1	OT7SAOJP	moderate	Biomarker	[144]
MED1	OTOO24C4	moderate	Biomarker	[664]
MED31	OTFVKXJE	moderate	Biomarker	[664]
METRNL	OTB0DDL0	moderate	Altered Expression	[665]
MFN1	OTCBXQZF	moderate	Altered Expression	[666]
MMUT	OTBBBV70	moderate	Altered Expression	[667]
MPST	OTCDPH5D	moderate	Biomarker	[668]
MSTO1	OT37XCNP	moderate	Biomarker	[668]
MYOCD	OTSJNHTH	moderate	Altered Expression	[669]
NAIF1	OT0B3H72	moderate	Biomarker	[670]
NCOA2	OTMQFPBB	moderate	Altered Expression	[149]
ND1	OTCLGIXV	moderate	Genetic Variation	[671]
NMS	OTFYS4LO	moderate	Biomarker	[672]
NRSN2	OT4OS3M2	moderate	Biomarker	[673]
PANX3	OTKRQZ1T	moderate	Altered Expression	[674]
PAQR3	OTTKJ9Y4	moderate	Biomarker	[675]
PDCD5	OT6T2DDL	moderate	Altered Expression	[676]
PHLDA1	OTFTWMIQ	moderate	Altered Expression	[677]
PIGR	OT6GLSUL	moderate	Altered Expression	[678]
PLCG2	OTGVC9MY	moderate	Biomarker	[141]
PLCL1	OTJL2C79	moderate	Altered Expression	[679]
PLXNA1	OTN0BING	moderate	Biomarker	[680]
PPP2R2B	OTSFVC82	moderate	Altered Expression	[156]
PRAP1	OT48QD82	moderate	Biomarker	[681]
PRDX1	OTZ3BEC4	moderate	Altered Expression	[682]
RAMP2	OTGQXLH5	moderate	Biomarker	[683]
RANBP1	OTQE226K	moderate	Biomarker	[684]
RASSF5	OT6Q41I2	moderate	Altered Expression	[685]
RB1	OT9VMY7B	moderate	Biomarker	[686]
REV3L	OT0OP8EJ	moderate	Genetic Variation	[687]
RGS1	OTGXJYMG	moderate	Biomarker	[688]
RLN2	OTY3OG71	moderate	Biomarker	[689]
RPA3	OT8JAQGL	moderate	Altered Expression	[635]
RPL10	OTBHOZGC	moderate	Biomarker	[680]
RPRM	OTNNBAS1	moderate	Altered Expression	[690]
RPS15A	OT0BUA12	moderate	Biomarker	[691]
RPS3	OT0K3TMH	moderate	Altered Expression	[692]
SCPEP1	OT43LYEZ	moderate	Genetic Variation	[693]
SCUBE3	OT2EADLC	moderate	Altered Expression	[643]
SDF4	OTQ7WFYW	moderate	Biomarker	[639]
SEMA6D	OTU0UAZS	moderate	Biomarker	[172]
SERPINE2	OTYF5340	moderate	Altered Expression	[694]
SPOCD1	OTF4K46N	moderate	Altered Expression	[695]
SPON1	OTC06MY4	moderate	Biomarker	[696]
SRGAP2	OTUWFMCQ	moderate	Biomarker	[171]
SSX2	OT2Z6RLL	moderate	Altered Expression	[697]
TAF15	OTNE038N	moderate	Biomarker	[688]
TMPRSS13	OTMAOAP3	moderate	Biomarker	[662]
TNFRSF6B	OTKAN9G7	moderate	Altered Expression	[418]
TOPORS	OT1ERFFQ	moderate	Biomarker	[420]
A2ML1	OTWNUXIS	Strong	Altered Expression	[698]
AADAC	OT8VACT2	Strong	Posttranslational Modification	[699]
AATF	OT1QOKLD	Strong	Biomarker	[700]
ACTG2	OTRDWUO0	Strong	Altered Expression	[317]
ADAMTS2	OTTK22NO	Strong	Altered Expression	[701]
ADAMTS3	OT2U6VF5	Strong	Altered Expression	[702]
ADGRF1	OTRAOBYH	Strong	Altered Expression	[703]
AGFG1	OTI8ZKC4	Strong	Biomarker	[381]
AIRE	OTA7G1Y1	Strong	Altered Expression	[704]
AKAP12	OTCVRDDX	Strong	Biomarker	[705]
ALDOA	OTWRFTIB	Strong	Biomarker	[479]
ALPP	OTZU4G9W	Strong	Biomarker	[21]
AMBN	OTWASIMQ	Strong	Biomarker	[706]
ANGPTL2	OTB6JG41	Strong	Biomarker	[707]
ANKIB1	OTGKB7Y2	Strong	Biomarker	[708]
APOD	OTT77XW8	Strong	Biomarker	[709]
ARHGAP24	OTCQCEZS	Strong	Altered Expression	[710]
ARHGAP35	OTJ8POG0	Strong	Altered Expression	[711]
ARPC1A	OTAEEXGQ	Strong	Biomarker	[712]
ARR3	OTRZ00CH	Strong	Biomarker	[353]
ASS1	OT4ZMG0Q	Strong	Biomarker	[713]
ASXL1	OTX931AW	Strong	Biomarker	[393]
ATAD5	OTI8ABKF	Strong	Biomarker	[714]
ATF2	OTNIZPEA	Strong	Genetic Variation	[322]
ATF6	OTAFHAVI	Strong	Biomarker	[715]
ATG5	OT4T5SMS	Strong	Biomarker	[201]
ATP6	OTPHOGLX	Strong	Genetic Variation	[716]
AXIN1	OTRGZGZ5	Strong	Altered Expression	[717]
AXIN2	OTRMGQNU	Strong	Biomarker	[87]
BAG1	OTRQNIA4	Strong	Biomarker	[718]
BAG6	OT4Z0S2U	Strong	Biomarker	[719]
BARD1	OTTC0Z9Y	Strong	Biomarker	[720]
BCL2L11	OTNQQWFJ	Strong	Altered Expression	[721]
BCOR	OTG013AX	Strong	Biomarker	[722]
BHLHE41	OTY9GJ1Y	Strong	Biomarker	[723]
BIRC6	OTCQJAB0	Strong	Altered Expression	[724]
BLCAP	OTGJVU0C	Strong	Altered Expression	[725]
BLID	OT479VJV	Strong	Biomarker	[726]
BMP3	OTCTI0UW	Strong	Altered Expression	[727]
BUB3	OTU91HAU	Strong	Biomarker	[728]
BUD31	OTN3HZYF	Strong	Altered Expression	[729]
CALML3	OTM8DNQU	Strong	Biomarker	[730]
CAMK2A	OTJGX19T	Strong	Biomarker	[731]
CAMK2N1	OTKCR5XL	Strong	Biomarker	[732]
CAPRIN1	OTEJAMS3	Strong	Biomarker	[733]
CAV2	OT1FGRQX	Strong	Biomarker	[734]
CBFB	OTIAC6W4	Strong	Altered Expression	[33]
CBX3	OTOP9RLD	Strong	Altered Expression	[735]
CBX4	OT4XVRRF	Strong	Biomarker	[63]
CCDC80	OTOZSYEM	Strong	Genetic Variation	[736]
CCL18	OT7JYSK9	Strong	Biomarker	[737]
CCN4	OT69BER9	Strong	Altered Expression	[738]
CCNC	OTMVK4K4	Strong	Biomarker	[739]
CCNG1	OT17IA9L	Strong	Biomarker	[740]
CD109	OTDADBM4	Strong	Biomarker	[369]
CD151	OTF3UZS7	Strong	Biomarker	[741]
CD63	OT2UGZA9	Strong	Altered Expression	[706]
CD99	OTPUZ5DE	Strong	Altered Expression	[742]
CDC5L	OTTPFUU5	Strong	Biomarker	[743]
CDCA5	OTZLCQ5U	Strong	Altered Expression	[231]
CDH4	OT8LH3HN	Strong	Biomarker	[744]
CDK11A	OTN5TSGQ	Strong	Altered Expression	[745]
CDKN2D	OT2TTZPZ	Strong	Biomarker	[746]
CDKN3	OTBE3H07	Strong	Altered Expression	[747]
CFHR1	OT72R16T	Strong	Biomarker	[748]
CIB1	OT4BVCRU	Strong	Biomarker	[107]
CISH	OT8T5NYL	Strong	Biomarker	[749]
CITED2	OT812TV7	Strong	Biomarker	[705]
CKAP4	OTDUC9ME	Strong	Altered Expression	[384]
CLDN10	OT2CVAKY	Strong	Altered Expression	[750]
CLDN12	OTO55YZI	Strong	Biomarker	[751]
CLDN8	OT7IIWXG	Strong	Altered Expression	[752]
CLIC4	OT6KTPKD	Strong	Biomarker	[753]
CLOCK	OTNEOJY7	Strong	Biomarker	[42]
CLUAP1	OTESP4WL	Strong	Altered Expression	[754]
CNN1	OTVPG39Z	Strong	Biomarker	[755]
CNOT1	OTTEU05F	Strong	Altered Expression	[756]
COIL	OTP4I4DL	Strong	Biomarker	[298]
COL9A1	OTWBR27Y	Strong	Altered Expression	[390]
COL9A2	OT1ZBDBV	Strong	Altered Expression	[390]
COL9A3	OTCUJOEK	Strong	Altered Expression	[390]
COMP	OTS2FPMI	Strong	Altered Expression	[390]
COTL1	OT6YCNLF	Strong	Biomarker	[730]
CRABP2	OTY01V9G	Strong	Altered Expression	[757]
CRADD	OT02TZ4S	Strong	Altered Expression	[758]
CREB3	OT9617UO	Strong	Altered Expression	[759]
CRIP1	OT0EICG3	Strong	Biomarker	[760]
CSN3	OTR61MI8	Strong	Biomarker	[761]
CSRP3	OTECBJMV	Strong	Biomarker	[730]
CTBP1	OTVYH2DH	Strong	Altered Expression	[531]
CTTN	OTJRG4ES	Strong	Altered Expression	[762]
CUL4A	OTTBV70J	Strong	Biomarker	[763]
CUL4B	OT2QX4DO	Strong	Biomarker	[764]
CXCL6	OTFTCQ4O	Strong	Biomarker	[765]
CYC1	OT0962IM	Strong	Altered Expression	[766]
DAP3	OTNPEZYM	Strong	Altered Expression	[767]
DAXX	OTX6O7PL	Strong	Biomarker	[768]
DCAF1	OT3ZDVOE	Strong	Biomarker	[381]
DCAF11	OTNSGYK1	Strong	Biomarker	[764]
DCAF13	OTQQ0QXT	Strong	Biomarker	[764]
DCLRE1C	OTW3KB1I	Strong	Biomarker	[769]
DCTN2	OTMB4IXD	Strong	Altered Expression	[770]
DCTN6	OTI8PIN9	Strong	Posttranslational Modification	[107]
DDB1	OTTR2L3Z	Strong	Biomarker	[764]
DDX10	OTH48438	Strong	Biomarker	[771]
DHDDS	OTVLYBUS	Strong	Altered Expression	[471]
DLG2	OTQ3BD8U	Strong	Genetic Variation	[772]
DNAJC3	OT7ROIJF	Strong	Biomarker	[773]
DNASE1L3	OTEUIMC2	Strong	Altered Expression	[774]
DOCK4	OTH3XY8B	Strong	Biomarker	[775]
DRAM1	OTIJTXEN	Strong	Altered Expression	[776]
DTX1	OTYX91DX	Strong	Biomarker	[777]
E2F6	OT2PN28R	Strong	Biomarker	[778]
EBF2	OTFWZE51	Strong	Altered Expression	[779]
ECT2	OTQDUCT6	Strong	Biomarker	[780]
EEF1D	OTM5ZD8Y	Strong	Biomarker	[781]
EEF1E1	OTRA6XOB	Strong	Genetic Variation	[202]
EFEMP1	OTZVUOOB	Strong	Biomarker	[782]
EFNA1	OTU2NUA2	Strong	Altered Expression	[783]
EFNB1	OT7JJW8P	Strong	Altered Expression	[784]
EFS	OT06O7XL	Strong	Altered Expression	[785]
EGR2	OTAVQ78J	Strong	Altered Expression	[786]
EHD1	OTDMEKLV	Strong	Altered Expression	[787]
EIF3A	OTFABY9G	Strong	Biomarker	[369]
EIF3C	OTR8RF9X	Strong	Altered Expression	[788]
ELK1	OTH9MXD6	Strong	Altered Expression	[318]
EMILIN1	OT94R6M1	Strong	Biomarker	[789]
ENDOG	OT5IM7B3	Strong	Biomarker	[790]
EPS15	OT7NPP8U	Strong	Altered Expression	[787]
ERCC3	OTVAW3P1	Strong	Genetic Variation	[791]
ERCC4	OTFIOPG1	Strong	Genetic Variation	[792]
ERCC5	OTQAKFJM	Strong	Genetic Variation	[793]
ERG	OTOTX9VU	Strong	Genetic Variation	[794]
ERP29	OTNKANMH	Strong	Altered Expression	[795]
ESD	OTUSIBPS	Strong	Biomarker	[796]
ESPL1	OTMGEVOK	Strong	Altered Expression	[797]
EWSR1	OT7SRHV3	Strong	Biomarker	[798]
FADD	OTV7GFHH	Strong	Biomarker	[799]
FANCM	OTNJG99Z	Strong	Genetic Variation	[800]
FAU	OTGTVOWK	Strong	Biomarker	[801]
FBLIM1	OTFHXMON	Strong	Biomarker	[802]
FBP1	OTQBANEP	Strong	Biomarker	[147]
FBXW11	OT2A6RLR	Strong	Biomarker	[803]
FBXW4	OTEGSZOX	Strong	Posttranslational Modification	[699]
FCN2	OTTHJBKZ	Strong	Altered Expression	[231]
FERMT2	OTZNPWWX	Strong	Altered Expression	[804]
FGF13	OTHNNVSG	Strong	Altered Expression	[805]
FGF5	OTQXGHBY	Strong	Altered Expression	[806]
FKBP14	OT55W5WC	Strong	Biomarker	[807]
FLI1	OT0EV3LX	Strong	Biomarker	[808]
FLII	OT7G9JG6	Strong	Biomarker	[809]
FOSB	OTW6C05J	Strong	Altered Expression	[449]
FOXA1	OTEBY0TD	Strong	Altered Expression	[810]
FOXF1	OT2CJZ5K	Strong	Biomarker	[811]
FOXK1	OTLZGS7J	Strong	Altered Expression	[812]
FOXN3	OTOJYJZP	Strong	Biomarker	[395]
FOXP2	OTVX6A59	Strong	Altered Expression	[813]
FOXP4	OTHCGIEZ	Strong	Biomarker	[814]
FOXR1	OTL8V888	Strong	Altered Expression	[815]
FRS2	OTDMD800	Strong	Biomarker	[816]
FRZB	OTTO3DPY	Strong	Altered Expression	[817]
FSD1	OT8P6PT3	Strong	Altered Expression	[818]
FSD1L	OTBQ48RF	Strong	Altered Expression	[818]
FTL	OTYQA8A6	Strong	Biomarker	[819]
FXYD6	OTHOQXGF	Strong	Altered Expression	[820]
FZD1	OTZATHVS	Strong	Altered Expression	[821]
FZD5	OTXFFY56	Strong	Altered Expression	[822]
GADD45A	OTDRV63V	Strong	Biomarker	[823]
GCHFR	OTEOT8GI	Strong	Altered Expression	[231]
GDE1	OTU6FSBF	Strong	Genetic Variation	[824]
GDF10	OTEVXGJ7	Strong	Biomarker	[825]
GFRA1	OT3WBVYB	Strong	Biomarker	[826]
GNL3	OTILGYO4	Strong	Altered Expression	[827]
GOPC	OTRBGH71	Strong	Biomarker	[802]
GORASP1	OTQS91S7	Strong	Altered Expression	[370]
GPR68	OT1NXSMN	Strong	Altered Expression	[828]
GSDME	OT1ZWY32	Strong	Biomarker	[829]
GSTK1	OTDNGWAF	Strong	Altered Expression	[201]
H2AX	OT18UX57	Strong	Biomarker	[830]
H2BC21	OT0FDCUC	Strong	Biomarker	[831]
H3-3B	OT9XHQ3C	Strong	Genetic Variation	[832]
H4C1	OTB71W46	Strong	Biomarker	[831]
HACE1	OTEZULKD	Strong	Altered Expression	[833]
HAS3	OTPM8IL8	Strong	Biomarker	[834]
HBP1	OTDPGGDV	Strong	Genetic Variation	[835]
HIC1	OTI9TWY4	Strong	Biomarker	[836]
HLA-DOA	OTZE5Q7R	Strong	Genetic Variation	[837]
HLA-DRB4	OTNXIHQU	Strong	Genetic Variation	[799]
HMGN5	OTUUAHVQ	Strong	Biomarker	[838]
HOXA9	OTKNK5H0	Strong	Biomarker	[839]
HOXB1	OTGC0EKI	Strong	Altered Expression	[840]
HOXB7	OTC7WYU8	Strong	Biomarker	[841]
HOXB8	OTKHOD17	Strong	Biomarker	[842]
HOXC10	OT5WF17M	Strong	Altered Expression	[843]
HSPB2	OTS01646	Strong	Biomarker	[293]
HVCN1	OT4ALYU4	Strong	Genetic Variation	[844]
IER3	OTZJI5FZ	Strong	Posttranslational Modification	[845]
IFI16	OT4SPU0U	Strong	Biomarker	[846]
IFI27	OTI2XGIT	Strong	Posttranslational Modification	[107]
IFI44L	OTXKORJP	Strong	Altered Expression	[847]
IGF2BP1	OT9G360P	Strong	Biomarker	[848]
IGF2BP3	OTB97VIK	Strong	Altered Expression	[849]
IL17RA	OTVVI8ER	Strong	Biomarker	[850]
IL3	OT0CQ35N	Strong	Biomarker	[851]
ING2	OT6H0EWF	Strong	Biomarker	[204]
ING4	OT0VVG4V	Strong	Biomarker	[852]
ING5	OTRNNSFM	Strong	Altered Expression	[853]
IPO9	OT1DGLQE	Strong	Altered Expression	[580]
IRS4	OTTOL40K	Strong	Altered Expression	[240]
IRX2	OTBHXXQ2	Strong	Biomarker	[854]
JAG1	OT3LGT6K	Strong	Biomarker	[855]
JTB	OT314JB6	Strong	Altered Expression	[213]
JUNB	OTG2JXV5	Strong	Altered Expression	[449]
JUND	OTNKACJD	Strong	Altered Expression	[449]
KAT5	OTL7257A	Strong	Biomarker	[856]
KCNIP3	OTCQPEM4	Strong	Altered Expression	[857]
KDM2B	OTDMCVW7	Strong	Biomarker	[856]
KDM4D	OTN6KAE6	Strong	Altered Expression	[858]
KDM6A	OTZM3MJJ	Strong	Altered Expression	[321]
KIF22	OTY6X6BL	Strong	Biomarker	[859]
KIF5B	OTT34MT8	Strong	Biomarker	[50]
KLF2	OTIP1UFX	Strong	Altered Expression	[450]
KLF5	OT1ABI9N	Strong	Biomarker	[197]
KLF6	OTQY9S7F	Strong	Biomarker	[860]
KLF8	OTUC5CDB	Strong	Biomarker	[861]
KMT2C	OTC59BCO	Strong	Biomarker	[862]
LAMP3	OTN0XL3W	Strong	Biomarker	[863]
LAMTOR1	OTIBJBW9	Strong	Genetic Variation	[202]
LARP4	OTB10IJH	Strong	Biomarker	[864]
LATS1	OTOOCG4R	Strong	Biomarker	[318]
LHX2	OTK61NP8	Strong	Biomarker	[865]
LIMA1	OTONPC9R	Strong	Biomarker	[732]
LRRC17	OT3NZSX3	Strong	Biomarker	[732]
LSAMP	OTYXVQX2	Strong	Altered Expression	[866]
LTBP2	OTS88GSD	Strong	Biomarker	[867]
LUM	OTSRC874	Strong	Biomarker	[868]
LYPD5	OTGP7UKA	Strong	Biomarker	[343]
LZIC	OTT07ZC7	Strong	Biomarker	[869]
MACC1	OTV3DLX0	Strong	Biomarker	[870]
MAD2L1	OTXNGZCG	Strong	Biomarker	[141]
MAFK	OTZJUE4P	Strong	Genetic Variation	[202]
MAP1LC3B	OTUYHB84	Strong	Altered Expression	[724]
MAP2K3	OTI2OREX	Strong	Biomarker	[871]
MAP2K4	OTZPZX11	Strong	Biomarker	[872]
MED19	OTT9RT5N	Strong	Biomarker	[486]
MEF2D	OT7CEIG0	Strong	Altered Expression	[873]
MFAP1	OTZN4FT3	Strong	Altered Expression	[874]
MICB	OTS2DVDW	Strong	Altered Expression	[875]
MID1	OTWN1PGU	Strong	Altered Expression	[876]
MMS19	OTAXB34N	Strong	Genetic Variation	[877]
MNAT1	OTXLOYCB	Strong	Altered Expression	[878]
MNDA	OTCTKR47	Strong	Altered Expression	[879]
MPP1	OTA2ENZQ	Strong	Altered Expression	[880]
MSH3	OTD3YPVL	Strong	Biomarker	[881]
MSH6	OT46FP09	Strong	Biomarker	[882]
MSX2	OT1WDKE1	Strong	Biomarker	[883]
MTX1	OTLSDNZO	Strong	Biomarker	[884]
MUC4	OTLT11V1	Strong	Biomarker	[885]
MVP	OTJGHJRB	Strong	Altered Expression	[886]
MXI1	OTUQ9E0D	Strong	Biomarker	[887]
MYL12B	OTXMLQOT	Strong	Altered Expression	[888]
MYL2	OT78PC0C	Strong	Altered Expression	[888]
MYL9	OT6B22JB	Strong	Altered Expression	[888]
MYO18B	OTGYY4NK	Strong	Biomarker	[889]
NANS	OTMQ2FUH	Strong	Biomarker	[890]
NDC80	OTS7D306	Strong	Biomarker	[891]
NEU1	OTH9BY8Y	Strong	Altered Expression	[892]
NEURL1	OT2C4P70	Strong	Altered Expression	[892]
NGDN	OTBXTCN5	Strong	Biomarker	[893]
NKD1	OTY3MO97	Strong	Altered Expression	[894]
NME2	OTCYGLHV	Strong	Altered Expression	[895]
NOB1	OTW0YNSL	Strong	Biomarker	[896]
NOC2L	OTNT7R33	Strong	Biomarker	[897]
NOVA1	OT6A9KHY	Strong	Altered Expression	[898]
NPRL2	OTOB10MO	Strong	Biomarker	[899]
NR2F1	OTGWZWYL	Strong	Biomarker	[900]
NSD2	OTQ6SW4R	Strong	Biomarker	[901]
NSG1	OTRIMA50	Strong	Biomarker	[902]
NT5C3A	OT67KZJA	Strong	Biomarker	[903]
NUDT21	OTZHKWAR	Strong	Biomarker	[904]
OBP2A	OTBIJ5TI	Strong	Biomarker	[859]
OVOL2	OTFM1GKF	Strong	Altered Expression	[905]
OXA1L	OTS0BFRD	Strong	Biomarker	[906]
OXT	OT48M72Z	Strong	Biomarker	[907]
P2RX5	OTLBR20R	Strong	Biomarker	[355]
P4HTM	OTKELL7F	Strong	Biomarker	[908]
PACC1	OTKBS8CC	Strong	Biomarker	[909]
PAEP	OTQA0NV4	Strong	Altered Expression	[910]
PAFAH1B1	OT9T2TCJ	Strong	Biomarker	[393]
PAK5	OT32WQGL	Strong	Altered Expression	[911]
PAX1	OT0Y3MIM	Strong	Biomarker	[912]
PAX3	OTN5PJZV	Strong	Altered Expression	[913]
PDCD4	OTZ6NXUX	Strong	Altered Expression	[131]
PDLIM5	OTLQVV22	Strong	Biomarker	[323]
PDLIM7	OTAZVODU	Strong	Biomarker	[914]
PDPN	OTBUV19I	Strong	Altered Expression	[915]
PDZD2	OTPPVRGY	Strong	Biomarker	[916]
PELP1	OTVXQNOT	Strong	Altered Expression	[917]
PGAM1	OTZ5DB06	Strong	Biomarker	[388]
PGAP2	OTUW3SAX	Strong	Biomarker	[714]
PHC3	OTTTLIAP	Strong	Biomarker	[918]
PHLDA2	OTMV9DPP	Strong	Altered Expression	[919]
PIK3R3	OTXGJ8N1	Strong	Altered Expression	[880]
PKD1	OT5ALRZ5	Strong	Altered Expression	[920]
PMCH	OT3D9SA4	Strong	Altered Expression	[921]
PMP22	OTXWYWCZ	Strong	Biomarker	[922]
POLD4	OTG578YH	Strong	Biomarker	[923]
POLE4	OTCMWUT6	Strong	Biomarker	[923]
POLG2	OTDBMZJB	Strong	Altered Expression	[880]
POLR2C	OTZ0ULJ9	Strong	Altered Expression	[473]
POT1	OTNBXJCQ	Strong	Biomarker	[412]
POTEF	OTV3WXYE	Strong	Biomarker	[924]
POU1F1	OTXT8A5C	Strong	Altered Expression	[462]
POU2F1	OTK7ELJ0	Strong	Biomarker	[925]
POU5F1	OTDHHN7O	Strong	Biomarker	[926]
PPP1R11	OTSHYPPW	Strong	Altered Expression	[487]
PPRC1	OT6GB3WR	Strong	Altered Expression	[927]
PRDM2	OT8L7CGX	Strong	Altered Expression	[928]
PRDX2	OTLWCY9T	Strong	Biomarker	[929]
PRMT6	OT5V3XIN	Strong	Biomarker	[930]
PRND	OTH4EEMI	Strong	Altered Expression	[931]
PRRT2	OTCJUBDO	Strong	Altered Expression	[932]
PSMA6	OTJ6RPX5	Strong	Altered Expression	[933]
PSMC2	OTJ4V337	Strong	Biomarker	[934]
PSMD12	OTWICA51	Strong	Altered Expression	[880]
PSMD9	OT6Y5CC3	Strong	Posttranslational Modification	[107]
PTHLH	OTI1JF13	Strong	Altered Expression	[935]
PTPA	OTRGFOI7	Strong	Biomarker	[936]
PTPRU	OTHDO0QG	Strong	Altered Expression	[463]
PTRH1	OTOAOS93	Strong	Biomarker	[937]
PTTG1	OTIMYS4W	Strong	Altered Expression	[938]
PTTG1IP	OTX21QTE	Strong	Biomarker	[939]
PXN	OTVMMUOF	Strong	Altered Expression	[940]
RAB10	OT8ZN26V	Strong	Biomarker	[941]
RAB31	OTMLXQZ0	Strong	Biomarker	[942]
RAB3D	OTGKRR3C	Strong	Biomarker	[943]
RABGEF1	OTWC3Z3R	Strong	Biomarker	[412]
RAC2	OTAOHFNH	Strong	Biomarker	[944]
RAD21	OTQS84ZF	Strong	Biomarker	[945]
RALGAPB	OTY8CGA3	Strong	Altered Expression	[698]
RAP1A	OT5RH6TI	Strong	Biomarker	[412]
RAPH1	OTMQXW7S	Strong	Altered Expression	[946]
RASGRF1	OTNWJ7EN	Strong	Altered Expression	[947]
RB1CC1	OTZK8PFX	Strong	Altered Expression	[948]
RBP2	OTR8QG5V	Strong	Altered Expression	[757]
RCBTB1	OTAYELI8	Strong	Biomarker	[949]
RDX	OTNSYUN6	Strong	Biomarker	[679]
RECQL	OTPCH3JH	Strong	Genetic Variation	[950]
RECQL4	OT59LSW7	Strong	Autosomal recessive	[951]
RECQL5	OTVZMP1Q	Strong	Genetic Variation	[950]
RFC2	OTJ9N6BD	Strong	Biomarker	[952]
RHOBTB2	OT2DATFX	Strong	Biomarker	[953]
RIPK3	OTL1D484	Strong	Biomarker	[954]
RNASE3	OTVE2XD1	Strong	Biomarker	[235]
RPAIN	OTBMXAYK	Strong	Biomarker	[381]
RPL7A	OT6E6UKF	Strong	Altered Expression	[955]
S100A2	OTTGHJ1H	Strong	Biomarker	[845]
SAA4	OTCE1WXO	Strong	Altered Expression	[956]
SASH1	OTQA8BD4	Strong	Altered Expression	[957]
SCAI	OTAK3TMO	Strong	Biomarker	[958]
SDC4	OTKUVUGZ	Strong	Altered Expression	[959]
SDHC	OTC8G2MX	Strong	Genetic Variation	[960]
SEMA4C	OTF5JHQ0	Strong	Biomarker	[961]
SEMA6A	OTDQ7QAW	Strong	Biomarker	[251]
SEPTIN1	OT4GVSU3	Strong	Biomarker	[962]
SFRP2	OT8GZ0CA	Strong	Biomarker	[963]
SGSM3	OTIB1P8A	Strong	Genetic Variation	[964]
SHKBP1	OTJXWLEH	Strong	Biomarker	[965]
SHOX	OTE0YZJO	Strong	Altered Expression	[966]
SIRT7	OT5M4OT4	Strong	Biomarker	[967]
SIX1	OT70YYWM	Strong	Biomarker	[968]
SKA1	OTDYJ12A	Strong	Biomarker	[473]
SLBP	OTVYYQRT	Strong	Biomarker	[969]
SLC12A9	OTR7VRAK	Strong	Biomarker	[970]
SMAD2	OTC6VB4K	Strong	Biomarker	[971]
SNAI1	OTDPYAMC	Strong	Altered Expression	[972]
SNAI2	OT7Y8EJ2	Strong	Biomarker	[973]
SND1	OTT734JN	Strong	Biomarker	[974]
SNRNP25	OT2MR6O2	Strong	Biomarker	[975]
SOX18	OTPUMHWA	Strong	Biomarker	[976]
SOX3	OT1CRCOB	Strong	Biomarker	[977]
SOX7	OTOZOFAG	Strong	Altered Expression	[978]
SOX9	OTVDJFGN	Strong	Altered Expression	[979]
SP7	OT07ETZT	Strong	Biomarker	[980]
SPAG8	OTZC5XP9	Strong	Biomarker	[981]
SPG7	OT8OY9ST	Strong	Biomarker	[353]
SPINK1	OTSUVAL2	Strong	Biomarker	[982]
SPOP	OTP0107S	Strong	Altered Expression	[983]
SPRY2	OTH0CRCZ	Strong	Biomarker	[984]
SQSTM1	OTGY5D5J	Strong	Autosomal dominant	[407]
SRCIN1	OTQZNQQ5	Strong	Altered Expression	[985]
SRSF3	OTOFT707	Strong	Biomarker	[986]
SSR1	OTQ6GDL2	Strong	Biomarker	[987]
STK35	OTLEMU48	Strong	Biomarker	[988]
SUMO1	OTJFD4P5	Strong	Altered Expression	[989]
SUV39H2	OTU0F4LL	Strong	Biomarker	[990]
SYT1	OTVTPOI6	Strong	Altered Expression	[370]
SYT7	OTBWAOWY	Strong	Biomarker	[991]
TAS1R1	OTOGG3AH	Strong	Altered Expression	[426]
TAT	OT2CJ91O	Strong	Biomarker	[992]
TBL1Y	OTA0F7TM	Strong	Biomarker	[109]
TBPL2	OTDEC1KO	Strong	Altered Expression	[993]
TBX18	OT3BEBLN	Strong	Biomarker	[994]
TBX2	OTTOT7A9	Strong	Altered Expression	[995]
TBX5	OT70PISV	Strong	Biomarker	[803]
TCEAL1	OTAPG2L5	Strong	Biomarker	[902]
TCF21	OT393IMA	Strong	Altered Expression	[996]
TCF7	OT1ID822	Strong	Altered Expression	[129]
TERF2IP	OT3M5P3G	Strong	Biomarker	[412]
TET1	OTZDHT1D	Strong	Altered Expression	[997]
TGFBI	OTR443C5	Strong	Biomarker	[998]
THBS3	OTDKMUBD	Strong	Altered Expression	[999]
TICAM2	OTK7GIJ5	Strong	Posttranslational Modification	[107]
TIMM8A	OTDX9687	Strong	Biomarker	[309]
TIMP3	OTDGQAD1	Strong	Altered Expression	[1000]
TINF2	OT861N2N	Strong	Biomarker	[412]
TMED7	OTONO8E6	Strong	Posttranslational Modification	[107]
TNFAIP1	OT37EWR0	Strong	Biomarker	[1001]
TNFAIP8L1	OTVVKOTV	Strong	Altered Expression	[1002]
TOP3A	OT3CKUI9	Strong	Biomarker	[1003]
TP53INP1	OT2363Z9	Strong	Biomarker	[1004]
TP73	OT0LUO47	Strong	Altered Expression	[710]
TPPP2	OTI3WA6X	Strong	Genetic Variation	[202]
TPR	OTUBBA4W	Strong	Biomarker	[1005]
TRADD	OTBOSJHO	Strong	Biomarker	[799]
TRAF4	OTJLRVMC	Strong	Biomarker	[1006]
TRAT1	OTMPUNPD	Strong	Biomarker	[1007]
TRIM13	OTQIUACB	Strong	Biomarker	[353]
TRIM14	OTLQKUG0	Strong	Biomarker	[1008]
TRIM66	OT0VJCP6	Strong	Biomarker	[1009]
TRPS1	OT7XPPEL	Strong	Altered Expression	[1010]
TSPAN31	OT8WQ83R	Strong	Biomarker	[890]
AMPH	OTWPGWZX	Definitive	Biomarker	[1011]
ANXA3	OTDD8OI7	Definitive	Altered Expression	[1012]
ANXA6	OT9KIQ0Y	Definitive	Altered Expression	[1013]
ATG4B	OTQ4RNRM	Definitive	Biomarker	[1014]
BTF3	OT5ZZFJL	Definitive	Biomarker	[1015]
CBX2	OTOQ5WS4	Definitive	Biomarker	[1016]
CCNB2	OTIEXTDK	Definitive	Biomarker	[938]
CCNB3	OT5V72D3	Definitive	Biomarker	[1017]
CD81	OTQFXNAZ	Definitive	Altered Expression	[1018]
CDC34	OTNBK390	Definitive	Biomarker	[1019]
CDC6	OTX93FE7	Definitive	Altered Expression	[1020]
CLEC5A	OT19WV30	Definitive	Biomarker	[235]
CPXM2	OTDJNOTR	Definitive	Altered Expression	[1021]
CTBP2	OTGZGT87	Definitive	Altered Expression	[1022]
CTPS2	OT2X9YO1	Definitive	Biomarker	[455]
DDOST	OT39PDMS	Definitive	Altered Expression	[1023]
EDA	OTAKS5WS	Definitive	Biomarker	[1024]
FAM83H	OTN0SF11	Definitive	Altered Expression	[1025]
FEN1	OT6QGG7O	Definitive	Altered Expression	[1026]
FLOT2	OTZ0QR5L	Definitive	Altered Expression	[1027]
GADD45GIP1	OT4IZ4TP	Definitive	Biomarker	[229]
HCP5	OTV0YRI8	Definitive	Altered Expression	[1028]
HELQ	OTL1STJT	Definitive	Biomarker	[1029]
HNRNPD	OT5UO1FA	Definitive	Biomarker	[1030]
HOXB2	OTTD6HMV	Definitive	Biomarker	[1031]
ING1	OTEZBRKW	Definitive	Biomarker	[1032]
MBTD1	OT2P6943	Definitive	Altered Expression	[1033]
MCF2L	OTEURA8N	Definitive	Altered Expression	[1023]
METTL3	OTSXP1M3	Definitive	Biomarker	[1034]
MTUS1	OTBPALMU	Definitive	Biomarker	[1035]
MYO10	OTHB78ZQ	Definitive	Altered Expression	[549]
NFIB	OTX94PD0	Definitive	Genetic Variation	[1036]
NUPR1	OT4FU8C0	Definitive	Altered Expression	[1037]
OPN1LW	OTFNUZ7O	Definitive	Biomarker	[1038]
ORC2	OTLIYP8M	Definitive	Altered Expression	[1039]
PAG1	OTFOJUIQ	Definitive	Biomarker	[1038]
PCBP4	OTDLL4NB	Definitive	Biomarker	[1038]
PCK2	OTJ8LX4N	Definitive	Biomarker	[1040]
PEA15	OTKCKTSX	Definitive	Altered Expression	[878]
PFN2	OT5SSSA7	Definitive	Biomarker	[1041]
PPP2R2A	OT9297OG	Definitive	Biomarker	[936]
PQBP1	OTXCBEAH	Definitive	Biomarker	[1040]
PRB2	OTAD4JZ0	Definitive	Biomarker	[1042]
QKI	OTTAUGLB	Definitive	Biomarker	[1043]
RAB13	OTIQ484I	Definitive	Biomarker	[1044]
RRAS2	OT83NCEB	Definitive	Altered Expression	[1045]
RUVBL1	OTWV19L7	Definitive	Altered Expression	[549]
SLC16A4	OT1YXBKC	Definitive	Altered Expression	[454]
SLX4IP	OTRZQJV9	Definitive	Biomarker	[1046]
SRA1	OTYOGMTG	Definitive	Altered Expression	[1047]
STAG2	OTR6X1Q7	Definitive	Biomarker	[1048]
TP53I3	OTSCM68G	Definitive	Biomarker	[455]
TRIAP1	OTEAUJXN	Definitive	Biomarker	[1049]

This Disease Is Related to 502 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ACKR3	TTRQJTC	Limited	Biomarker	[13]
ADORA3	TTJFY5U	Limited	Altered Expression	[14]
ALPL	TTMR5UV	Limited	Genetic Variation	[15]
AMOT	TTI48OS	Limited	Altered Expression	[16]
APC2	TTSMK36	Limited	Biomarker	[17]
APEX1	TTHGL48	Limited	Altered Expression	[18]
AQP3	TTLDNMQ	Limited	Altered Expression	[19]
ARG2	TTV1AG6	Limited	Biomarker	[20]
ASRGL1	TT4WT91	Limited	Biomarker	[21]
BMP2	TTP3IGX	Limited	Biomarker	[22]
BMP6	TT07RIB	Limited	Biomarker	[23]
BMP7	TTKOBRA	Limited	Altered Expression	[24]
CARM1	TTIZQFJ	Limited	Biomarker	[25]
CCN2	TTIL516	Limited	Biomarker	[26]
CD274	TT8ZLTI	Limited	Biomarker	[27]
CD44	TTWFBT7	Limited	Biomarker	[28]
CD6	TTMF6KC	Limited	Biomarker	[29]
CD74	TTCMYP9	Limited	Biomarker	[30]
CDC20	TTBKFDV	Limited	Biomarker	[31]
CDH3	TTARMD9	Limited	Biomarker	[32]
CDK19	TTNABU9	Limited	Biomarker	[33]
CDK6	TTO0FDJ	Limited	Biomarker	[34]
CDKN1A	TT9GUW0	Limited	Altered Expression	[35]
CEACAM6	TTIGH2W	Limited	Biomarker	[36]
CHEK1	TTTU902	Limited	Biomarker	[37]
CHEK2	TT9ABMF	Limited	Biomarker	[38]
COL18A1	TT63DI9	Limited	Biomarker	[39]
CRK	TTFEUYR	Limited	Biomarker	[40]
CRY1	TT5MLZR	Limited	Biomarker	[41]
CRY2	TTAO58M	Limited	Altered Expression	[42]
CSE1L	TTTRULD	Limited	Biomarker	[43]
CYP3A4	TTWP7HQ	Limited	Biomarker	[44]
DEPTOR	TTLYP6D	Limited	Altered Expression	[45]
DGKZ	TTSBBXL	Limited	Biomarker	[46]
DLK1	TTF4AVB	Limited	Biomarker	[47]
EPAS1	TTWPA54	Limited	Altered Expression	[48]
EPHA7	TTAHTVG	Limited	Biomarker	[49]
EPHB2	TTKPV6O	Limited	Biomarker	[50]
ERBB4	TTWALCO	Limited	Biomarker	[51]
ESRRA	TTPNQAC	Limited	Biomarker	[52]
EYA2	TTUY9C6	Limited	Altered Expression	[53]
F8	TT1290U	Limited	Biomarker	[54]
FFAR1	TTB8FUC	Limited	Altered Expression	[55]
FFAR4	TT08JVB	Limited	Altered Expression	[55]
FOS	TTOM5AU	Limited	Biomarker	[56]
FOXP1	TT0MUCI	Limited	Biomarker	[57]
FUT3	TTUPAD7	Limited	Altered Expression	[58]
GAL	TTXZAJ5	Limited	Altered Expression	[59]
GLI2	TT045OH	Limited	Biomarker	[60]
GPNMB	TT7315J	Limited	Altered Expression	[61]
GPR137	TTATO6X	Limited	Altered Expression	[62]
GRM4	TTICZ1O	Limited	Altered Expression	[63]
HMGA1	TTBA219	Limited	Biomarker	[64]
HSF1	TTN6STZ	Limited	Altered Expression	[65]
IGFBP1	TTCJTWF	Limited	Altered Expression	[66]
IGFBP5	TTDWEA8	Limited	Altered Expression	[67]
ITGA5	TTHIZP9	Limited	Biomarker	[68]
ITGB1	TTBVIQC	Limited	Biomarker	[69]
KIF11	TTBGTCW	Limited	Biomarker	[70]
LNPEP	TTY2KP7	Limited	Biomarker	[71]
LSS	TT7O8ZA	Limited	Biomarker	[72]
MALT1	TTCI81G	Limited	Altered Expression	[73]
MAPK12	TTYT93M	Limited	Biomarker	[74]
MAPK14	TTQBR95	Limited	Biomarker	[40]
MARCKS	TTHRM39	Limited	Altered Expression	[75]
MELTF	TT8OBT3	Limited	Biomarker	[76]
MMP3	TTUZ2L5	Limited	Altered Expression	[77]
MSI1	TTSM4BA	Limited	Altered Expression	[78]
MST1R	TTBQ3OC	Limited	Biomarker	[79]
NDUFA13	TTRU1NG	Limited	Altered Expression	[80]
NUF2	TTIXBFP	Limited	Altered Expression	[81]
PCNA	TTLG1PD	Limited	Biomarker	[82]
PF4	TTSG7Q5	Limited	Altered Expression	[83]
PLK1	TTH4IP0	Limited	Biomarker	[84]
PRMT1	TTVOJAI	Limited	Biomarker	[85]
PROM1	TTXMZ81	Limited	Altered Expression	[86]
PTH	TT6F7GZ	Limited	Biomarker	[87]
PTK2	TTON5IT	Limited	Biomarker	[88]
QPCT	TTJ7YTV	Limited	Biomarker	[89]
RECK	TTRZBW7	Limited	Altered Expression	[90]
RENBP	TTZCG0Q	Limited	Altered Expression	[91]
ROCK1	TTZN7RP	Limited	Biomarker	[92]
RSF1	TTMP86V	Limited	Biomarker	[93]
S100A4	TTPR5SX	Limited	Biomarker	[94]
SDC2	TT5H2F0	Limited	Biomarker	[95]
SEMA3A	TTVKD3S	Limited	Biomarker	[96]
SH3GL1	TTTYNAM	Limited	Biomarker	[97]
SKP2	TT5B2EO	Limited	Biomarker	[98]
SLC12A1	TTS087L	Limited	Biomarker	[99]
SLC18A2	TTNZRI3	Limited	Biomarker	[100]
SLC34A2	TTQPZTM	Limited	Altered Expression	[101]
SLC38A1	TT1YE9Z	Limited	Altered Expression	[102]
SLC3A2	TT5CZSM	Limited	Biomarker	[103]
SPHK2	TTCN0M9	Limited	Biomarker	[104]
SPOCK1	TTF23RE	Limited	Biomarker	[105]
SRR	TTZFUY6	Limited	Biomarker	[106]
STMN1	TT7W5OT	Limited	Biomarker	[107]
TACSTD2	TTP2HE5	Limited	Biomarker	[108]
TBL1X	TTAL6S1	Limited	Biomarker	[109]
TDP2	TTYF26D	Limited	Biomarker	[110]
TNFRSF11A	TT3K9S2	Limited	Autosomal dominant	[111]
TNFRSF11A	TT3K9S2	Limited	Altered Expression	[112]
TNFRSF12A	TTKPS7V	Limited	Biomarker	[113]
TNFSF10	TTA5MS9	Limited	Biomarker	[114]
TNK2	TTIET93	Limited	Biomarker	[115]
TNKS2	TTFQI4H	Limited	Biomarker	[116]
TNNC1	TT8RDXP	Limited	Altered Expression	[117]
TP53BP1	TTX4UE9	Limited	Biomarker	[118]
TPT1	TT3PTB6	Limited	Altered Expression	[119]
TREM2	TTQRMSJ	Limited	Altered Expression	[120]
XIAP	TTK3WBU	Limited	Biomarker	[121]
YAP1	TT8UN2D	Limited	Altered Expression	[122]
AIMP2	TTXWHGF	Disputed	Biomarker	[40]
BCL2L2	TTQ79W8	Disputed	Biomarker	[123]
CCK	TT90CMU	Disputed	Biomarker	[124]
CDH6	TT9QHUK	Disputed	Biomarker	[125]
EGF	TTED8JB	Disputed	Biomarker	[126]
FN1	TTPJ921	Disputed	Genetic Variation	[127]
FOXM1	TTD3KOX	Disputed	Biomarker	[128]
GSK3B	TTRSMW9	Disputed	Biomarker	[129]
KDM5B	TTCLI75	Disputed	Biomarker	[130]
MAPK3	TT1MG9E	Disputed	Biomarker	[131]
NMUR1	TTI7T1Q	Disputed	Biomarker	[132]
PFKFB2	TTQYVKD	Disputed	Altered Expression	[133]
PIK3CB	TT9H4P3	Disputed	Biomarker	[134]
PRKG2	TTDWFCQ	Disputed	Altered Expression	[135]
ROBO1	TTND1YP	Disputed	Biomarker	[133]
SLC19A1	TT09I7D	Disputed	Altered Expression	[136]
SLIT2	TTDWK85	Disputed	Biomarker	[133]
ACLY	TT0Z6Y2	moderate	Altered Expression	[137]
AKT1	TTWTSCV	moderate	Biomarker	[138]
ALPI	TTHYMUV	moderate	Biomarker	[139]
BECN1	TT5M7LN	moderate	Altered Expression	[140]
BRD4	TTSRAOU	moderate	Biomarker	[71]
BUB1	TT78309	moderate	Biomarker	[141]
CCN1	TTPK79J	moderate	Altered Expression	[142]
CCND3	TT1JXNR	moderate	Biomarker	[143]
CDCA8	TT04YCM	moderate	Biomarker	[141]
CMA1	TT8VUE0	moderate	Biomarker	[144]
CTAG1A	TTE5ITK	moderate	Biomarker	[145]
EIF2AK3	TT79U1M	moderate	Biomarker	[146]
EZH2	TT9MZCQ	moderate	Biomarker	[147]
F2RL3	TTD0652	moderate	Biomarker	[148]
FGR	TTPOGS1	moderate	Altered Expression	[149]
FOLR1	TTVC37M	moderate	Biomarker	[150]
FSCN1	TTTRS9B	moderate	Biomarker	[151]
GDF2	TTAP4T1	moderate	Biomarker	[152]
HDAC5	TTUELN5	moderate	Biomarker	[153]
HPGDS	TTCYE56	moderate	Altered Expression	[154]
IAPP	TTHN8EM	moderate	Biomarker	[139]
IL16	TTW4R0B	moderate	Genetic Variation	[155]
ISG15	TTVOH3T	moderate	Altered Expression	[156]
KCNMB4	TT1AQ50	moderate	Biomarker	[143]
KDM4C	TTV8CRH	moderate	Posttranslational Modification	[157]
LOX	TTQHNAM	moderate	Altered Expression	[158]
LPAR1	TTQ6S1K	moderate	Genetic Variation	[159]
LPAR5	TTABCJ6	moderate	Biomarker	[160]
MAP3K9	TTUNSIX	moderate	Altered Expression	[161]
MAPK8	TT0K6EO	moderate	Biomarker	[162]
MET	TTNDSF4	moderate	Biomarker	[163]
MMP2	TTLM12X	moderate	Altered Expression	[164]
MMP8	TTGA1IV	moderate	Altered Expression	[165]
MYC	TTNQ5ZP	moderate	Altered Expression	[166]
NCL	TTK1V5Q	moderate	Biomarker	[167]
NELL1	TT7H4BF	moderate	Altered Expression	[168]
NRP2	TTRXUVC	moderate	Altered Expression	[169]
PAWR	TT3I4WV	moderate	Biomarker	[148]
PLCG1	TT6T4JI	moderate	Biomarker	[141]
PTPRZ1	TT4SEA8	moderate	Genetic Variation	[170]
RASA1	TTPNZ1F	moderate	Biomarker	[171]
RUNX2	TTD6SZ8	moderate	Altered Expression	[129]
SEMA4D	TT5UT28	moderate	Biomarker	[172]
TAGLN	TTDRZ9H	moderate	Biomarker	[173]
TBK1	TTMP03S	moderate	Altered Expression	[174]
TGFA	TTTLQFR	moderate	Biomarker	[175]
TIAM1	TTNU6I5	moderate	Biomarker	[176]
TNFRSF18	TTG6LA7	moderate	Biomarker	[177]
TPP1	TTOVYPT	moderate	Biomarker	[178]
TRIM59	TT613U4	moderate	Biomarker	[179]
UBC	TTBP3XA	moderate	Biomarker	[180]
VDR	TTK59TV	moderate	Genetic Variation	[181]
VEGFA	TT3LJ9K	moderate	Altered Expression	[182]
VTCN1	TTCK85E	moderate	Altered Expression	[183]
WRN	TT2H5WQ	Moderate	Autosomal recessive	[12]
WWP1	TTBWMKT	moderate	Biomarker	[184]
ABCC1	TTOI92F	Strong	Altered Expression	[185]
ABCC3	TTVLG21	Strong	Genetic Variation	[186]
ABCC4	TTUEAFL	Strong	Altered Expression	[187]
ABCG1	TTMWDGU	Strong	Biomarker	[188]
ADAM9	TTTYQNS	Strong	Biomarker	[189]
ADAMTS1	TTS2TEI	Strong	Biomarker	[190]
ADAMTS4	TTYG6BU	Strong	Altered Expression	[191]
AGPAT2	TT9AYVR	Strong	Biomarker	[192]
AKT2	TTH24WI	Strong	Biomarker	[193]
ALCAM	TT2AFT6	Strong	Biomarker	[194]
ANPEP	TTPHMWB	Strong	Biomarker	[195]
ANXA2	TT4YANI	Strong	Altered Expression	[196]
ANXA5	TT2Z83I	Strong	Biomarker	[197]
APLNR	TTJ8E43	Strong	Biomarker	[198]
ARL2	TTIDSFT	Strong	Altered Expression	[199]
ATF3	TTCE793	Strong	Biomarker	[126]
ATF4	TTQCKWT	Strong	Altered Expression	[200]
ATG7	TTLVB9Z	Strong	Biomarker	[201]
ATRAID	TTFLIKM	Strong	Genetic Variation	[202]
AURKA	TTPS3C0	Strong	Biomarker	[141]
AURKB	TT9RTBL	Strong	Altered Expression	[203]
BACE2	TT69DB8	Strong	Biomarker	[204]
BCL2A1	TTGT9C7	Strong	Altered Expression	[205]
BGN	TT0JPVF	Strong	Biomarker	[206]
BIRC2	TTQ5LRD	Strong	Altered Expression	[207]
BIRC3	TTAIWZN	Strong	Altered Expression	[208]
BIRC7	TTHZ8TA	Strong	Genetic Variation	[209]
BMI1	TTIPNSR	Strong	Biomarker	[210]
BMP1	TT0L58T	Strong	Biomarker	[211]
BMPR2	TTGKF90	Strong	Altered Expression	[212]
BPHL	TTTZ3EU	Strong	Biomarker	[213]
BRCA2	TTUARD6	Strong	Biomarker	[214]
BRD7	TT07ZS1	Strong	Altered Expression	[215]
CA9	TT2LVK8	Strong	Biomarker	[216]
CASP6	TTKW4ML	Strong	Biomarker	[217]
CASP9	TTB6T7O	Strong	Altered Expression	[218]
CASR	TTBUYHA	Strong	Altered Expression	[134]
CCNA2	TTAMQ62	Strong	Biomarker	[219]
CCNB1	TT9P6OW	Strong	Biomarker	[220]
CCNE1	TTCEJ4F	Strong	Altered Expression	[221]
CD248	TTYJWT7	Strong	Biomarker	[222]
CD47	TT28S46	Strong	Biomarker	[223]
CD86	TT53XHB	Strong	Biomarker	[224]
CDH11	TTRGWZC	Strong	Altered Expression	[225]
CDH2	TT1WS0T	Strong	Biomarker	[226]
CDH5	TTXLCFO	Strong	Biomarker	[227]
CDK1	TTH6V3D	Strong	Biomarker	[228]
CDK11B	TT5Q79O	Strong	Biomarker	[33]
CDK2	TT7HF4W	Strong	Altered Expression	[229]
CDK5	TTL4Q97	Strong	Biomarker	[230]
CDK5R1	TTBYM6V	Strong	Altered Expression	[231]
CDK8	TTBJR4L	Strong	Biomarker	[232]
CDK9	TT1LVF2	Strong	Biomarker	[233]
CDKN2C	TTBRUGA	Strong	Genetic Variation	[202]
CEBPA	TT5LWG1	Strong	Altered Expression	[234]
CEBPB	TTUI35N	Strong	Biomarker	[235]
CFLAR	TTJZQYH	Strong	Biomarker	[236]
CNTN2	TT2Z1WB	Strong	Altered Expression	[237]
COL1A2	TTUABC1	Strong	Biomarker	[238]
CREB1	TTH4AN3	Strong	Biomarker	[239]
CSNK1G2	TT0UZJ9	Strong	Altered Expression	[240]
CSPG4	TT7MYXI	Strong	Biomarker	[241]
CTLA4	TTI2S1D	Strong	Biomarker	[27]
CTSK	TTDZN01	Strong	Altered Expression	[242]
CX3CL1	TT1OFBQ	Strong	Biomarker	[243]
CXCL12	TT4UGTF	Strong	Biomarker	[244]
CXCR1	TTMWT8Z	Strong	Altered Expression	[245]
DCN	TTB3XAN	Strong	Biomarker	[246]
DDX5	TTZKPVC	Strong	Altered Expression	[247]
DEK	TT1NMGV	Strong	Biomarker	[248]
DHFR	TTYZVDJ	Strong	Altered Expression	[249]
DIABLO	TTN74LE	Strong	Biomarker	[207]
DKK1	TTE3RAC	Strong	Biomarker	[250]
DKK3	TTY2ZV6	Strong	Biomarker	[251]
DPEP1	TTYUENF	Strong	Biomarker	[252]
DSG3	TTEO4P8	Strong	Biomarker	[253]
DUSP1	TTG8HIM	Strong	Biomarker	[254]
DYRK1B	TTYGQ8A	Strong	Altered Expression	[255]
E2F1	TTASI04	Strong	Biomarker	[256]
E2F2	TT5FYX0	Strong	Biomarker	[257]
E2F3	TTWIJYH	Strong	Altered Expression	[258]
EIF2AK2	TTXEZJ4	Strong	Biomarker	[259]
EIF4E	TTZGCP6	Strong	Altered Expression	[260]
EPHA2	TTRJB2G	Strong	Biomarker	[261]
ETS2	TT9AH0M	Strong	Genetic Variation	[262]
F3	TT38MDJ	Strong	Altered Expression	[263]
FASN	TT7AOUD	Strong	Biomarker	[264]
FDPS	TTIKWV4	Strong	Biomarker	[265]
FGF1	TTMY81X	Strong	Altered Expression	[266]
FOLR2	TTT54CI	Strong	Altered Expression	[150]
FOSL1	TTY8LZG	Strong	Biomarker	[267]
FOSL2	TT689IR	Strong	Biomarker	[268]
FOXC2	TTLBAP1	Strong	Biomarker	[269]
FOXO1	TTLRVIA	Strong	Biomarker	[270]
FPR2	TTOJ1NF	Strong	Biomarker	[271]
G3BP1	TTG0R8Z	Strong	Biomarker	[272]
GAK	TT0AGBL	Strong	Biomarker	[273]
GH1	TTT3YKH	Strong	Biomarker	[274]
GHR	TTHJWYD	Strong	Biomarker	[275]
GHRHR	TTG4R8V	Strong	Biomarker	[276]
GLI1	TTJOMH6	Strong	Biomarker	[277]
GLIPR1	TTEQF1O	Strong	Biomarker	[278]
GLUL	TTURQ2G	Strong	Altered Expression	[279]
GPI	TT19JIZ	Strong	Altered Expression	[280]
GRM1	TTVBPDM	Strong	Biomarker	[281]
GRM5	TTHS256	Strong	Altered Expression	[282]
GZMB	TTKEPHX	Strong	Biomarker	[283]
HAL	TTXQOZW	Strong	Biomarker	[284]
HDAC2	TTSHTOI	Strong	Biomarker	[285]
HDAC4	TTTQGH8	Strong	Biomarker	[286]
HDAC6	TT5ZKDI	Strong	Biomarker	[287]
HK2	TTK02H8	Strong	Altered Expression	[288]
HMGCR	TTPADOQ	Strong	Altered Expression	[289]
HOXA5	TTXSVQP	Strong	Biomarker	[290]
HSD11B1	TTN7BL9	Strong	Biomarker	[291]
HSD11B2	TT9H85R	Strong	Altered Expression	[291]
HSP90AA1	TT78R5H	Strong	Biomarker	[129]
HSP90B1	TTFPKXQ	Strong	Biomarker	[292]
HSPA5	TTW26OG	Strong	Altered Expression	[292]
HSPB3	TTLH8WG	Strong	Biomarker	[293]
IGF2R	TTPNE41	Strong	Biomarker	[294]
IGFBP3	TTZHNQA	Strong	Biomarker	[295]
IL11	TTGUYTR	Strong	Biomarker	[296]
IL11RA	TTZPLJS	Strong	Biomarker	[296]
IL12A	TTRTK6Y	Strong	Genetic Variation	[297]
IL1R1	TTWOTEA	Strong	Biomarker	[298]
IL24	TT1EPXZ	Strong	Biomarker	[299]
IL31RA	TT9HPX0	Strong	Biomarker	[300]
ILK	TT7ALZG	Strong	Biomarker	[301]
IMP3	TTEJA2R	Strong	Altered Expression	[302]
IMPDH2	TTTB4UP	Strong	Altered Expression	[303]
IRF8	TTHUBNK	Strong	Biomarker	[304]
IRS1	TTAJSQ0	Strong	Biomarker	[305]
ITGA2	TTSJ542	Strong	Altered Expression	[306]
ITGA4	TTJMF9P	Strong	Biomarker	[307]
ITGA6	TT165T3	Strong	Biomarker	[308]
ITGAV	TTT1R2L	Strong	Biomarker	[309]
KCNH1	TT9XKUC	Strong	Biomarker	[310]
KDM2A	TT8XTY2	Strong	Biomarker	[311]
KDM6B	TTDIJUQ	Strong	Altered Expression	[312]
KIF26B	TTQWICZ	Strong	Biomarker	[50]
KISS1	TTU2O6T	Strong	Biomarker	[313]
KLF4	TTTI53X	Strong	Biomarker	[314]
KLK3	TTS78AZ	Strong	Biomarker	[315]
KLRK1	TTLRN4A	Strong	Biomarker	[316]
KYNU	TTWQM3J	Strong	Altered Expression	[317]
LATS2	TTML7FG	Strong	Biomarker	[318]
LDHA	TTW76JE	Strong	Biomarker	[319]
LGALS1	TTO3NYT	Strong	Altered Expression	[59]
LGR4	TTY6C71	Strong	Altered Expression	[320]
LIF	TTGZ5WN	Strong	Altered Expression	[321]
LILRB1	TTC0QRJ	Strong	Biomarker	[322]
LIMK1	TTWL9TY	Strong	Altered Expression	[323]
LIMK2	TTASMD8	Strong	Biomarker	[324]
LPA	TTU9LGY	Strong	Biomarker	[325]
LPAR3	TTE2YJR	Strong	Genetic Variation	[159]
LRP5	TT7VMG4	Strong	Biomarker	[326]
MAGEA10	TT1VNVM	Strong	Biomarker	[327]
MAGEA4	TT9EQUY	Strong	Biomarker	[327]
MAP3K10	TT9FN4J	Strong	Biomarker	[328]
MAP3K20	TTTUZ3O	Strong	Altered Expression	[329]
MAP3K5	TTOQCD8	Strong	Biomarker	[330]
MAP3K8	TTGECUM	Strong	Biomarker	[331]
MAPK7	TTU6FSC	Strong	Biomarker	[332]
MAPK8IP1	TTXKZ8Q	Strong	Biomarker	[261]
MAPKAP1	TTWDKCL	Strong	Biomarker	[333]
MCAM	TTHRE05	Strong	Altered Expression	[334]
MCL1	TTL53M6	Strong	Biomarker	[335]
MDK	TTV8UE7	Strong	Altered Expression	[336]
MDM4	TT9OUDQ	Strong	Biomarker	[337]
MELK	TTBZOTY	Strong	Biomarker	[230]
MGLL	TTZ963I	Strong	Biomarker	[338]
MMP11	TTZW4MV	Strong	Altered Expression	[339]
MMP13	TTHY57M	Strong	Altered Expression	[340]
MMP16	TTNP4CU	Strong	Biomarker	[341]
MMP7	TTMTWOS	Strong	Biomarker	[342]
MTA1	TTO4HUS	Strong	Altered Expression	[343]
MTAP	TTDBX7N	Strong	Genetic Variation	[344]
MTNR1A	TT0WAIE	Strong	Altered Expression	[345]
MYCN	TT9JBY5	Strong	Genetic Variation	[346]
NES	TTHZ752	Strong	Altered Expression	[347]
NME1	TTDY8JH	Strong	Altered Expression	[348]
NNT	TTKIH76	Strong	Biomarker	[349]
NOTCH3	TTVX7IA	Strong	Altered Expression	[342]
NPPB	TTY63XT	Strong	Altered Expression	[317]
NR1H2	TTXA6PH	Strong	Genetic Variation	[350]
NR1H3	TTECBXN	Strong	Altered Expression	[351]
NR1I2	TT7LCTF	Strong	Biomarker	[352]
NR1I3	TTRANFM	Strong	Biomarker	[353]
NR3C1	TTOZRK6	Strong	Genetic Variation	[354]
NR5A2	TTAU3SY	Strong	Biomarker	[355]
NRP1	TTIPJCB	Strong	Altered Expression	[356]
ODC1	TTUMGNO	Strong	Biomarker	[357]
OXTR	TTSCIUP	Strong	Biomarker	[358]
P2RY2	TTOZHQC	Strong	Altered Expression	[359]
PARG	TT39J16	Strong	Biomarker	[213]
PDCD1LG2	TTW14O3	Strong	Biomarker	[324]
PDGFA	TTSM78N	Strong	Biomarker	[360]
PDK1	TTCZOF2	Strong	Biomarker	[361]
PECAM1	TT4EZB2	Strong	Altered Expression	[362]
PFKFB3	TTTHMQJ	Strong	Altered Expression	[363]
PGC	TT7K6AD	Strong	Altered Expression	[364]
PIM1	TTTN5QW	Strong	Biomarker	[365]
PKM	TT4LOT8	Strong	Biomarker	[366]
PLD1	TT3T17P	Strong	Altered Expression	[182]
PLK2	TT976FS	Strong	Altered Expression	[234]
PLK4	TTGPNZQ	Strong	Biomarker	[367]
PLXDC1	TTPSK7A	Strong	Altered Expression	[368]
PML	TTLH9NY	Strong	Biomarker	[118]
POLA1	TTGPJ0U	Strong	Biomarker	[369]
PPM1D	TTENJAB	Strong	Biomarker	[370]
PRAME	TTPH7T0	Strong	Biomarker	[371]
PRKCG	TTRFOXJ	Strong	Genetic Variation	[372]
PRLR	TTBPXMA	Strong	Altered Expression	[373]
PSMD10	TT2H4LN	Strong	Altered Expression	[374]
PTGER1	TTG1QMU	Strong	Biomarker	[375]
PTH1R	TTFPD47	Strong	Biomarker	[87]
PTN	TTA9EJK	Strong	Altered Expression	[376]
PTPN7	TT2C1DT	Strong	Altered Expression	[254]
RAB22A	TTAJ746	Strong	Biomarker	[377]
RAD51	TTC0G1L	Strong	Biomarker	[378]
RBPJ	TT72D4Z	Strong	Biomarker	[379]
RHAG	TTVHFE8	Strong	Biomarker	[380]
RIPK1	TTVJHX8	Strong	Biomarker	[381]
ROCK2	TTGWKQJ	Strong	Biomarker	[92]
ROR2	TTUDPCI	Strong	Biomarker	[382]
ROS1	TTSZ6Y3	Strong	Biomarker	[383]
RPE65	TTBOH16	Strong	Altered Expression	[384]
RPS6KA3	TTUM2ZR	Strong	Biomarker	[385]
S100A12	TTQ4ESF	Strong	Biomarker	[386]
S100A6	TT716MY	Strong	Biomarker	[387]
S1PR3	TTDYP7I	Strong	Biomarker	[388]
SATB1	TTLFRIC	Strong	Biomarker	[389]
SCN8A	TT54ERL	Strong	Altered Expression	[390]
SENP1	TTW9HY5	Strong	Altered Expression	[391]
SERPINF1	TTR59S1	Strong	Biomarker	[392]
SF3B1	TTL2WUI	Strong	Biomarker	[393]
SIRT1	TTUF2HO	Strong	Biomarker	[394]
SIRT6	TTUXYWF	Strong	Biomarker	[395]
SLC1A3	TT8WRDA	Strong	Altered Expression	[396]
SLC22A2	TT0XOJN	Strong	Altered Expression	[397]
SLC2A4	TTP6MT5	Strong	Altered Expression	[398]
SLC7A11	TTBZMIO	Strong	Biomarker	[399]
SLCO1B1	TTFGXEB	Strong	Genetic Variation	[400]
SMAD1	TT9GR53	Strong	Altered Expression	[401]
SMAD7	TT0J32Z	Strong	Altered Expression	[402]
SMPD2	TTE5VI6	Strong	Biomarker	[403]
SOST	TTYRO4F	Strong	Altered Expression	[404]
SOX5	TTXHSZK	Strong	Biomarker	[405]
SP1	TTZEP6S	Strong	Altered Expression	[406]
SQSTM1	TTOT2RY	Strong	Autosomal dominant	[407]
SRC	TT6PKBN	Strong	Altered Expression	[133]
STRAP	TT165DP	Strong	Biomarker	[408]
STS	TTHM0R1	Strong	Biomarker	[409]
TACC3	TTQ4UFD	Strong	Altered Expression	[410]
TBL1XR1	TTYXT16	Strong	Altered Expression	[411]
TERF1	TT1Y6J2	Strong	Genetic Variation	[412]
TERF2	TT5XSLT	Strong	Biomarker	[412]
TGFB2	TTI0KH6	Strong	Biomarker	[413]
TGFBR1	TTP4520	Strong	Altered Expression	[304]
THBS1	TTKI0H1	Strong	Biomarker	[40]
TMSB4X	TTMVAIU	Strong	Altered Expression	[414]
TNFRSF10A	TT5WLRX	Strong	Biomarker	[415]
TNFRSF10B	TTW20TU	Strong	Biomarker	[416]
TNFRSF13C	TT7NJSE	Strong	Altered Expression	[417]
TNFRSF25	TTDV6BQ	Strong	Biomarker	[418]
TNFRSF9	TTPW9LJ	Strong	Biomarker	[194]
TNKS	TTVUSO7	Strong	Altered Expression	[419]
TOP1	TTGTQHC	Strong	Biomarker	[420]
TRAF6	TTCDR6M	Strong	Biomarker	[421]
TRIM27	TTTO3QN	Strong	Biomarker	[271]
TRIM37	TTAMCSL	Strong	Altered Expression	[422]
TRPM8	TTXDKTO	Strong	Biomarker	[423]
TRPV1	TTMI6F5	Strong	Altered Expression	[424]
TWIST1	TTX1MY7	Strong	Altered Expression	[425]
TXNRD1	TTR7UJ3	Strong	Altered Expression	[426]
UBE2T	TT0A1R8	Strong	Biomarker	[427]
ULK1	TT4D7MJ	Strong	Biomarker	[428]
USP1	TTG9MT5	Strong	Altered Expression	[429]
USP7	TTXU3EQ	Strong	Biomarker	[430]
VCP	TTHNLSB	Strong	Biomarker	[431]
VEGFD	TTOM5H4	Strong	Altered Expression	[432]
VWF	TT3SZBT	Strong	Biomarker	[433]
WEE1	TTJFOAL	Strong	Altered Expression	[107]
WNK1	TTJ9UMX	Strong	Altered Expression	[370]
WNT5A	TTKG7F8	Strong	Biomarker	[434]
WRN	TT2H5WQ	Strong	Biomarker	[435]
WT1	TTZ8UT4	Strong	Altered Expression	[436]
XPA	TTGT87E	Strong	Genetic Variation	[437]
XRCC5	TTCB9KW	Strong	Biomarker	[438]
ZEB2	TTT2WK4	Strong	Altered Expression	[439]
ALOX5AP	TTDMBF5	Definitive	Biomarker	[235]
ANO1	TTOJI4S	Definitive	Biomarker	[440]
CD276	TT6CQUM	Definitive	Altered Expression	[441]
CDC25A	TTLZS4Q	Definitive	Biomarker	[442]
CDK12	TTJ21A9	Definitive	Biomarker	[443]
COPS5	TTSTNJR	Definitive	Biomarker	[444]
FBXO11	TT6G10V	Definitive	Biomarker	[445]
FZD7	TTUQMO5	Definitive	Altered Expression	[446]
HDGF	TTKGV26	Definitive	Altered Expression	[447]
HOXA13	TTN26OM	Definitive	Biomarker	[381]
ITCH	TT5SEWD	Definitive	Altered Expression	[448]
JUN	TTS7IR5	Definitive	Altered Expression	[449]
KAT2B	TTVK7SB	Definitive	Biomarker	[201]
LRP6	TTSXOWE	Definitive	Biomarker	[450]
NPEPPS	TT371QC	Definitive	Biomarker	[315]
OLR1	TTKSND3	Definitive	Biomarker	[451]
PDGFB	TTQA6SX	Definitive	Altered Expression	[452]
RHOB	TT6LPFO	Definitive	Biomarker	[453]
SLC16A3	TTG6VD5	Definitive	Altered Expression	[454]
SLC1A1	TTG2A6F	Definitive	Biomarker	[455]
SLC29A1	TTLXAKE	Definitive	Biomarker	[456]
SOX2	TTCNOT6	Definitive	Biomarker	[457]
STAR	TTEI40H	Definitive	Biomarker	[458]
STK39	TTYQTIU	Definitive	Biomarker	[459]
TNFRSF11B	TT2CJ75	Definitive	Altered Expression	[112]
TNFSF11	TT9E8HR	Definitive	Biomarker	[112]

This Disease Is Related to 8 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ABCC5	DTYVM24	Limited	Biomarker	[44]
SLC25A22	DTJCWP8	Limited	Altered Expression	[460]
ABCB6	DTF9Y2V	Strong	Biomarker	[461]
SLC20A1	DTMULXV	Strong	Altered Expression	[462]
SLC20A2	DTFD4VB	Strong	Altered Expression	[462]
SLC25A3	DTCRIWV	Strong	Altered Expression	[463]
SLCO6A1	DTIFXNS	Strong	Altered Expression	[201]
SLC31A1	DTP8L4F	Definitive	Biomarker	[464]

This Disease Is Related to 21 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
EGLN3	DEMQTKH	Limited	Biomarker	[465]
GLDC	DEIN8FB	Limited	Genetic Variation	[466]
NAT10	DEZV4AP	Limited	Biomarker	[21]
PCYT1A	DEQYXD4	Limited	Altered Expression	[467]
ALDH1B1	DEXI4UQ	Disputed	Biomarker	[468]
COLGALT2	DE8RIZD	moderate	Biomarker	[469]
THOP1	DE95LJC	moderate	Altered Expression	[470]
AKR1C1	DE7P2FB	Strong	Biomarker	[128]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[109]
CES2	DETHCPD	Strong	Genetic Variation	[471]
DTYMK	DEOTVYU	Strong	Genetic Variation	[472]
FPGS	DECWT2V	Strong	Biomarker	[473]
GLS	DE3E0VT	Strong	Biomarker	[474]
HSD17B10	DEGSPC9	Strong	Biomarker	[475]
MAT2B	DEKF1OH	Strong	Biomarker	[476]
MT2A	DEFKGT7	Strong	Altered Expression	[477]
NT5C2	DE1DOKJ	Strong	Altered Expression	[478]
SULT1A3	DEP7E8X	Strong	Biomarker	[479]
SULT1E1	DESTKG6	Strong	Biomarker	[331]
FADS1	DE05S8C	Definitive	Altered Expression	[480]
PSAT1	DEBS17P	Definitive	Biomarker	[315]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02502786) Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7731).
• [4] Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
• [5] ClinicalTrials.gov (NCT04886765) A Phase I/II, Multi-center, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ALMB-0168 in Patients With Osteosarcoma. U.S.National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] ClinicalTrials.gov (NCT02107963) A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors
• [8] ClinicalTrials.gov (NCT01953900) iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
• [9] ClinicalTrials.gov (NCT03612466) A Dose Finding Study of CycloSam Combined With External Beam Radiotherapy. U.S. National Institutes of Health.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027277)
• [11] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [12] Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017 Aug;13(8):480-491. doi: 10.1038/nrendo.2017.16. Epub 2017 Mar 24.
• [13] CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment.Tumour Biol. 2017 May;39(5):1010428317701631. doi: 10.1177/1010428317701631.
• [14] Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of NF-B and osteosarcoma progression.Nat Commun. 2016 Nov 25;7:13561. doi: 10.1038/ncomms13561.
• [15] Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes. PLoS One. 2015 Jul 10;10(7):e0131998.
• [16] Long non-coding RNA small nucleolar RNA host gene 12 (SNHG12) promotes cell proliferation and migration by upregulating angiomotin gene expression in human osteosarcoma cells.Tumour Biol. 2016 Mar;37(3):4065-73. doi: 10.1007/s13277-015-4256-7. Epub 2015 Oct 20.
• [17] Overexpressing circular RNA hsa_circ_0002052 impairs osteosarcoma progression via inhibiting Wnt/-catenin pathway by regulating miR-1205/APC2 axis.Biochem Biophys Res Commun. 2018 Aug 25;502(4):465-471. doi: 10.1016/j.bbrc.2018.05.184. Epub 2018 Jun 5.
• [18] MicroRNA-765 sensitizes osteosarcoma cells to cisplatin via downregulating APE1 expression.Onco Targets Ther. 2019 Sep 3;12:7203-7214. doi: 10.2147/OTT.S194800. eCollection 2019.
• [19] MicroRNA-488 inhibits proliferation, invasion and EMT in osteosarcoma cell lines by targeting aquaporin 3.Int J Oncol. 2018 Oct;53(4):1493-1504. doi: 10.3892/ijo.2018.4483. Epub 2018 Jul 16.
• [20] Hypoxic Proliferation of Osteosarcoma Cells Depends on Arginase II.Cell Physiol Biochem. 2016;39(2):802-13. doi: 10.1159/000447790. Epub 2016 Aug 1.
• [21] Lung cells support osteosarcoma cell migration and survival.BMC Cancer. 2017 Jan 25;17(1):78. doi: 10.1186/s12885-017-3047-5.
• [22] Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/-catenin signaling pathway.J Orthop Res. 2019 Jul;37(7):1638-1648. doi: 10.1002/jor.24244. Epub 2019 Mar 28.
• [23] Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma.Pathol Oncol Res. 2020 Apr;26(2):1041-1048. doi: 10.1007/s12253-019-00645-w. Epub 2019 Apr 13.
• [24] The effect of bone morphogenetic protein-7 on the expression of type I inositol 1,4,5-trisphosphate receptor in G-292 osteosarcoma cells and primary osteoblast cultures.Arch Oral Biol. 2000 Feb;45(2):159-66. doi: 10.1016/s0003-9969(99)00122-3.
• [25] The Overexpression of CARM1 Promotes Human Osteosarcoma Cell Proliferation through the pGSK3/-Catenin/cyclinD1 Signaling Pathway.Int J Biol Sci. 2017 Jul 18;13(8):976-984. doi: 10.7150/ijbs.19191. eCollection 2017.
• [26] CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.J Cell Physiol. 2019 Jun;234(6):9297-9307. doi: 10.1002/jcp.27611. Epub 2018 Oct 14.
• [27] Advances in immune checkpoint inhibitors for bone sarcoma therapy.J Bone Oncol. 2019 Jan 29;15:100221. doi: 10.1016/j.jbo.2019.100221. eCollection 2019 Apr.
• [28] An Unexpected Role of Hyaluronic Acid in Trafficking siRNA Across the Cellular Barrier: The First Biomimetic, Anionic, Non-Viral Transfection Method.Angew Chem Int Ed Engl. 2019 Feb 25;58(9):2815-2819. doi: 10.1002/anie.201900099. Epub 2019 Jan 31.
• [29] Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: a network meta-analysis of randomized controlled trials.J Orthop Surg Res. 2017 Mar 29;12(1):52. doi: 10.1186/s13018-017-0544-9.
• [30] The antibody-drug conjugate target landscape across a broad range of tumour types.Ann Oncol. 2017 Dec 1;28(12):3083-3091. doi: 10.1093/annonc/mdx541.
• [31] Diosgenin exerts its tumor suppressive function via inhibition of Cdc20 in osteosarcoma cells.Cell Cycle. 2019 Feb;18(3):346-358. doi: 10.1080/15384101.2019.1568748. Epub 2019 Jan 22.
• [32] The cyclin-dependent kinase inhibitor flavopiridol (alvocidib) inhibits metastasis of human osteosarcoma cells.Oncotarget. 2018 May 4;9(34):23505-23518. doi: 10.18632/oncotarget.25239. eCollection 2018 May 4.
• [33] Transcriptional activation of CBF by CDK11(p110) is necessary to promote osteosarcoma cell proliferation.Cell Commun Signal. 2019 Oct 14;17(1):125. doi: 10.1186/s12964-019-0440-5.
• [34] miR?94 inhibits cell proliferation and metastasis via targeting of CDK6 in osteosarcoma.Mol Med Rep. 2017 Dec;16(6):8627-8634. doi: 10.3892/mmr.2017.7709. Epub 2017 Oct 4.
• [35] Downregulation of microRNA-95-3p suppresses cell growth of osteosarcoma via CDKN1A/p21 expression.Oncol Rep. 2018 Jan;39(1):289-297. doi: 10.3892/or.2017.6065. Epub 2017 Nov 1.
• [36] CEACAM6 is associated with osteosarcoma metastasis and facilitates epithelial-mesenchymal transition in osteosarcoma cells.Onco Targets Ther. 2018 May 28;11:3159-3166. doi: 10.2147/OTT.S161807. eCollection 2018.
• [37] Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.Mol Cancer Ther. 2017 Apr;16(4):694-704. doi: 10.1158/1535-7163.MCT-16-0504. Epub 2017 Jan 30.
• [38] Licochalcone A Suppresses the Proliferation of Osteosarcoma Cells through Autophagy and ATM-Chk2 Activation.Molecules. 2019 Jul 2;24(13):2435. doi: 10.3390/molecules24132435.
• [39] Rh-endostatin Concomitant with Chemotherapy Versus Single Agent Chemotherapy for Treating Soft Tissue and Bone Sarcomas: A Systematic Review and Meta-Analysis.J Pharm Pharm Sci. 2018;21(1):386-397. doi: 10.18433/jpps30034.
• [40] Artemisinin inhibits angiogenesis by regulating p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma.J Cell Biochem. 2019 Jul;120(7):11462-11470. doi: 10.1002/jcb.28424. Epub 2019 Feb 11.
• [41] Cry 1 Regulates the Clock Gene Network and Promotes Proliferation and Migration Via the Akt/P53/P21 Pathway in Human Osteosarcoma Cells.J Cancer. 2018 Jun 14;9(14):2480-2491. doi: 10.7150/jca.25213. eCollection 2018.
• [42] Cryptochrome 2 (CRY2) Suppresses Proliferation and Migration and Regulates Clock Gene Network in Osteosarcoma Cells.Med Sci Monit. 2018 Jun 7;24:3856-3862. doi: 10.12659/MSM.908596.
• [43] CSE1L interaction with MSH6 promotes osteosarcoma progression and predicts poor patient survival.Sci Rep. 2017 Apr 7;7:46238. doi: 10.1038/srep46238.
• [44] Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma.J Bone Oncol. 2018 May 3;12:44-48. doi: 10.1016/j.jbo.2018.04.003. eCollection 2018 Sep.
• [45] Downregulation of DEPTOR inhibits the proliferation, migration, and survival of osteosarcoma through PI3K/Akt/mTOR pathway.Onco Targets Ther. 2017 Sep 8;10:4379-4391. doi: 10.2147/OTT.S143518. eCollection 2017.
• [46] DGKZ Acts as a Potential Oncogene in Osteosarcoma Proliferation Through Its Possible Interaction With ERK1/2 and MYC Pathway.Front Oncol. 2019 Jan 4;8:655. doi: 10.3389/fonc.2018.00655. eCollection 2018.
• [47] LncRNA DLX6-AS1/miR-129-5p/DLK1 axis aggravates stemness of osteosarcoma through Wnt signaling.Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):260-266. doi: 10.1016/j.bbrc.2018.11.019. Epub 2018 Nov 13.
• [48] A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma.Acta Biomater. 2019 Apr 15;89:372-381. doi: 10.1016/j.actbio.2019.02.051. Epub 2019 Mar 2.
• [49] MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7.PLoS One. 2017 Jun 12;12(6):e0175553. doi: 10.1371/journal.pone.0175553. eCollection 2017.
• [50] Kinesins in MAPK cascade: How kinesin motors are involved in the MAPK pathway?.Gene. 2019 Feb 5;684:1-9. doi: 10.1016/j.gene.2018.10.042. Epub 2018 Oct 17.
• [51] Clinicopathological and prognostic values of ErbB receptor family amplification in primary osteosarcoma.Scand J Clin Lab Invest. 2019 Dec;79(8):601-612. doi: 10.1080/00365513.2019.1683764. Epub 2019 Oct 30.
• [52] Curcumin Promotes Osteosarcoma Cell Death by Activating miR-125a/ERR Signal Pathway.J Cell Biochem. 2017 Jan;118(1):74-81. doi: 10.1002/jcb.25612. Epub 2016 Jun 3.
• [53] miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2.Artif Cells Nanomed Biotechnol. 2018;46(sup3):S1004-S1010. doi: 10.1080/21691401.2018.1525391. Epub 2018 Nov 19.
• [54] In-vitro cytocompatibility of dental resin monomers on osteoblast-like cells.J Dent. 2017 Oct;65:76-82. doi: 10.1016/j.jdent.2017.07.008. Epub 2017 Jul 12.
• [55] Different effects of G-protein-coupled receptor 120 (GPR120) and GPR40 on cell motile activity of highly migratory osteosarcoma cells.Biochem Biophys Res Commun. 2017 Mar 11;484(3):675-680. doi: 10.1016/j.bbrc.2017.01.175. Epub 2017 Jan 31.
• [56] FOS Expression in Osteoid Osteoma and Osteoblastoma: A Valuable Ancillary Diagnostic Tool.Am J Surg Pathol. 2019 Dec;43(12):1661-1667. doi: 10.1097/PAS.0000000000001355.
• [57] miR-181d-5p-FOXP1 feedback loop modulates the progression of osteosarcoma.Biochem Biophys Res Commun. 2018 Sep 10;503(3):1434-1441. doi: 10.1016/j.bbrc.2018.07.060. Epub 2018 Jul 19.
• [58] Identification of Key Genes and miRNAs in Osteosarcoma Patients with Chemoresistance by Bioinformatics Analysis.Biomed Res Int. 2018 Apr 22;2018:4761064. doi: 10.1155/2018/4761064. eCollection 2018.
• [59] Human Galectin-1 and its inhibitors: Privileged target for cancer and HIV. Mini Rev Med Chem. 2019 Mar 4.
• [60] miR-141-3p suppresses proliferation and promotes apoptosis by targeting GLI2 in osteosarcoma cells.Oncol Rep. 2018 Feb;39(2):747-754. doi: 10.3892/or.2017.6150. Epub 2017 Dec 12.
• [61] Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.Pediatr Blood Cancer. 2016 Jan;63(1):32-8. doi: 10.1002/pbc.25688. Epub 2015 Aug 25.
• [62] Small interfering RNA-mediated silencing of G-protein-coupled receptor 137 inhibits growth of osteosarcoma cells.J Bone Oncol. 2017 Dec 23;11:17-22. doi: 10.1016/j.jbo.2017.12.001. eCollection 2018 Jun.
• [63] GRM4 inhibits the proliferation, migration, and invasion of human osteosarcoma cells through interaction with CBX4.Biosci Biotechnol Biochem. 2020 Feb;84(2):279-289. doi: 10.1080/09168451.2019.1673147. Epub 2019 Oct 4.
• [64] microRNA-758 inhibits the malignant phenotype of osteosarcoma cells by directly targeting HMGA1 and deactivating the Wnt/-catenin pathway.Am J Cancer Res. 2019 Jan 1;9(1):36-52. eCollection 2019.
• [65] Prognostic role of HSF1 overexpression in solid tumors: a pooled analysis of 3,159 patients.Onco Targets Ther. 2018 Jan 17;11:383-393. doi: 10.2147/OTT.S153682. eCollection 2018.
• [66] Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.J Clin Endocrinol Metab. 2017 Sep 1;102(9):3480-3490. doi: 10.1210/jc.2017-00558.
• [67] The Wilms tumor protein WT1 stimulates transcription of the gene encoding insulin-like growth factor binding protein 5 (IGFBP5).Gene. 2017 Jul 1;619:21-29. doi: 10.1016/j.gene.2017.03.037. Epub 2017 Mar 30.
• [68] Synergistic suppression of a disintegrin acurhagin-C in combination with AZD4547 and reparixin on terminating development for human osteosarcoma MG-63 cell.Biochem Biophys Res Commun. 2017 Oct 21;492(3):513-519. doi: 10.1016/j.bbrc.2017.08.046. Epub 2017 Aug 18.
• [69] NF-B signaling and integrin-1 inhibition attenuates osteosarcoma metastasis via increased cell apoptosis.Int J Biol Macromol. 2019 Feb 15;123:1035-1043. doi: 10.1016/j.ijbiomac.2018.11.003. Epub 2018 Nov 3.
• [70] Observation of significant biomarkers in osteosarcoma via integrating module- identification method with attract.Cancer Biomark. 2017 Jul 19;20(1):87-93. doi: 10.3233/CBM-170144.
• [71] Inhibition of STAT3 blocks protein synthesis and tumor metastasis in osteosarcoma cells.J Exp Clin Cancer Res. 2018 Oct 4;37(1):244. doi: 10.1186/s13046-018-0914-0.
• [72] Single-walled carbon nanotube: One specific inhibitor of cancer stem cells in osteosarcoma upon downregulation of the TGF1 signaling.Biomaterials. 2017 Dec;149:29-40. doi: 10.1016/j.biomaterials.2017.09.032. Epub 2017 Sep 26.
• [73] MALT1 is a critical mediator of PAR1-driven NF-B activation and metastasis in multiple tumor types.Oncogene. 2019 Dec;38(49):7384-7398. doi: 10.1038/s41388-019-0958-4. Epub 2019 Aug 16.
• [74] miR-187 inhibits tumor growth and invasion by directly targeting MAPK12 in osteosarcoma.Exp Ther Med. 2017 Aug;14(2):1045-1050. doi: 10.3892/etm.2017.4624. Epub 2017 Jun 16.
• [75] miR?4c?p acts as a tumor suppressor gene in osteosarcoma by targeting MARCKS.Mol Med Rep. 2017 Mar;15(3):1204-1210. doi: 10.3892/mmr.2017.6108. Epub 2017 Jan 11.
• [76] Overexpression of long non-coding RNA MFI2 promotes cell proliferation and suppresses apoptosis in human osteosarcoma.Oncol Rep. 2016 Oct;36(4):2033-40. doi: 10.3892/or.2016.5013. Epub 2016 Aug 11.
• [77] miR-134 inhibits osteosarcoma cell invasion and metastasis through targeting MMP1 and MMP3 invitro and invivo.FEBS Lett. 2019 May;593(10):1089-1101. doi: 10.1002/1873-3468.13387. Epub 2019 May 8.
• [78] Knockdown of MSI1 inhibited the cell proliferation of human osteosarcoma cells by targeting p21 and p27.Oncol Lett. 2017 Nov;14(5):5271-5278. doi: 10.3892/ol.2017.6870. Epub 2017 Sep 1.
• [79] Met interacts with EGFR and Ron in canine osteosarcoma.Vet Comp Oncol. 2013 Jun;11(2):124-39. doi: 10.1111/j.1476-5829.2011.00309.x. Epub 2011 Dec 8.
• [80] Overexpression of GRIM-19 accelerates radiation-induced osteosarcoma cells apoptosis by p53 stabilization.Life Sci. 2018 Sep 1;208:232-238. doi: 10.1016/j.lfs.2018.07.015. Epub 2018 Jul 10.
• [81] Silencing of NUF2 inhibits proliferation of human osteosarcoma Saos-2 cells.Eur Rev Med Pharmacol Sci. 2016;20(6):1071-9.
• [82] CCEPR is a novel clinical biomarker for prognosis and regulates cell proliferation through PCNA in osteosarcoma.J Cell Biochem. 2019 Aug;120(8):12796-12802. doi: 10.1002/jcb.28550. Epub 2019 Mar 12.
• [83] The prognostic significance of circulating serum amyloid A and CXC chemokine ligand 4 in osteosarcoma.Pediatr Blood Cancer. 2017 Dec;64(12):10.1002/pbc.26659. doi: 10.1002/pbc.26659. Epub 2017 May 24.
• [84] PLK1 contributes to autophagy by regulating MYC stabilization in osteosarcoma cells.Onco Targets Ther. 2019 Sep 12;12:7527-7536. doi: 10.2147/OTT.S210575. eCollection 2019.
• [85] PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer.Cancer Res. 2017 Sep 1;77(17):4613-4625. doi: 10.1158/0008-5472.CAN-17-0216. Epub 2017 Jun 27.
• [86] LncRNA HIF2PUT inhibited osteosarcoma stem cells proliferation, migration and invasion by regulating HIF2 expression.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1342-1348. doi: 10.1080/21691401.2019.1596934.
• [87] PTHR1 May Be Involved in Progression of Osteosarcoma by Regulating miR-124-3p-AR-Tgfb1i1, miR-27a-3p-PPARG-Abca1, and miR-103/590-3p-AXIN2 Axes.DNA Cell Biol. 2019 Nov;38(11):1323-1337. doi: 10.1089/dna.2019.4880. Epub 2019 Sep 19.
• [88] Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.Technol Cancer Res Treat. 2018 Jan-Dec;18:1533033819853262. doi: 10.1177/1533033819853262.
• [89] Clinicopathological Features of a Series of 27 Cases of Post-Denosumab Treated Giant Cell Tumors of Bones: A Single Institutional Experience at a Tertiary Cancer Referral Centre, India.Pathol Oncol Res. 2017 Jan;23(1):157-164. doi: 10.1007/s12253-016-0123-0. Epub 2016 Oct 8.
• [90] Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma.Clin Sci (Lond). 2016 Jun 1;130(11):921-30. doi: 10.1042/CS20150509. Epub 2016 Mar 18.
• [91] Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma.Future Oncol. 2017 Sep;13(21):1883-1891. doi: 10.2217/fon-2017-0180. Epub 2017 Aug 2.
• [92] microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma.Pathol Oncol Res. 2020 Apr;26(2):877-883. doi: 10.1007/s12253-019-00633-0. Epub 2019 Mar 12.
• [93] RSF1 functions as an oncogene in osteosarcoma and is regulated by XIST/miR-193a-3p axis.Biomed Pharmacother. 2017 Nov;95:207-214. doi: 10.1016/j.biopha.2017.08.068. Epub 2017 Sep 12.
• [94] MicroRNA-187 Inhibits Growth and Metastasis of Osteosarcoma by Downregulating S100A4.Cancer Invest. 2018 Jan 2;36(1):1-9. doi: 10.1080/07357907.2017.1415348. Epub 2018 Jan 5.
• [95] MiR-20a-5p represses the multi-drug resistance of osteosarcoma by targeting the SDC2 gene.Cancer Cell Int. 2017 Nov 2;17:100. doi: 10.1186/s12935-017-0470-2. eCollection 2017.
• [96] Bidirectional regulation of bone formation by exogenous and osteosarcoma-derived Sema3A.Sci Rep. 2018 May 2;8(1):6877. doi: 10.1038/s41598-018-25290-2.
• [97] Essential role of SH3GL1 in interleukin-6(IL-6)- and vascular endothelial growth factor (VEGF)-triggered p130(cas)-mediated proliferation and migration of osteosarcoma cells.Hum Cell. 2017 Oct;30(4):300-310. doi: 10.1007/s13577-017-0178-6. Epub 2017 Jul 12.
• [98] S-phase kinase-associated protein 2 is involved in epithelial-mesenchymal transition in methotrexate-resistant osteosarcoma cells.Int J Oncol. 2018 Jun;52(6):1841-1852. doi: 10.3892/ijo.2018.4345. Epub 2018 Mar 29.
• [99] OS9 Protein Interacts with Na-K-2Cl Co-transporter (NKCC2) and Targets Its Immature Form for the Endoplasmic Reticulum-associated Degradation Pathway.J Biol Chem. 2016 Feb 26;291(9):4487-502. doi: 10.1074/jbc.M115.702514. Epub 2015 Dec 31.
• [100] Association of SNPs in dopamine and serotonin pathway genes and their interacting genes with temperament traits in Charolais cows.J Appl Genet. 2017 Aug;58(3):363-371. doi: 10.1007/s13353-016-0383-0. Epub 2016 Dec 16.
• [101] SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.DNA Cell Biol. 2017 Sep;36(9):775-780. doi: 10.1089/dna.2017.3750. Epub 2017 Aug 4.
• [102] Increased SNAT1 is a marker of human osteosarcoma and potential therapeutic target.Oncotarget. 2017 Sep 5;8(45):78930-78939. doi: 10.18632/oncotarget.20693. eCollection 2017 Oct 3.
• [103] SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway.Oncol Rep. 2017 May;37(5):2575-2582. doi: 10.3892/or.2017.5530. Epub 2017 Mar 27.
• [104] SphK2 over-expression promotes osteosarcoma cell growth.Oncotarget. 2017 Nov 6;8(62):105525-105535. doi: 10.18632/oncotarget.22314. eCollection 2017 Dec 1.
• [105] SPOCK1 promotes the growth of Osteosarcoma cells through mTOR-S6K signaling pathway.Biomed Pharmacother. 2017 Nov;95:564-570. doi: 10.1016/j.biopha.2017.08.116. Epub 2017 Sep 12.
• [106] MiR-193a-3p and miR-193a-5p suppress the metastasis of human osteosarcoma cells by down-regulating Rab27B and SRR, respectively. Clin Exp Metastasis. 2016 Apr;33(4):359-72.
• [107] p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma.Sci Rep. 2019 Apr 16;9(1):6161. doi: 10.1038/s41598-019-42450-0.
• [108] TROP2 promotes cell proliferation and migration in osteosarcoma through PI3K/AKT signaling.Mol Med Rep. 2018 Aug;18(2):1782-1788. doi: 10.3892/mmr.2018.9083. Epub 2018 May 29.
• [109] Tegavivint and the beta-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma. J Natl Cancer Inst. 2019 Nov 1;111(11):1216-1227.
• [110] Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells.BMB Rep. 2013 Feb;46(2):113-8. doi: 10.5483/bmbrep.2013.46.2.150.
• [111] Genetic and molecular aspects of osteosarcoma. J Musculoskelet Neuronal Interact. 2002 Dec;2(6):554-60.
• [112] The Intrinsic and Extrinsic Implications of RANKL/RANK Signaling in Osteosarcoma: From Tumor Initiation to Lung Metastases.Cancers (Basel). 2018 Oct 24;10(11):398. doi: 10.3390/cancers10110398.
• [113] miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma.Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418786656. doi: 10.1177/2058738418786656.
• [114] Author Correction: Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation.Exp Mol Med. 2018 Aug 17;50(8):1-3. doi: 10.1038/s12276-018-0127-9.
• [115] miR-24 represses metastasis of human osteosarcoma cells by targeting Ack1 via AKT/MMPs pathway.Biochem Biophys Res Commun. 2017 Apr 29;486(2):211-217. doi: 10.1016/j.bbrc.2017.02.045. Epub 2017 Feb 8.
• [116] Identification of Novel Target for Osteosarcoma by Network Analysis.Med Sci Monit. 2018 Aug 25;24:5914-5924. doi: 10.12659/MSM.909973.
• [117] mTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells.Mol Cells. 2014 Feb;37(2):118-25. doi: 10.14348/molcells.2014.2247. Epub 2014 Feb 19.
• [118] DNA-damage response in chromatin of ribosomal genes and the surrounding genome.Gene. 2013 Jun 15;522(2):156-67. doi: 10.1016/j.gene.2013.03.108. Epub 2013 Apr 6.
• [119] siRNA targeting TCTP suppresses osteosarcoma cell growth and induces apoptosis in vitro and in vivo.Biotechnol Appl Biochem. 2016 Jan-Feb;63(1):5-14. doi: 10.1002/bab.1335. Epub 2015 Dec 22.
• [120] The Alzheimer's disease-associated TREM2 gene is regulated by p53 tumor suppressor protein.Neurosci Lett. 2018 Aug 10;681:62-67. doi: 10.1016/j.neulet.2018.05.037. Epub 2018 May 26.
• [121] Suppression of ERK/NF-B Activation Is Associated With Amentoflavone-Inhibited Osteosarcoma Progression In Vivo.Anticancer Res. 2019 Jul;39(7):3669-3675. doi: 10.21873/anticanres.13515.
• [122] miR-1285-3p is a potential prognostic marker in human osteosarcoma and functions as a tumor suppressor by targeting YAP1.Cancer Biomark. 2019;25(1):1-10. doi: 10.3233/CBM-180013.
• [123] miR-422a inhibits osteosarcoma proliferation by targeting BCL2L2 and KRAS.Biosci Rep. 2018 Mar 21;38(2):BSR20170339. doi: 10.1042/BSR20170339. Print 2018 Apr 27.
• [124] Lycorine Induces Apoptosis and G1 Phase Arrest Through ROS/p38 MAPK Signaling Pathway in Human Osteosarcoma Cells In Vitro and In Vivo.Spine (Phila Pa 1976). 2020 Feb 1;45(3):E126-E139. doi: 10.1097/BRS.0000000000003217.
• [125] miR-223-3p Inhibits Human Osteosarcoma Metastasis and Progression by Directly Targeting CDH6.Mol Ther. 2018 May 2;26(5):1299-1312. doi: 10.1016/j.ymthe.2018.03.009. Epub 2018 Mar 14.
• [126] Network Pharmacology Integrated Molecular Docking Reveals the Antiosteosarcoma Mechanism of Biochanin A.Evid Based Complement Alternat Med. 2019 Jan 6;2019:1410495. doi: 10.1155/2019/1410495. eCollection 2019.
• [127] Clinicopathological and prognostic values of fibronectin and integrin v3 expression in primary osteosarcoma.World J Surg Oncol. 2019 Jan 28;17(1):23. doi: 10.1186/s12957-019-1566-z.
• [128] Avasimibe inhibits tumor growth by targeting FoxM1-AKR1C1 in osteosarcoma.Onco Targets Ther. 2019 Jan 24;12:815-823. doi: 10.2147/OTT.S165647. eCollection 2019.
• [129] HSP90 regulates osteosarcoma cell apoptosis by targeting the p53/TCF-1-mediated transcriptional network.J Cell Physiol. 2020 Apr;235(4):3894-3904. doi: 10.1002/jcp.29283. Epub 2019 Oct 9.
• [130] Histone Demethylase JARID1B Is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression via Demethylation of H3K27me3.Oncol Res. 2018 Apr 10;26(3):373-384. doi: 10.3727/096504017X14939809845080. Epub 2017 May 11.
• [131] Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion.J Cell Physiol. 2020 May;235(5):4734-4745. doi: 10.1002/jcp.29351. Epub 2019 Oct 21.
• [132] Abnormal DNA methylation may contribute to the progression of osteosarcoma.Mol Med Rep. 2018 Jan;17(1):193-199. doi: 10.3892/mmr.2017.7869. Epub 2017 Oct 25.
• [133] SLIT2/ROBO1 axis contributes to the Warburg effect in osteosarcoma through activation of SRC/ERK/c-MYC/PFKFB2 pathway.Cell Death Dis. 2018 Mar 9;9(3):390. doi: 10.1038/s41419-018-0419-y.
• [134] Calcium-sensing receptor activating ERK1/2 and PI3K-Akt pathways to induce the proliferation of osteosarcoma cells.Clin Exp Pharmacol Physiol. 2020 Mar;47(3):517-519. doi: 10.1111/1440-1681.13209. Epub 2019 Nov 24.
• [135] Cyclic Guanosine Monophosphate (cGMP)-Dependent Protein Kinase II Blocks Epidermal Growth Factor (EGF)/Epidermal Growth Factor Receptor (EGFR)-Induced Biological Effects on Osteosarcoma Cells.Med Sci Monit. 2018 Apr 4;24:1997-2002. doi: 10.12659/msm.905892.
• [136] Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.J Pediatr. 2009 May;154(5):688-93. doi: 10.1016/j.jpeds.2008.11.030. Epub 2009 Jan 21.
• [137] miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer.Oncotarget. 2016 Jul 12;7(28):44252-44265. doi: 10.18632/oncotarget.10020.
• [138] PTEN loss activates a functional AKT/CXCR4 signaling axis to potentiate tumor growth and lung metastasis in human osteosarcoma cells.Clin Exp Metastasis. 2020 Feb;37(1):173-185. doi: 10.1007/s10585-019-09998-7. Epub 2019 Sep 30.
• [139] IAP antagonists sensitize murine osteosarcoma cells to killing by TNF.Oncotarget. 2016 Jun 7;7(23):33866-86. doi: 10.18632/oncotarget.8980.
• [140] MiR-100 up-regulation enhanced cell autophagy and apoptosis induced by cisplatin in osteosarcoma by targeting mTOR.Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5867-5873. doi: 10.26355/eurrev_201809_15913.
• [141] Gene expression profiling analysis of osteosarcoma cell lines.Mol Med Rep. 2015 Sep;12(3):4266-4272. doi: 10.3892/mmr.2015.3958. Epub 2015 Jun 18.
• [142] CYR61 triggers osteosarcoma metastatic spreading via an IGF1R-dependent EMT-like process.BMC Cancer. 2019 Jan 14;19(1):62. doi: 10.1186/s12885-019-5282-4.
• [143] Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma.J Hematol Oncol. 2014 Oct 10;7:76. doi: 10.1186/s13045-014-0076-2.
• [144] Downregulation of MCT1 inhibits tumor growth, metastasis and enhances chemotherapeutic efficacy in osteosarcoma through regulation of the NF-B pathway.Cancer Lett. 2014 Jan 1;342(1):150-8. doi: 10.1016/j.canlet.2013.08.042. Epub 2013 Sep 3.
• [145] Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.Oncotarget. 2014 Nov 15;5(21):10791-802. doi: 10.18632/oncotarget.2505.
• [146] PERK-mediated Autophagy in Osteosarcoma Cells Resists ER Stress-induced Cell Apoptosis.Int J Biol Sci. 2015 May 23;11(7):803-12. doi: 10.7150/ijbs.11100. eCollection 2015.
• [147] GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells.Cancer Biol Ther. 2020;21(3):213-222. doi: 10.1080/15384047.2019.1680061. Epub 2019 Oct 25.
• [148] Involvement of PAR-4 in cannabinoid-dependent sensitization of osteosarcoma cells to TRAIL-induced apoptosis.Int J Biol Sci. 2014 Apr 8;10(5):466-78. doi: 10.7150/ijbs.8337. eCollection 2014.
• [149] Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1.Tumour Biol. 2014 Apr;35(4):3087-94. doi: 10.1007/s13277-013-1406-7. Epub 2013 Nov 27.
• [150] The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.Clin Cancer Res. 2007 May 1;13(9):2557-67. doi: 10.1158/1078-0432.CCR-06-1343.
• [151] Fascin-1 enhances experimental osteosarcoma tumor formation and metastasis and is related to poor patient outcome.BMC Cancer. 2019 Jan 17;19(1):83. doi: 10.1186/s12885-019-5303-3.
• [152] [Corrigendum] All-trans retinoic acid restored the osteogenic ability of BMP9 in osteosarcoma through the p38 MAPK pathway.Int J Oncol. 2019 Aug;55(2):547. doi: 10.3892/ijo.2019.4817. Epub 2019 May 29.
• [153] HDAC5 promotes osteosarcoma progression by upregulation of Twist 1 expression.Tumour Biol. 2014 Feb;35(2):1383-7. doi: 10.1007/s13277-013-1189-x. Epub 2013 Oct 5.
• [154] Multifunctional Pt(iv) complexes containing a glutathione S-transferase inhibitor lead to enhancing anticancer activity and preventing metastasis of osteosarcoma cells.Metallomics. 2019 Feb 20;11(2):317-326. doi: 10.1039/c8mt00296g.
• [155] Association of interleukin 16 gene polymorphisms and plasma IL16 level with osteosarcoma risk.Sci Rep. 2016 Oct 5;6:34607. doi: 10.1038/srep34607.
• [156] Identification of differentially expressed genes in the development of osteosarcoma using RNA-seq.Oncotarget. 2016 Dec 27;7(52):87194-87205. doi: 10.18632/oncotarget.13554.
• [157] Histone demethylase JMJD2C: epigenetic regulators in tumors.Oncotarget. 2017 Jul 12;8(53):91723-91733. doi: 10.18632/oncotarget.19176. eCollection 2017 Oct 31.
• [158] Expression of lysyl oxidase in human osteosarcoma and its clinical significance: a tumor suppressive role of LOX in human osteosarcoma cells.Int J Oncol. 2013 Nov;43(5):1578-86. doi: 10.3892/ijo.2013.2067. Epub 2013 Aug 21.
• [159] Mutations of lysophosphatidic acid receptor genes in human osteosarcoma cells.Pathobiology. 2010;77(5):278-82. doi: 10.1159/000319875. Epub 2010 Nov 29.
• [160] Lysophosphatidic acid receptor-5 negatively regulates cell motile and invasive activities of human sarcoma cell lines.Mol Cell Biochem. 2014 Aug;393(1-2):17-22. doi: 10.1007/s11010-014-2042-2. Epub 2014 Mar 28.
• [161] MiRNA profile of osteosarcoma with CD117 and stro-1 expression: miR-1247 functions as an onco-miRNA by targeting MAP3K9.Int J Clin Exp Pathol. 2015 Feb 1;8(2):1451-8. eCollection 2015.
• [162] Use of Saikosaponin D and JNK inhibitor SP600125, alone or in combination, inhibits malignant properties of human osteosarcoma U2 cells.Am J Transl Res. 2019 Apr 15;11(4):2070-2080. eCollection 2019.
• [163] Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.Int J Cancer. 2019 Aug 15;145(4):979-993. doi: 10.1002/ijc.32180. Epub 2019 Feb 15.
• [164] Proscillaridin A induces apoptosis and inhibits the metastasis of osteosarcoma invitro and invivo.Biochem Biophys Res Commun. 2020 Jan 22;521(4):880-886. doi: 10.1016/j.bbrc.2019.11.012. Epub 2019 Nov 7.
• [165] MicroRNA-539 suppresses osteosarcoma cell invasion and migration in vitro and targeting Matrix metallopeptidase-8.Int J Clin Exp Pathol. 2015 Jul 1;8(7):8075-82. eCollection 2015.
• [166] Interaction between the BAG1S isoform and HSP70 mediates the stability of anti-apoptotic proteins and the survival of osteosarcoma cells expressing oncogenic MYC.BMC Cancer. 2019 Mar 22;19(1):258. doi: 10.1186/s12885-019-5454-2.
• [167] GSK3 negatively regulates HIF1 mRNA stability via nucleolin in the MG63 osteosarcoma cell line.Biochem Biophys Res Commun. 2014 Jan 10;443(2):598-603. doi: 10.1016/j.bbrc.2013.12.020. Epub 2013 Dec 11.
• [168] Knockdown of neuropilin-1 suppresses invasion, angiogenesis, and increases the chemosensitivity to doxorubicin in osteosarcoma cells - an in vitro study.Eur Rev Med Pharmacol Sci. 2014;18(12):1735-41.
• [169] Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma.Mol Cancer. 2015 Apr 17;14:86. doi: 10.1186/s12943-015-0359-4.
• [170] The Protein Tyrosine Phosphatase Rptp Suppresses Osteosarcoma Development in Trp53-Heterozygous Mice.PLoS One. 2015 Sep 11;10(9):e0137745. doi: 10.1371/journal.pone.0137745. eCollection 2015.
• [171] Slit-Robo GTPase-Activating Protein 2 as a metastasis suppressor in osteosarcoma.Sci Rep. 2016 Dec 14;6:39059. doi: 10.1038/srep39059.
• [172] A Sleeping Beauty forward genetic screen identifies new genes and pathways driving osteosarcoma development and metastasis.Nat Genet. 2015 Jun;47(6):615-24. doi: 10.1038/ng.3293. Epub 2015 May 11.
• [173] The downregulation of miR-144 is associated with the growth and invasion of osteosarcoma cells through the regulation of TAGLN expression.Int J Mol Med. 2014 Dec;34(6):1565-72. doi: 10.3892/ijmm.2014.1963. Epub 2014 Oct 10.
• [174] MiR-203 Determines Poor Outcome and Suppresses Tumor Growth by Targeting TBK1 in Osteosarcoma.Cell Physiol Biochem. 2015;37(5):1956-66. doi: 10.1159/000438556. Epub 2015 Nov 20.
• [175] MiR 376c inhibits osteoblastogenesis by targeting Wnt3 and ARF-GEF-1 -facilitated augmentation of beta-catenin transactivation.J Cell Biochem. 2018 Apr;119(4):3293-3303. doi: 10.1002/jcb.26490. Epub 2017 Dec 26.
• [176] The Downregulation of MiR-182 Is Associated with the Growth and Invasion of Osteosarcoma Cells through the Regulation of TIAM1 Expression.PLoS One. 2015 May 14;10(5):e0121175. doi: 10.1371/journal.pone.0121175. eCollection 2015.
• [177] Dendritic cells combined with anti-GITR antibody produce antitumor effects in osteosarcoma.Oncol Rep. 2015 Oct;34(4):1995-2001. doi: 10.3892/or.2015.4161. Epub 2015 Jul 29.
• [178] Suppression of telomere-binding protein TPP1 resulted in telomere dysfunction and enhanced radiation sensitivity in telomerase-negative osteosarcoma cell line.Biochem Biophys Res Commun. 2014 Mar 7;445(2):363-8. doi: 10.1016/j.bbrc.2014.02.001. Epub 2014 Feb 7.
• [179] Silencing Trim59 inhibits invasion/migration and epithelial-to-mesenchymal transition via TGF-/Smad2/3 signaling pathway in bladder cancer cells.Onco Targets Ther. 2017 Mar 9;10:1503-1512. doi: 10.2147/OTT.S130139. eCollection 2017.
• [180] Selecting key genes associated with osteosarcoma based on a differential expression network.Genet Mol Res. 2015 Dec 22;14(4):17708-17. doi: 10.4238/2015.December.21.44.
• [181] Association of vitamin D receptor gene polymorphisms with osteosarcoma risk and prognosis.J Bone Oncol. 2018 Nov 30;14:100208. doi: 10.1016/j.jbo.2018.100208. eCollection 2019 Feb.
• [182] MicroRNA-638 expression change in osteosarcoma patients via PLD1 and VEGF expression.Exp Ther Med. 2019 May;17(5):3899-3906. doi: 10.3892/etm.2019.7429. Epub 2019 Mar 22.
• [183] B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma.Biomed Res Int. 2015;2015:156432. doi: 10.1155/2015/156432. Epub 2015 Apr 14.
• [184] Knockdown of WWP1 inhibits growth and invasion, but induces apoptosis of osteosarcoma cells.Int J Clin Exp Pathol. 2015 Jul 1;8(7):7869-77. eCollection 2015.
• [185] LncRNA FENDRR sensitizes doxorubicin-resistance of osteosarcoma cells through down-regulating ABCB1 and ABCC1.Oncotarget. 2017 May 18;8(42):71881-71893. doi: 10.18632/oncotarget.17985. eCollection 2017 Sep 22.
• [186] Quantitative Assessment of the Association between ABC Polymorphisms and Osteosarcoma Response: a Meta-analysis.Asian Pac J Cancer Prev. 2015;16(11):4659-64. doi: 10.7314/apjcp.2015.16.11.4659.
• [187] The overexpression of MRP4 is related to multidrug resistance in osteosarcoma cells.J Cancer Res Ther. 2015 Jan-Mar;11(1):18-23. doi: 10.4103/0973-1482.143334.
• [188] ABCG1 and Pgp identify drug resistant, self-renewing osteosarcoma cells.Cancer Lett. 2019 Jul 1;453:142-157. doi: 10.1016/j.canlet.2019.03.011. Epub 2019 Mar 22.
• [189] MicroRNA?02a suppresses cell proliferation, migration and invasion in osteosarcoma by targeting ADAM9.Mol Med Rep. 2017 Sep;16(3):3565-3572. doi: 10.3892/mmr.2017.6975. Epub 2017 Jul 14.
• [190] ADAMTS-1 increases the three-dimensional growth of osteoblasts through type I collagen processing.Bone. 2007 Aug;41(2):231-8. doi: 10.1016/j.bone.2007.04.187. Epub 2007 Apr 27.
• [191] Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase.J Biol Chem. 2003 May 23;278(21):19549-57. doi: 10.1074/jbc.M300767200. Epub 2003 Mar 19.
• [192] MicroRNA-340-5p modulates cisplatin resistance by targeting LPAAT in osteosarcoma.Braz J Med Biol Res. 2017 Apr 20;50(5):e6359. doi: 10.1590/1414-431X20176359.
• [193] PI3K isoform-dependent activation of RhoA regulates Wnt5a-induced osteosarcoma cell migration.Cancer Cell Int. 2017 Feb 14;17:27. doi: 10.1186/s12935-017-0396-8. eCollection 2017.
• [194] Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.J Exp Clin Cancer Res. 2019 Apr 17;38(1):168. doi: 10.1186/s13046-019-1147-6.
• [195] Possible contribution of aminopeptidase N(APN/CD13) to migration and invasion of human osteosarcoma cell lines.Int J Oncol. 2014 Dec;45(6):2475-85. doi: 10.3892/ijo.2014.2664. Epub 2014 Sep 22.
• [196] Effects of MicroRNA-206 on Osteosarcoma Cell Proliferation, Apoptosis, Migration and Invasion by Targeting ANXA2 Through the AKT Signaling Pathway.Cell Physiol Biochem. 2018;45(4):1410-1422. doi: 10.1159/000487567. Epub 2018 Feb 15.
• [197] MicroRNA-493-5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel-like factor 5.J Cell Physiol. 2019 Aug;234(8):13525-13533. doi: 10.1002/jcp.28030. Epub 2019 Feb 17.
• [198] APLNR promotes the progression of osteosarcoma by stimulating cell proliferation and invasion.Anticancer Drugs. 2019 Oct;30(9):940-947. doi: 10.1097/CAD.0000000000000785.
• [199] MicroRNA-497-5p Suppresses Tumor Cell Growth of Osteosarcoma by Targeting ADP Ribosylation Factor-Like Protein 2. Cancer Biother Radiopharm. 2017 Dec;32(10):371-378.
• [200] ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.Theranostics. 2019 Aug 14;9(21):6334-6353. doi: 10.7150/thno.36818. eCollection 2019.
• [201] PCAF regulates H3 phosphorylation and promotes autophagy in osteosarcoma cells.Biomed Pharmacother. 2019 Oct;118:109395. doi: 10.1016/j.biopha.2019.109395. Epub 2019 Aug 29.
• [202] Alterations of the p15, p16,and p18 genes in osteosarcoma.Cancer Genet Cytogenet. 1996 Feb;86(2):136-42. doi: 10.1016/0165-4608(95)00216-2.
• [203] Aurora B kinase as a novel molecular target for inhibition the growth of osteosarcoma.Mol Carcinog. 2019 Jun;58(6):1056-1067. doi: 10.1002/mc.22993. Epub 2019 Mar 1.
• [204] Prognostic scoring system for osteosarcoma using network-regularized high-dimensional Cox-regression analysis and potential therapeutic targets.J Cell Physiol. 2019 Aug;234(8):13851-13857. doi: 10.1002/jcp.28065. Epub 2019 Jan 3.
• [205] Expression of a novel Bcl-2 related gene, Bfl-1, in various human cancers and cancer cell lines.Anticancer Res. 1997 Nov-Dec;17(6D):4619-22.
• [206] Biglycan Regulates MG63 Osteosarcoma Cell Growth Through a LPR6/-Catenin/IGFR-IR Signaling Axis.Front Oncol. 2018 Oct 23;8:470. doi: 10.3389/fonc.2018.00470. eCollection 2018.
• [207] Synergistic Effects of a Smac Mimetic with Doxorubicin Against Human Osteosarcoma.Anticancer Res. 2017 Nov;37(11):6097-6106. doi: 10.21873/anticanres.12058.
• [208] MicroRNA-34a inhibits tumor invasion and metastasis in osteosarcoma partly by effecting C-IAP2 and Bcl-2.Tumour Biol. 2017 Jun;39(6):1010428317705761. doi: 10.1177/1010428317705761.
• [209] Research progress on the livin gene and osteosarcomas.Asian Pac J Cancer Prev. 2014;15(20):8577-9. doi: 10.7314/apjcp.2014.15.20.8577.
• [210] MicroRNA-330-3p Expression Indicates Good Prognosis and Suppresses Cell Proliferation by Targeting Bmi-1 in Osteosarcoma.Cell Physiol Biochem. 2018;46(2):442-450. doi: 10.1159/000488612. Epub 2018 Mar 26.
• [211] Expression of bone morphogenetic proteins in human osteogenic and epithelial tumor cells.Pathol Int. 1996 Jan;46(1):9-14. doi: 10.1111/j.1440-1827.1996.tb03527.x.
• [212] BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.Oncotarget. 2017 Apr 24;8(35):58625-58641. doi: 10.18632/oncotarget.17382. eCollection 2017 Aug 29.
• [213] Hydrogen peroxide-induced poly(ADP-ribosyl)ation regulates osteogenic differentiation-associated cell death.Free Radic Biol Med. 2012 Oct 15;53(8):1552-64. doi: 10.1016/j.freeradbiomed.2012.08.567. Epub 2012 Aug 20.
• [214] The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.J Exp Clin Cancer Res. 2018 May 21;37(1):107. doi: 10.1186/s13046-018-0772-9.
• [215] Up-Regulation of MiR-300 Promotes Proliferation and Invasion of Osteosarcoma by Targeting BRD7.PLoS One. 2015 May 26;10(5):e0127682. doi: 10.1371/journal.pone.0127682. eCollection 2015.
• [216] Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor- axis.Biochem Biophys Res Commun. 2019 Apr 30;512(2):360-366. doi: 10.1016/j.bbrc.2019.03.040. Epub 2019 Mar 17.
• [217] A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.Cancer Invest. 2009 Aug;27(7):774-80. doi: 10.1080/07357900802427935.
• [218] Anticancer effects of 10-hydroxycamptothecin induce apoptosis of human osteosarcoma through activating caspase-3, p53 and cytochrome c pathways.Oncol Lett. 2018 Feb;15(2):2459-2464. doi: 10.3892/ol.2017.7610. Epub 2017 Dec 13.
• [219] The microRNAs miR-449a and miR-424 suppress osteosarcoma by targeting cyclin A2 expression.J Biol Chem. 2019 Mar 22;294(12):4381-4400. doi: 10.1074/jbc.RA118.005778. Epub 2019 Jan 24.
• [220] JNK Inactivation Induces Polyploidy and Drug-Resistance in Coronarin D-Treated Osteosarcoma Cells.Molecules. 2018 Aug 23;23(9):2121. doi: 10.3390/molecules23092121.
• [221] MicroRNA-874-mediated inhibition of the major G(1)/S phase cyclin, CCNE1, is lost in osteosarcomas.J Biol Chem. 2017 Dec 29;292(52):21264-21281. doi: 10.1074/jbc.M117.808287. Epub 2017 Nov 6.
• [222] Endosialinexpressing bone sarcoma stemlike cells are highly tumorinitiating and invasive.Mol Med Rep. 2015 Oct;12(4):5665-70. doi: 10.3892/mmr.2015.4218. Epub 2015 Aug 12.
• [223] Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma.Cell Death Dis. 2019 Jan 15;10(2):36. doi: 10.1038/s41419-018-1285-3.
• [224] Cross-Species Gene Expression Analysis Reveals Gene Modules Implicated in Human Osteosarcoma.Front Genet. 2019 Aug 7;10:697. doi: 10.3389/fgene.2019.00697. eCollection 2019.
• [225] Diagnostic investigations of PLA2G16 and CDH11 expression levels as independent prognostic markers of human osteosarcoma.Arch Med Sci. 2017 Oct;13(6):1347-1351. doi: 10.5114/aoms.2016.59710. Epub 2016 May 5.
• [226] SIRT6 inhibits proliferation and invasion in osteosarcoma cells by targeting N-cadherin.Oncol Lett. 2019 Jan;17(1):1237-1244. doi: 10.3892/ol.2018.9676. Epub 2018 Nov 8.
• [227] The role of VE-cadherin in osteosarcoma cells.Pathol Oncol Res. 2010 Mar;16(1):111-7. doi: 10.1007/s12253-009-9198-1. Epub 2009 Sep 17.
• [228] Cyclin-dependent kinase 1-mediated AMPK phosphorylation regulates chromosome alignment and mitotic progression.J Cell Sci. 2019 Oct 28;132(20):jcs236000. doi: 10.1242/jcs.236000.
• [229] CRIF1 as a potential target to improve the radiosensitivity of osteosarcoma.Proc Natl Acad Sci U S A. 2019 Oct 8;116(41):20511-20516. doi: 10.1073/pnas.1906578116. Epub 2019 Sep 23.
• [230] Potential mechanisms underlying CDK5 related Osteosarcoma progression.Expert Opin Ther Targets. 2017 May;21(5):455-460. doi: 10.1080/14728222.2017.1310194. Epub 2017 Mar 28.
• [231] p35 is required for CDK5 activation in cellular senescence.J Biol Chem. 2010 May 7;285(19):14671-80. doi: 10.1074/jbc.M109.066118. Epub 2010 Feb 24.
• [232] A Kinase-Independent Role for Cyclin-Dependent Kinase 19 in p53 Response.Mol Cell Biol. 2017 Jun 15;37(13):e00626-16. doi: 10.1128/MCB.00626-16. Print 2017 Jul 1.
• [233] Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma.EBioMedicine. 2019 Jan;39:182-193. doi: 10.1016/j.ebiom.2018.12.022. Epub 2018 Dec 20.
• [234] CHOP negatively regulates Polo-like kinase 2 expression via recruiting C/EBP to the upstream-promoter in human osteosarcoma cell line during ER stress.Int J Biochem Cell Biol. 2017 Aug;89:207-215. doi: 10.1016/j.biocel.2017.06.012. Epub 2017 Jun 24.
• [235] Transcription factor CEBPB inhibits the proliferation of osteosarcoma by regulating downstream target gene CLEC5A.J Clin Lab Anal. 2019 Nov;33(9):e22985. doi: 10.1002/jcla.22985. Epub 2019 Jul 31.
• [236] Identification and validation of microRNAs and their targets expressed in osteosarcoma.Oncol Lett. 2019 Nov;18(5):5628-5636. doi: 10.3892/ol.2019.10864. Epub 2019 Sep 13.
• [237] Functional interaction of HTLV-1 tax protein with the POZ domain of the transcriptional repressor BCL6.Oncogene. 2009 Oct 22;28(42):3723-34. doi: 10.1038/onc.2009.230. Epub 2009 Aug 24.
• [238] Type I procollagen synthesis is regulated by steroids and related hormones in human osteosarcoma cells.J Cell Biochem. 1998 Feb 1;68(2):151-63.
• [239] Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway.J Bone Oncol. 2019 Mar 1;16:100228. doi: 10.1016/j.jbo.2019.100228. eCollection 2019 Jun.
• [240] Phosphorylation of IRS4 by CK12 promotes its degradation by CHIP through the ubiquitin/lysosome pathway.Theranostics. 2018 Jun 7;8(13):3643-3653. doi: 10.7150/thno.26021. eCollection 2018.
• [241] Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma.Ther Adv Med Oncol. 2019 Jun 6;11:1758835919855491. doi: 10.1177/1758835919855491. eCollection 2019.
• [242] Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis.Mol Carcinog. 2008 Jan;47(1):66-73. doi: 10.1002/mc.20362.
• [243] MiR-485-5p inhibits metastasis and proliferation of osteosarcoma by targeting CX3CL1.Eur Rev Med Pharmacol Sci. 2018 Nov;22(21):7197-7204. doi: 10.26355/eurrev_201811_16253.
• [244] Epigenetic Regulation of CXCL12 Plays a Critical Role in Mediating Tumor Progression and the Immune Response In Osteosarcoma.Cancer Res. 2018 Jul 15;78(14):3938-3953. doi: 10.1158/0008-5472.CAN-17-3801. Epub 2018 May 7.
• [245] CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin.Cancer Lett. 2015 Dec 28;369(2):405-15. doi: 10.1016/j.canlet.2015.09.002. Epub 2015 Sep 21.
• [246] Modeling familial cancer with induced pluripotent stem cells.Cell. 2015 Apr 9;161(2):240-54. doi: 10.1016/j.cell.2015.02.045.
• [247] Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3322-3328. doi: 10.1080/21691401.2019.1648285.
• [248] Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.Mol Cell Biol. 2006 Oct;26(20):7506-19. doi: 10.1128/MCB.00430-06. Epub 2006 Aug 7.
• [249] DHFR and MDR1 upregulation is associated with chemoresistance in osteosarcoma stem-like cells.Oncol Lett. 2017 Jul;14(1):171-179. doi: 10.3892/ol.2017.6132. Epub 2017 May 8.
• [250] MicroRNA-152 inhibits cell proliferation of osteosarcoma by directly targeting Wnt/-catenin signaling pathway in a DKK1-dependent manner.Oncol Rep. 2018 Aug;40(2):767-774. doi: 10.3892/or.2018.6456. Epub 2018 May 22.
• [251] MiR-92a modulates proliferation, apoptosis, migration, and invasion of osteosarcoma cell lines by targeting Dickkopf-related protein 3.Biosci Rep. 2019 Apr 26;39(4):BSR20190410. doi: 10.1042/BSR20190410. Print 2019 Apr 30.
• [252] 99mTc-MDP SPECT-CT and Ultrasound in the Diagnosis and Staging of Thyroid Metastasis From Osteosarcoma.Clin Nucl Med. 2018 Apr;43(4):e109-e110. doi: 10.1097/RLU.0000000000002004.
• [253] Improved microfluidic platform for simultaneous multiple drug screening towards personalized treatment.Biosens Bioelectron. 2019 Jan 1;123:237-243. doi: 10.1016/j.bios.2018.09.001. Epub 2018 Sep 2.
• [254] Triptolide induces mitochondrial apoptosis through modulating dual specificity phosphatase 1/mitogen-activated protein kinases cascade in osteosarcoma cells.Neoplasma. 2018;65(1):21-33. doi: 10.4149/neo_2018_170109N16.
• [255] The kinase Mirk is a potential therapeutic target in osteosarcoma.Carcinogenesis. 2010 Apr;31(4):552-8. doi: 10.1093/carcin/bgp330. Epub 2009 Dec 30.
• [256] Chromatin remodeling protein HELLS is upregulated by inactivation of the RB-E2F pathway and is nonessential for osteosarcoma tumorigenesis.Oncotarget. 2018 Aug 24;9(66):32580-32592. doi: 10.18632/oncotarget.25953. eCollection 2018 Aug 24.
• [257] miR-218 suppresses the proliferation of osteosarcoma through downregulation of E2F2.Oncol Lett. 2019 Jan;17(1):571-577. doi: 10.3892/ol.2018.9576. Epub 2018 Oct 15.
• [258] MicroRNA-152 Suppresses Human Osteosarcoma Cell Proliferation and Invasion by Targeting E2F Transcription Factor 3.Oncol Res. 2018 Jun 11;26(5):765-773. doi: 10.3727/096504017X15021536183535. Epub 2017 Aug 15.
• [259] Double-stranded RNA-dependent protein kinase is involved in 2-methoxyestradiol-mediated cell death of osteosarcoma cells.J Bone Miner Res. 2007 Jan;22(1):29-36. doi: 10.1359/jbmr.060914.
• [260] Up-regulation of microRNA-496 suppresses proliferation, invasion, migration and invivo tumorigenicity of human osteosarcoma cells by targeting eIF4E.Biochimie. 2019 Aug;163:1-11. doi: 10.1016/j.biochi.2019.04.017. Epub 2019 Apr 16.
• [261] Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.Int J Nanomedicine. 2018 Jul 3;13:3853-3866. doi: 10.2147/IJN.S150017. eCollection 2018.
• [262] Integrative genome analysis of somatic p53 mutant osteosarcomas identifies Ets2-dependent regulation of small nucleolar RNAs by mutant p53 protein.Genes Dev. 2017 Sep 15;31(18):1847-1857. doi: 10.1101/gad.304972.117. Epub 2017 Oct 11.
• [263] Platelet-Derived TGF- Induces Tissue Factor Expression via the Smad3 Pathway in Osteosarcoma Cells.J Bone Miner Res. 2018 Nov;33(11):2048-2058. doi: 10.1002/jbmr.3537. Epub 2018 Jul 20.
• [264] Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma.Cell Death Dis. 2019 Apr 1;10(4):298. doi: 10.1038/s41419-019-1532-2.
• [265] Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells.J Cell Mol Med. 2008 Jun;12(3):928-41. doi: 10.1111/j.1582-4934.2008.00141.x.
• [266] Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors.Mol Cell Proteomics. 2018 May;17(5):850-870. doi: 10.1074/mcp.RA117.000538. Epub 2018 Jan 25.
• [267] Effects of FOSL1 silencing on osteosarcoma cell proliferation, invasion and migration through the ERK/AP-1 signaling pathway.J Cell Physiol. 2019 Apr;234(4):3598-3612. doi: 10.1002/jcp.27048. Epub 2018 Nov 23.
• [268] miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2.Sci Rep. 2018 Jan 12;8(1):606. doi: 10.1038/s41598-017-18739-3.
• [269] Long Noncoding RNA FOXC2-AS1 Predicts Poor Survival in Breast Cancer Patients and Promotes Cell Proliferation.Oncol Res. 2019 Feb 5;27(2):219-226. doi: 10.3727/096504018X15213126075068. Epub 2018 Mar 21.
• [270] Trichostatin A activates FOXO1 and induces autophagy in osteosarcoma.Arch Med Sci. 2019 Jan;15(1):204-213. doi: 10.5114/aoms.2018.73860. Epub 2018 Mar 2.
• [271] Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice.Anticancer Res. 2017 Mar;37(3):1005-1011. doi: 10.21873/anticanres.11410.
• [272] Separate domains of G3BP promote efficient clustering of alphavirus replication complexes and recruitment of the translation initiation machinery.PLoS Pathog. 2019 Jun 14;15(6):e1007842. doi: 10.1371/journal.ppat.1007842. eCollection 2019 Jun.
• [273] Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.Mol Cancer Ther. 2010 Dec;9(12):3342-50. doi: 10.1158/1535-7163.MCT-10-0637. Epub 2010 Sep 29.
• [274] Increased risk of bone tumors after growth hormone treatment in childhood: A population-based cohort study in France.Cancer Med. 2018 Jul;7(7):3465-3473. doi: 10.1002/cam4.1602. Epub 2018 Jun 14.
• [275] Growth hormone receptor promotes osteosarcoma cell growth and metastases.FEBS Open Bio. 2020 Jan;10(1):127-134. doi: 10.1002/2211-5463.12761. Epub 2019 Dec 18.
• [276] Characterization of receptors for growth hormone-releasing hormone in human osteosarcomas and Ewing's sarcomas.Int J Oncol. 2006 Aug;29(2):463-9.
• [277] Activation of hedgehog signaling in mesenchymal stem cells induces cartilage and bone tumor formation via Wnt/-Catenin.Elife. 2019 Sep 4;8:e50208. doi: 10.7554/eLife.50208.
• [278] GLIPR1 inhibits the proliferation and induces the differentiation of cancer-initiating cells by regulating miR-16 in osteosarcoma.Oncol Rep. 2016 Sep;36(3):1585-91. doi: 10.3892/or.2016.4949. Epub 2016 Jul 19.
• [279] Characterization of the glutametergic system in MG-63 osteoblast-like osteosarcoma cells.Anticancer Res. 2004 Nov-Dec;24(6):3923-9.
• [280] Hyperthermia reduces migration of osteosarcoma by suppression of autocrine motility factor.Oncol Rep. 2012 Dec;28(6):1953-8. doi: 10.3892/or.2012.2066. Epub 2012 Oct 1.
• [281] High expression of metabotropic glutamate receptor 4: correlation with clinicopathologic characteristics and prognosis of osteosarcoma.J Cancer Res Clin Oncol. 2014 Mar;140(3):419-26. doi: 10.1007/s00432-013-1581-3. Epub 2014 Jan 8.
• [282] Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.PLoS One. 2017 Feb 23;12(2):e0171256. doi: 10.1371/journal.pone.0171256. eCollection 2017.
• [283] PDL1/PD? axis serves an important role in natural killer cellinduced cytotoxicity in osteosarcoma.Oncol Rep. 2019 Nov;42(5):2049-2056. doi: 10.3892/or.2019.7299. Epub 2019 Sep 3.
• [284] Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines.Clin Chim Acta. 2000 Jun;296(1-2):17-33. doi: 10.1016/s0009-8981(00)00198-4.
• [285] HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.Cell Biol Toxicol. 2019 Oct;35(5):423-433. doi: 10.1007/s10565-019-09459-7. Epub 2019 Jan 31.
• [286] Histone Deacetylase 4 Promotes Osteosarcoma Cell Proliferation and Invasion by Regulating Expression of Proliferating Cell Nuclear Antigen.Front Oncol. 2019 Sep 6;9:870. doi: 10.3389/fonc.2019.00870. eCollection 2019.
• [287] Role of the HDAC6/STAT3 pathway in regulating PD-L1 expression in osteosarcoma cell lines.Cancer Chemother Pharmacol. 2019 Feb;83(2):255-264. doi: 10.1007/s00280-018-3721-6. Epub 2018 Nov 14.
• [288] miR?85 regulates the growth of osteosarcoma cells via targeting Hexokinase 2.Mol Med Rep. 2019 Sep;20(3):2774-2782. doi: 10.3892/mmr.2019.10534. Epub 2019 Jul 25.
• [289] MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.Biochem Biophys Res Commun. 2015 Apr 10;459(3):367-73. doi: 10.1016/j.bbrc.2015.02.101. Epub 2015 Feb 26.
• [290] HOXA5 overexpression promotes osteosarcoma cell apoptosis through the p53 and p38 MAPK pathway.Gene. 2019 Mar 20;689:18-23. doi: 10.1016/j.gene.2018.11.081. Epub 2018 Dec 3.
• [291] Expression of 11-hydroxysteroid dehydrogenase enzymes in human osteosarcoma: potential role in pathogenesis and as targets for treatments.Endocr Relat Cancer. 2012 Jul 22;19(4):589-98. doi: 10.1530/ERC-12-0079. Print 2012 Aug.
• [292] Protein profiling of osteosarcoma tissue and soft callus unveils activation of the unfolded protein response pathway.Int J Oncol. 2019 May;54(5):1704-1718. doi: 10.3892/ijo.2019.4737. Epub 2019 Feb 28.
• [293] Analysis of HSP27 and the Autophagy Marker LC3B(+) Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients.Mol Cancer Ther. 2018 Jun;17(6):1315-1323. doi: 10.1158/1535-7163.MCT-17-0901. Epub 2018 Mar 28.
• [294] Detection and targeting insulin growth factor receptor type 2 (IGF2R) in osteosarcoma PDX in mouse models and in canine osteosarcoma tumors.Sci Rep. 2019 Aug 7;9(1):11476. doi: 10.1038/s41598-019-47808-y.
• [295] IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.J Cell Biochem. 2004 May 1;92(1):77-91. doi: 10.1002/jcb.20046.
• [296] Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.Adv Exp Med Biol. 2017;995:33-51. doi: 10.1007/978-3-319-53156-4_2.
• [297] Association of interleukin-12 polymorphisms and serum IL-12p40 levels with osteosarcoma risk.DNA Cell Biol. 2013 Oct;32(10):605-10. doi: 10.1089/dna.2013.2098. Epub 2013 Aug 30.
• [298] Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma.Cancer Res. 2004 Mar 15;64(6):2047-53. doi: 10.1158/0008-5472.can-03-3096.
• [299] ZBTB7A Enhances Osteosarcoma Chemoresistance by Transcriptionally Repressing lncRNALINC00473-IL24 Activity.Neoplasia. 2017 Nov;19(11):908-918. doi: 10.1016/j.neo.2017.08.008. Epub 2017 Sep 21.
• [300] Human recipient cell for oncogene transfection studies.Mol Cell Biol. 1987 Mar;7(3):1280-4. doi: 10.1128/mcb.7.3.1280-1284.1987.
• [301] MicroR-542-3p can mediate ILK and further inhibit cell proliferation, migration and invasion in osteosarcoma cells.Aging (Albany NY). 2019 Jan 11;11(1):18-32. doi: 10.18632/aging.101698.
• [302] The distribution of IGF2 and IMP3 in osteosarcoma and its relationship with angiogenesis.J Mol Histol. 2012 Feb;43(1):63-70. doi: 10.1007/s10735-011-9370-2. Epub 2011 Nov 1.
• [303] Overexpression of inosine 5'-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells.PLoS One. 2010 Aug 16;5(8):e12179. doi: 10.1371/journal.pone.0012179.
• [304] Upregulation of transforming growth factor-beta type I receptor by interferon consensus sequence-binding protein in osteosarcoma cells.Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):761-772. doi: 10.1016/j.bbamcr.2019.01.015. Epub 2019 Jan 31.
• [305] MicroRNA?66 inhibits cell proliferation and invasion in osteosarcoma by directly targeting insulin receptor substrate 1.Mol Med Rep. 2019 Apr;19(4):3345-3352. doi: 10.3892/mmr.2019.9956. Epub 2019 Feb 14.
• [306] CD49b inhibits osteogenic differentiation and plays an important role in osteosarcoma progression.Oncotarget. 2017 Sep 23;8(50):87848-87859. doi: 10.18632/oncotarget.21254. eCollection 2017 Oct 20.
• [307] Adhesion of osteosarcoma cells to the 70-kDa core region of thrombospondin-1 is mediated by the alpha 4 beta 1 integrin.Biochem Biophys Res Commun. 2002 Apr 26;293(1):86-92. doi: 10.1016/S0006-291X(02)00180-8.
• [308] MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.IUBMB Life. 2018 May;70(5):411-419. doi: 10.1002/iub.1710. Epub 2018 Mar 23.
• [309] Ilex hainanensis Merr targets ITGAV to suppress the proliferation and metastasis of osteosarcoma cells.Onco Targets Ther. 2019 Jun 7;12:4499-4507. doi: 10.2147/OTT.S205688. eCollection 2019.
• [310] Silencing of Eag1 Gene Inhibits Osteosarcoma Proliferation and Migration by Targeting STAT3-VEGF Pathway.Biomed Res Int. 2015;2015:617316. doi: 10.1155/2015/617316. Epub 2015 Dec 9.
• [311] p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2891-2899. doi: 10.1080/21691401.2019.1638790.
• [312] Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.Clin Epigenetics. 2019 Jan 16;11(1):8. doi: 10.1186/s13148-018-0605-x.
• [313] Long non-coding RNA MNX1-AS1 promoted osteosarcoma proliferation and invasion via inhibiting KISS1.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6045-6052. doi: 10.26355/eurrev_201907_18417.
• [314] KLF4 functions as an oncogene in promoting cancer stem cell-like characteristics in osteosarcoma cells.Acta Pharmacol Sin. 2019 Apr;40(4):546-555. doi: 10.1038/s41401-018-0050-6. Epub 2018 Jun 21.
• [315] Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues.Oncotarget. 2019 Sep 10;10(52):5439-5453. doi: 10.18632/oncotarget.27145. eCollection 2019 Sep 10.
• [316] Decitabine Enhances V9V2 T Cell-Mediated Cytotoxic Effects on Osteosarcoma Cells via the NKG2DL-NKG2D Axis.Front Immunol. 2018 Jun 1;9:1239. doi: 10.3389/fimmu.2018.01239. eCollection 2018.
• [317] Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24.
• [318] ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2.Biomed Pharmacother. 2019 Jan;109:788-797. doi: 10.1016/j.biopha.2018.10.029. Epub 2018 Nov 5.
• [319] MiR-33b inhibits osteosarcoma cell proliferation through suppression of glycolysis by targeting Lactate Dehydrogenase A (LDHA).Cell Mol Biol (Noisy-le-grand). 2018 Aug 30;64(11):31-35.
• [320] Stat3 upregulates leucine-rich repeat-containing g protein-coupled receptor 4 expression in osteosarcoma cells.Biomed Res Int. 2013;2013:310691. doi: 10.1155/2013/310691. Epub 2013 Dec 25.
• [321] Epigenetic Profiling Identifies LIF as a Super-enhancer-Controlled Regulator of Stem Cell-like Properties in Osteosarcoma.Mol Cancer Res. 2020 Jan;18(1):57-67. doi: 10.1158/1541-7786.MCR-19-0470. Epub 2019 Oct 15.
• [322] Identification of biomarkers associated with the recurrence of osteosarcoma using ceRNA regulatory network analysis.Int J Mol Med. 2019 Apr;43(4):1723-1733. doi: 10.3892/ijmm.2019.4108. Epub 2019 Feb 25.
• [323] LIM kinase 1 serves an important role in the multidrug resistance of osteosarcoma cells.Oncol Lett. 2018 Jan;15(1):250-256. doi: 10.3892/ol.2017.7317. Epub 2017 Nov 1.
• [324] Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways.Cell Death Dis. 2019 Mar 18;10(4):261. doi: 10.1038/s41419-019-1497-1.
• [325] Involvement of LPA signaling via LPA receptor-2 in the promotion of malignant properties in osteosarcoma cells.Exp Cell Res. 2018 Aug 15;369(2):316-324. doi: 10.1016/j.yexcr.2018.05.037. Epub 2018 May 30.
• [326] The Roles of Low-Density Lipoprotein Receptor-Related Proteins 5, 6, and 8 in Cancer: A Review.J Oncol. 2019 Mar 26;2019:4536302. doi: 10.1155/2019/4536302. eCollection 2019.
• [327] Cancer-testis antigens MAGEA proteins are incorporated into extracellular vesicles released by cells.Oncotarget. 2019 Jun 4;10(38):3694-3708. doi: 10.18632/oncotarget.26979. eCollection 2019 Jun 4.
• [328] MicroRNA-155 targets MAP3K10 and regulates osteosarcoma cell growth.Pathol Res Pract. 2017 Apr;213(4):389-393. doi: 10.1016/j.prp.2016.12.028. Epub 2017 Feb 1.
• [329] Doxorubicin induces ZAK overexpression with a subsequent enhancement of apoptosis and attenuation of survivability in human osteosarcoma cells. Environ Toxicol. 2018 Feb;33(2):191-197. doi: 10.1002/tox.22507. Epub 2017 Nov 6.
• [330] Genomic heterogeneity of osteosarcoma - shift from single candidates to functional modules.PLoS One. 2015 Apr 7;10(4):e0123082. doi: 10.1371/journal.pone.0123082. eCollection 2015.
• [331] High-resolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue.Cytogenet Genome Res. 2004;107(1-2):77-82. doi: 10.1159/000079574.
• [332] Mechanism of miR-143-3p inhibiting proliferation, migration and invasion of osteosarcoma cells by targeting MAPK7.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2065-2071. doi: 10.1080/21691401.2019.1620252.
• [333] Nitidine Chloride Inhibits SIN1 Expression in Osteosarcoma Cells.Mol Ther Oncolytics. 2019 Feb 5;12:224-234. doi: 10.1016/j.omto.2019.01.005. eCollection 2019 Mar 29.
• [334] Different expression of CD146 in human normal and osteosarcoma cell lines.Med Oncol. 2012 Dec;29(4):2998-3002. doi: 10.1007/s12032-012-0158-3. Epub 2012 Jan 21.
• [335] circEPSTI1 Acts as a ceRNA to Regulate the Progression of Osteosarcoma.Curr Cancer Drug Targets. 2020;20(4):288-294. doi: 10.2174/1568009619666191107140948.
• [336] Oncolytic virotherapy for osteosarcoma using midkine promoter-regulated adenoviruses.Cancer Gene Ther. 2014 Mar;21(3):126-32. doi: 10.1038/cgt.2014.7. Epub 2014 Feb 28.
• [337] XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.Sci Rep. 2015 Jun 22;5:11465. doi: 10.1038/srep11465.
• [338] Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice.EBioMedicine. 2019 Jun;44:452-466. doi: 10.1016/j.ebiom.2019.05.048. Epub 2019 May 29.
• [339] MicroRNA-192 inhibits the proliferation, migration and invasion of osteosarcoma cells and promotes apoptosis by targeting matrix metalloproteinase-11.Oncol Lett. 2018 May;15(5):7265-7272. doi: 10.3892/ol.2018.8239. Epub 2018 Mar 12.
• [340] PAI-1, a target gene of miR-143, regulates invasion and metastasis by upregulating MMP-13 expression of human osteosarcoma.Cancer Med. 2016 May;5(5):892-902. doi: 10.1002/cam4.651. Epub 2016 Jan 28.
• [341] Elevated expression of microRNA-328-3p suppresses aggressive malignant behaviors via targeting matrix metalloprotease 16 in osteosarcoma.Onco Targets Ther. 2019 Mar 18;12:2063-2070. doi: 10.2147/OTT.S195022. eCollection 2019.
• [342] Overexpression of Notch3 is associated with metastasis and poor prognosis in osteosarcoma patients.Cancer Manag Res. 2019 Jan 8;11:547-559. doi: 10.2147/CMAR.S185495. eCollection 2019.
• [343] MicroRNA-183 suppresses the vitality, invasion and migration of human osteosarcoma cells by targeting metastasis-associated protein 1.Exp Ther Med. 2018 Jun;15(6):5058-5064. doi: 10.3892/etm.2018.6068. Epub 2018 Apr 13.
• [344] Common genetic variants in the 9p21 region and their associations with multiple tumours.Br J Cancer. 2013 Apr 2;108(6):1378-86. doi: 10.1038/bjc.2013.7. Epub 2013 Jan 29.
• [345] Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors.J Pineal Res. 2007 Sep;43(2):206-13. doi: 10.1111/j.1600-079X.2007.00464.x.
• [346] MYCN induces neuroblastoma in primary neural crest cells.Oncogene. 2017 Aug 31;36(35):5075-5082. doi: 10.1038/onc.2017.128. Epub 2017 May 1.
• [347] Nestin expression in high-grade osteosarcomas and its clinical significance.Oncol Rep. 2012 May;27(5):1592-8. doi: 10.3892/or.2012.1687. Epub 2012 Feb 14.
• [348] A therapeutic approach to treat prostate cancer by targeting Nm23-H1/h-Prune interaction.Naunyn Schmiedebergs Arch Pharmacol. 2015 Feb;388(2):257-69. doi: 10.1007/s00210-014-1035-8. Epub 2014 Aug 20.
• [349] Upregulation of long non-coding RNA NNT-AS1 promotes osteosarcoma progression by inhibiting the tumor suppressive miR-320a.Cancer Biol Ther. 2019;20(4):413-422. doi: 10.1080/15384047.2018.1538612. Epub 2018 Nov 29.
• [350] Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.Int J Clin Exp Pathol. 2015 Jan 1;8(1):894-9. eCollection 2015.
• [351] Liver X receptor inhibits osteosarcoma cell proliferation through up-regulation of FoxO1.Cell Physiol Biochem. 2013;32(1):180-6. doi: 10.1159/000350134. Epub 2013 Jul 12.
• [352] Pregnane X receptor and human malignancy.Histol Histopathol. 2013 Apr;28(4):405-20. doi: 10.14670/HH-28.405. Epub 2013 Feb 15.
• [353] Treating osteosarcoma with CAR T cells.Scand J Immunol. 2019 Mar;89(3):e12741. doi: 10.1111/sji.12741. Epub 2019 Jan 15.
• [354] Glucocorticoid Receptor Mutations and Hypersensitivity to Endogenous and Exogenous Glucocorticoids.J Clin Endocrinol Metab. 2018 Oct 1;103(10):3630-3639. doi: 10.1210/jc.2018-00352.
• [355] MicroRNA-381 suppresses the proliferation of osteosarcoma cells through LRH-1/Wnt/-catenin signaling pathway.Oncol Rep. 2018 Feb;39(2):589-596. doi: 10.3892/or.2017.6129. Epub 2017 Dec 4.
• [356] MicroRNA-1247 inhibits the viability and metastasis of osteosarcoma cells via targeting NRP1 and mediating Wnt/-catenin pathway.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7266-7274. doi: 10.26355/eurrev_201909_18831.
• [357] Identification of chemoradiation-resistant osteosarcoma stem cells using an imaging system for proteasome activity.Int J Oncol. 2014 Dec;45(6):2349-54. doi: 10.3892/ijo.2014.2671. Epub 2014 Sep 24.
• [358] Constitutive and ligand-induced nuclear localization of oxytocin receptor.J Cell Mol Med. 2007 Jan-Feb;11(1):96-110. doi: 10.1111/j.1582-4934.2007.00015.x.
• [359] Identification and cloning of human P2U purinoceptor present in osteoclastoma, bone, and osteoblasts.J Bone Miner Res. 1995 Jul;10(7):1137-45. doi: 10.1002/jbmr.5650100720.
• [360] Platelet-derived growth factor stimulates osteoprotegerin production in osteoblastic cells.J Cell Physiol. 2009 Feb;218(2):350-4. doi: 10.1002/jcp.21600.
• [361] MicroRNA-379 suppresses osteosarcoma progression by targeting PDK1.J Cell Mol Med. 2017 Feb;21(2):315-323. doi: 10.1111/jcmm.12966. Epub 2016 Oct 25.
• [362] Downregulation of Adrenomedullin Leads to the Inhibition of the Tumorigenesis via VEGF Pathway in Human and Nude Mice Osteosarcoma Models.Arch Med Res. 2019 Jan;50(1):47-57. doi: 10.1016/j.arcmed.2019.03.002. Epub 2019 Mar 16.
• [363] ROCK2 promotes osteosarcoma growth and metastasis by modifying PFKFB3 ubiquitination and degradation.Exp Cell Res. 2019 Dec 15;385(2):111689. doi: 10.1016/j.yexcr.2019.111689. Epub 2019 Oct 31.
• [364] PGC-1alpha/beta upregulation is associated with improved oxidative phosphorylation in cells harboring nonsense mtDNA mutations.Hum Mol Genet. 2007 Apr 15;16(8):993-1005. doi: 10.1093/hmg/ddm045. Epub 2007 Mar 6.
• [365] miR-486 inhibited osteosarcoma cells invasion and epithelial-mesenchymal transition by targeting PIM1.Cancer Biomark. 2018;23(2):269-277. doi: 10.3233/CBM-181527.
• [366] GLP2 Promotes Directed Differentiation from Osteosarcoma Cells to Osteoblasts and Inhibits Growth of Osteosarcoma Cells.Mol Ther Nucleic Acids. 2018 Mar 2;10:292-303. doi: 10.1016/j.omtn.2017.12.009. Epub 2017 Dec 21.
• [367] Targeting the centrosome and polo-like kinase 4 in osteosarcoma.Carcinogenesis. 2019 Jun 10;40(4):493-499. doi: 10.1093/carcin/bgy175.
• [368] Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma.Anticancer Res. 2009 Nov;29(11):4317-22.
• [369] p180, a novel recycling transmembrane glycoprotein with restricted cell type expression.Mol Cell Biol. 1990 Jun;10(6):2606-18. doi: 10.1128/mcb.10.6.2606-2618.1990.
• [370] P65-mediated miR-590 inhibition modulates the chemoresistance of osteosarcoma to doxorubicin through targeting wild-type p53-induced phosphatase 1.J Cell Biochem. 2019 Apr;120(4):5652-5665. doi: 10.1002/jcb.27849. Epub 2018 Nov 1.
• [371] Expression and prognostic relevance of PRAME in primary osteosarcoma.Biochem Biophys Res Commun. 2012 Mar 23;419(4):801-8. doi: 10.1016/j.bbrc.2012.02.110. Epub 2012 Feb 27.
• [372] Genetic variations in the PRKCG gene and osteosarcoma risk in a Chinese population: a case-control study.Tumour Biol. 2015 Jul;36(7):5241-7. doi: 10.1007/s13277-015-3182-z. Epub 2015 Feb 9.
• [373] Expression of prolactin receptors in human osteosarcoma cells.Biochem Biophys Res Commun. 1996 Dec 4;229(1):323-8. doi: 10.1006/bbrc.1996.1800.
• [374] Gankyrin promotes osteosarcoma tumorigenesis by forming a positive feedback loop with YAP.Cell Signal. 2020 Jan;65:109460. doi: 10.1016/j.cellsig.2019.109460. Epub 2019 Oct 31.
• [375] EP1 receptor is involved in prostaglandin E2-induced osteosarcoma growth.Bosn J Basic Med Sci. 2019 Aug 20;19(3):265-273. doi: 10.17305/bjbms.2019.4177.
• [376] miR-627-3p inhibits osteosarcoma cell proliferation and metastasis by targeting PTN.Aging (Albany NY). 2019 Aug 14;11(15):5744-5756. doi: 10.18632/aging.102157. Epub 2019 Aug 14.
• [377] LncRNA SNHG3/miRNA-151a-3p/RAB22A axis regulates invasion and migration of osteosarcoma.Biomed Pharmacother. 2019 Apr;112:108695. doi: 10.1016/j.biopha.2019.108695. Epub 2019 Feb 20.
• [378] Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z.
• [379] Down-regulation of RBP-J mediated by microRNA-133a suppresses dendritic cells and functions as a potential tumor suppressor in osteosarcoma.Exp Cell Res. 2016 Dec 10;349(2):264-272. doi: 10.1016/j.yexcr.2016.10.019. Epub 2016 Oct 26.
• [380] The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion.Curr Cancer Drug Targets. 2008 Aug;8(5):404-13. doi: 10.2174/156800908785133141.
• [381] Long noncoding RNA NEAT1 regulates the development of osteosarcoma through sponging miR-34a-5p to mediate HOXA13 expression as a competitive endogenous RNA.Mol Genet Genomic Med. 2019 Jun;7(6):e673. doi: 10.1002/mgg3.673. Epub 2019 May 1.
• [382] ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a.Cancer Cell Int. 2017 Nov 29;17:112. doi: 10.1186/s12935-017-0482-y. eCollection 2017.
• [383] Marrubenol inhibits osteosarcoma cancer cell growth by inducing autophagic cell death and inhibiting cancer cell migration and invasion.J BUON. 2018 May-Jun;23(3):729-734.
• [384] Np63 enhances the oncogenic phenotype of osteosarcoma cells by inducing the expression of GLI2.BMC Cancer. 2014 Aug 1;14:559. doi: 10.1186/1471-2407-14-559.
• [385] Downregulation of RSK2 influences the biological activities of human osteosarcoma cells through inactivating AKT/mTOR signaling pathways.Int J Oncol. 2016 Jun;48(6):2508-20. doi: 10.3892/ijo.2016.3481. Epub 2016 Apr 8.
• [386] Calcitonin gene-related peptide (CGRP) increases intracellular free Ca2+ concentrations but not cyclic AMP formation in CGRP receptor-positive osteosarcoma cells (OHS-4).Cytokine. 1999 Mar;11(3):200-7. doi: 10.1006/cyto.1998.0415.
• [387] S100A6 expression and function in human osteosarcoma.Clin Orthop Relat Res. 2008 Sep;466(9):2060-70. doi: 10.1007/s11999-008-0361-x. Epub 2008 Jul 9.
• [388] S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma.EBioMedicine. 2019 Feb;40:210-223. doi: 10.1016/j.ebiom.2018.12.038. Epub 2018 Dec 23.
• [389] MicroRNA?76a inhibits cell proliferation and invasion in osteosarcoma via directly targeting SATB1.Mol Med Rep. 2018 Sep;18(3):3521-3528. doi: 10.3892/mmr.2018.9344. Epub 2018 Aug 1.
• [390] Gene expression profile of the whole Mediator complex in human osteosarcoma and normal osteoblasts.Med Oncol. 2013 Dec;30(4):739. doi: 10.1007/s12032-013-0739-9. Epub 2013 Oct 8.
• [391] [Corrigendum] Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.Int J Oncol. 2019 Jun;54(6):2258. doi: 10.3892/ijo.2019.4752. Epub 2019 Mar 18.
• [392] Pigment epithelium-derived factor: a key mediator in bone homeostasis and potential for bone regenerative therapy.J Pharm Pharmacol. 2018 Sep;70(9):1127-1138. doi: 10.1111/jphp.12942. Epub 2018 Jul 5.
• [393] Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors.Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):52-61. doi: 10.1016/j.ijrobp.2018.08.037. Epub 2018 Aug 28.
• [394] Insulin/IGF-1R, SIRT1, and FOXOs Pathways-An Intriguing Interaction Platform for Bone and Osteosarcoma.Front Endocrinol (Lausanne). 2019 Mar 1;10:93. doi: 10.3389/fendo.2019.00093. eCollection 2019.
• [395] FOXN3 is downregulated in osteosarcoma and transcriptionally regulates SIRT6, and suppresses migration and invasion in osteosarcoma.Oncol Rep. 2019 Feb;41(2):1404-1414. doi: 10.3892/or.2018.6878. Epub 2018 Nov 21.
• [396] Regulation of the mGluR5, EAAT1 and GS expression by glucocorticoids in MG-63 osteoblast-like osteosarcoma cells.J Musculoskelet Neuronal Interact. 2007 Apr-Jun;7(2):113-8.
• [397] Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin.Oncologist. 2018 Jul;23(7):762-e79. doi: 10.1634/theoncologist.2018-0037. Epub 2018 Feb 14.
• [398] The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression.Cancer Res. 2004 Apr 1;64(7):2627-33. doi: 10.1158/0008-5472.can-03-0846.
• [399] Oestrogen-related receptor alpha mediates chemotherapy resistance of osteosarcoma cells via regulation of ABCB1.J Cell Mol Med. 2019 Mar;23(3):2115-2124. doi: 10.1111/jcmm.14123. Epub 2019 Jan 4.
• [400] Influence of the folate pathway and transporter polymorphisms on methotrexate treatment outcome in osteosarcoma. Pharmacogenet Genomics. 2014 Oct;24(10):514-21.
• [401] MicroRNA-26b inhibits metastasis of osteosarcoma via targeting CTGF and Smad1.Tumour Biol. 2015 Aug;36(8):6201-9. doi: 10.1007/s13277-015-3305-6. Epub 2015 Mar 12.
• [402] MicroRNA-181c Suppresses the Biological Progression of Osteosarcoma via Targeting SMAD7 and Regulating Transforming Growth Factor- (TGF-) Signaling Pathway.Med Sci Monit. 2019 Jun 28;25:4801-4810. doi: 10.12659/MSM.916939.
• [403] Lactosylceramide is required in apoptosis induced by N-Smase.Glycoconj J. 2006 May;23(3-4):147-57. doi: 10.1007/s10719-006-7920-8.
• [404] Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/-Catenin Signaling Pathway.Calcif Tissue Int. 2017 Jun;100(6):551-564. doi: 10.1007/s00223-016-0231-6. Epub 2017 Feb 28.
• [405] SP1-mediated upregulation of lncRNA ILF3-AS1 functions a ceRNA for miR-212 to contribute to osteosarcoma progression via modulation of SOX5.Biochem Biophys Res Commun. 2019 Apr 9;511(3):510-517. doi: 10.1016/j.bbrc.2019.02.110. Epub 2019 Feb 25.
• [406] MicroRNA-493 inhibits the proliferation and invasion of osteosarcoma cells through directly targeting specificity protein 1.Oncol Lett. 2018 May;15(5):8149-8156. doi: 10.3892/ol.2018.8268. Epub 2018 Mar 15.
• [407] Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151. doi: 10.1155/2011/548151. Epub 2011 Mar 8.
• [408] Oncogenic roles of serine-threonine kinase receptor-associated protein (STRAP) in osteosarcoma. Cancer Chemother Pharmacol. 2018 Dec;82(6):1039-1047.
• [409] Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.Crit Rev Oncol Hematol. 2019 Nov;143:1-13. doi: 10.1016/j.critrevonc.2019.07.002. Epub 2019 Jul 21.
• [410] Elevated Expression of Transforming Acidic Coiled-Coil Containing Protein 3 (TACC3) Is Associated With a Poor Prognosis in Osteosarcoma.Clin Orthop Relat Res. 2018 Sep;476(9):1848-1855. doi: 10.1097/CORR.0000000000000379.
• [411] Overexpression of TBL1XR1 confers tumorigenic capability and promotes recurrence of osteosarcoma.Eur J Pharmacol. 2019 Feb 5;844:259-267. doi: 10.1016/j.ejphar.2018.12.013. Epub 2018 Dec 7.
• [412] Telomere stability genes are not mutated in osteosarcoma cell lines.Cancer Genet Cytogenet. 2005 Jul 1;160(1):79-81. doi: 10.1016/j.cancergencyto.2004.12.004.
• [413] Hsa_circ_0000285 functions as a competitive endogenous RNA to promote osteosarcoma progression by sponging hsa-miRNA-599.Gene Ther. 2020 May;27(5):186-195. doi: 10.1038/s41434-019-0112-5. Epub 2019 Nov 29.
• [414] Thymosin 4 expression in human tissues and in tumors using tissue microarrays.Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):160-7. doi: 10.1097/PAI.0b013e3181f12237.
• [415] Ionizing radiation enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through up-regulations of death receptor 4 (DR4) and death receptor 5 (DR5) in human osteosarcoma cells.J Orthop Res. 2010 Jun;28(6):739-45. doi: 10.1002/jor.21056.
• [416] Chrysanthemulide A induces apoptosis through DR5 upregulation via JNK-mediated autophagosome accumulation in human osteosarcoma cells.J Cell Physiol. 2019 Aug;234(8):13191-13208. doi: 10.1002/jcp.27991. Epub 2018 Dec 17.
• [417] Aberrant expression of BAFF receptor, a member of the tumor necrosis factor receptor family, in malignant cells of nonhematopoietic origins.Genes Cells. 2008 Oct;13(10):1061-73. doi: 10.1111/j.1365-2443.2008.01227.x. Epub 2008 Sep 3.
• [418] Sodium valproate, a histone deacetylase inhibitor, modulates the vascular endothelial growth inhibitor-mediated cell death in human osteosarcoma and vascular endothelial cells.Int J Oncol. 2015 May;46(5):1994-2002. doi: 10.3892/ijo.2015.2924. Epub 2015 Mar 12.
• [419] Tankyrase1 antisense oligodeoxynucleotides suppress the proliferation, migration and invasion through Hippo/YAP pathway in human osteosarcoma cells.Pathol Res Pract. 2019 Jun;215(6):152381. doi: 10.1016/j.prp.2019.03.010. Epub 2019 Mar 5.
• [420] The E3 ligase Topors induces the accumulation of polysumoylated forms of DNA topoisomerase I in vitro and in vivo.FEBS Lett. 2007 Nov 27;581(28):5418-24. doi: 10.1016/j.febslet.2007.10.040. Epub 2007 Oct 30.
• [421] p16INK4a inhibits the proliferation of osteosarcoma cells through regulating the miR-146b-5p/TRAF6 pathway.Biosci Rep. 2019 Feb 1;39(2):BSR20181268. doi: 10.1042/BSR20181268. Print 2019 Feb 28.
• [422] TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. Oncol Lett. 2017 Dec;14(6):6365-6372.
• [423] Knockdown of TRPM8 suppresses cancer malignancy and enhances epirubicin-induced apoptosis in human osteosarcoma cells.Int J Biol Sci. 2013 Dec 22;10(1):90-102. doi: 10.7150/ijbs.7738. eCollection 2013.
• [424] Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways.Cell Cycle. 2019 Jun;18(12):1379-1392. doi: 10.1080/15384101.2019.1618119. Epub 2019 May 29.
• [425] Up-regulation of PCOLCE by TWIST1 promotes metastasis in Osteosarcoma.Theranostics. 2019 Jun 9;9(15):4342-4353. doi: 10.7150/thno.34090. eCollection 2019.
• [426] TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption.FASEB J. 1998 Jul;12(10):845-54. doi: 10.1096/fasebj.12.10.845.
• [427] Knockdown of UBE2T Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion by Suppressing the PI3K/Akt Signaling Pathway.Oncol Res. 2016;24(5):361-369. doi: 10.3727/096504016X14685034103310.
• [428] Silencing of SNHG6 induced cell autophagy by targeting miR-26a-5p/ULK1 signaling pathway in human osteosarcoma.Cancer Cell Int. 2019 Apr 3;19:82. doi: 10.1186/s12935-019-0794-1. eCollection 2019.
• [429] MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1.Oncol Lett. 2018 May;15(5):6947-6956. doi: 10.3892/ol.2018.8180. Epub 2018 Mar 6.
• [430] Ubiquitinspecific protease 7 promotes osteosarcoma cell metastasis by inducing epithelialmesenchymal transition.Oncol Rep. 2019 Jan;41(1):543-551. doi: 10.3892/or.2018.6835. Epub 2018 Oct 31.
• [431] Valosin-containing protein promotes metastasis of osteosarcoma through autophagy induction and anoikis inhibition via the ERK/NF-/beclin-1 signaling pathway.Oncol Lett. 2019 Oct;18(4):3823-3829. doi: 10.3892/ol.2019.10716. Epub 2019 Aug 6.
• [432] Expression of vascular endothelial growth factor-C and its receptor in osteosarcomas.Pathol Res Pract. 2008;204(8):575-82. doi: 10.1016/j.prp.2008.01.015. Epub 2008 Apr 28.
• [433] Feedback modulation of endothelial cells promotes epithelial-mesenchymal transition and metastasis of osteosarcoma cells by Von Willebrand Factor release.J Cell Biochem. 2019 Sep;120(9):15971-15979. doi: 10.1002/jcb.28875. Epub 2019 May 17.
• [434] WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.Cell Biol Int. 2018 May;42(5):598-607. doi: 10.1002/cbin.10936. Epub 2018 Feb 6.
• [435] A role for WRN in telomere-based DNA damage responses.Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15073-8. doi: 10.1073/pnas.0607332103. Epub 2006 Oct 2.
• [436] Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation.Oncotarget. 2017 Feb 21;8(8):13917-13931. doi: 10.18632/oncotarget.14715.
• [437] Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy.Pharmacogenomics J. 2012 Dec;12(6):476-83. doi: 10.1038/tpj.2011.33. Epub 2011 Aug 9.
• [438] Suppression of Ku80 correlates with radiosensitivity and telomere shortening in the U2OS telomerase-negative osteosarcoma cell line.Asian Pac J Cancer Prev. 2013;14(2):795-9. doi: 10.7314/apjcp.2013.14.2.795.
• [439] The proliferation and invasion of osteosarcoma are inhibited by miR-101 via targetting ZEB2.Biosci Rep. 2019 Feb 8;39(2):BSR20181283. doi: 10.1042/BSR20181283. Print 2019 Feb 28.
• [440] Upregulated TTYH2 expression is critical for the invasion and migration of U2OS human osteosarcoma cell lines.Biochem Biophys Res Commun. 2019 Aug 20;516(2):521-525. doi: 10.1016/j.bbrc.2019.06.047. Epub 2019 Jun 21.
• [441] B7-H3 and its role in bone cancers.Pathol Res Pract. 2019 Jun;215(6):152420. doi: 10.1016/j.prp.2019.04.012. Epub 2019 Apr 17.
• [442] MiRNA-98-5p inhibits the progression of osteosarcoma by regulating cell cycle via targeting CDC25A expression.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9793-9802. doi: 10.26355/eurrev_201911_19542.
• [443] Ex vivo screen identifies CDK12 as a metastatic vulnerability in osteosarcoma.J Clin Invest. 2019 Oct 1;129(10):4377-4392. doi: 10.1172/JCI127718.
• [444] CSN5 controls the growth of osteosarcoma via modulating the EGFR/PI3K/Akt axis.Exp Cell Res. 2019 Nov 15;384(2):111646. doi: 10.1016/j.yexcr.2019.111646. Epub 2019 Sep 24.
• [445] miR-376a inhibits the proliferation and invasion of osteosarcoma by targeting FBXO11.Hum Cell. 2019 Jul;32(3):390-396. doi: 10.1007/s13577-019-00256-2. Epub 2019 May 11.
• [446] LncRNA AWPPH promotes osteosarcoma progression via activation of Wnt/-catenin pathway through modulating miR-93-3p/FZD7 axis.Biochem Biophys Res Commun. 2019 Jun 30;514(3):1017-1022. doi: 10.1016/j.bbrc.2019.04.203. Epub 2019 May 12.
• [447] Upregulation of miR?5-3p inhibits growth of osteosarcoma by targeting HDGF.Pathol Res Pract. 2019 Aug;215(8):152492. doi: 10.1016/j.prp.2019.152492. Epub 2019 Jun 10.
• [448] The circular RNA circ-ITCH acts as a tumour suppressor in osteosarcoma via regulating miR-22.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3359-3367. doi: 10.1080/21691401.2019.1649273.
• [449] Role of Activator Protein-1 Complex on the Phenotype of Human Osteosarcomas Generated from Mesenchymal Stem Cells.Stem Cells. 2018 Oct;36(10):1487-1500. doi: 10.1002/stem.2869. Epub 2018 Aug 11.
• [450] CircRNA LRP6 promotes the development of osteosarcoma via negatively regulating KLF2 and APC levels.Am J Transl Res. 2019 Jul 15;11(7):4126-4138. eCollection 2019.
• [451] Oxidized low density lipoprotein receptor 1 promotes lung metastases of osteosarcomas through regulating the epithelial-mesenchymal transition.J Transl Med. 2019 Nov 12;17(1):369. doi: 10.1186/s12967-019-2107-9.
• [452] Transcriptional regulation of the SIS/PDGF-B gene in human osteosarcoma cells by the Sp family of transcription factors.J Biol Chem. 1996 May 17;271(20):11792-7. doi: 10.1074/jbc.271.20.11792.
• [453] MiR-19a Promotes Migration And Invasion By Targeting RHOB In Osteosarcoma.Onco Targets Ther. 2019 Sep 23;12:7801-7808. doi: 10.2147/OTT.S218047. eCollection 2019.
• [454] Monocarboxylate Transporter 4 (MCT4) Overexpression Is Correlated with Poor Prognosis of Osteosarcoma.Med Sci Monit. 2019 Jun 9;25:4278-4284. doi: 10.12659/MSM.912272.
• [455] Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling.Mol Med Rep. 2019 Aug;20(2):915-930. doi: 10.3892/mmr.2019.10323. Epub 2019 Jun 3.
• [456] Label-free detection of transporter activity via GPCR signalling in living cells: A case for SLC29A1, the equilibrative nucleoside transporter 1.Sci Rep. 2019 Sep 24;9(1):13802. doi: 10.1038/s41598-019-48829-3.
• [457] Targeting USP9x/SOX2 axis contributes to the anti-osteosarcoma effect of neogambogic acid.Cancer Lett. 2020 Jan 28;469:277-286. doi: 10.1016/j.canlet.2019.10.015. Epub 2019 Oct 9.
• [458] Overexpression of miR-20a promotes the progression of osteosarcoma by directly targeting QKI2.Oncol Lett. 2019 Jul;18(1):87-94. doi: 10.3892/ol.2019.10313. Epub 2019 May 3.
• [459] STK39, overexpressed in osteosarcoma, regulates osteosarcoma cell invasion and proliferation.Oncol Lett. 2017 Oct;14(4):4599-4604. doi: 10.3892/ol.2017.6728. Epub 2017 Aug 7.
• [460] SLC25A22 Promotes Proliferation and Metastasis of Osteosarcoma Cells via the PTEN Signaling Pathway.Technol Cancer Res Treat. 2018 Jan 1;17:1533033818811143. doi: 10.1177/1533033818811143.
• [461] Transcriptomic analysis associated with reversal of cisplatin sensitivity in drug resistant osteosarcoma cells after a drug holiday.BMC Cancer. 2019 Nov 5;19(1):1045. doi: 10.1186/s12885-019-6300-2.
• [462] Efficient tumor transduction and antitumor efficacy in experimental human osteosarcoma using retroviral replicating vectors.Cancer Gene Ther. 2019 Feb;26(1-2):41-47. doi: 10.1038/s41417-018-0037-y. Epub 2018 Jul 25.
• [463] Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996 Apr;11(4):535-43.
• [464] Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1.Phytother Res. 2019 Jul;33(7):1837-1850. doi: 10.1002/ptr.6373. Epub 2019 May 2.
• [465] PHD3 Acts as Tumor Suppressor in Mouse Osteosarcoma and Influences Tumor Vascularization via PDGF-C Signaling.Cancers (Basel). 2018 Dec 6;10(12):496. doi: 10.3390/cancers10120496.
• [466] Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Int J Cancer. 2018 Apr 15;142(8):1594-1601. doi: 10.1002/ijc.31195. Epub 2017 Dec 23.
• [467] Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.Oncotarget. 2017 May 9;8(19):31465-31477. doi: 10.18632/oncotarget.16356.
• [468] Upregulation of ALDH1B1 promotes tumor progression in osteosarcoma.Oncotarget. 2017 Dec 20;9(2):2502-2514. doi: 10.18632/oncotarget.23506. eCollection 2018 Jan 5.
• [469] Collagen Accumulation in Osteosarcoma Cells lacking GLT25D1 Collagen Galactosyltransferase.J Biol Chem. 2016 Aug 26;291(35):18514-24. doi: 10.1074/jbc.M116.723379. Epub 2016 Jul 11.
• [470] Knockdown of YAP1 inhibits the proliferation of osteosarcoma cells invitro and invivo.Oncol Rep. 2014 Sep;32(3):1265-72. doi: 10.3892/or.2014.3305. Epub 2014 Jul 3.
• [471] Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.Mol Cancer Ther. 2003 Aug;2(8):765-71.
• [472] Mutation of Gln125 to Asn selectively abolishes the thymidylate kinase activity of herpes simplex virus type 1 thymidine kinase.Mol Pharmacol. 2001 Feb;59(2):285-93. doi: 10.1124/mol.59.2.285.
• [473] SKA1 induces denovo MTX-resistance in osteosarcoma through inhibiting FPGS transcription.FEBS J. 2019 Jun;286(12):2399-2414. doi: 10.1111/febs.14808. Epub 2019 Apr 2.
• [474] Acetone immersion enhanced MALDI-MS imaging of small molecule metabolites in biological tissues.J Pharm Biomed Anal. 2019 Nov 30;176:112797. doi: 10.1016/j.jpba.2019.112797. Epub 2019 Aug 1.
• [475] Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.Int J Cancer. 2009 Aug 15;125(4):851-60. doi: 10.1002/ijc.24457.
• [476] MAT2B promotes proliferation and inhibits apoptosis in osteosarcoma by targeting epidermal growth factor receptor and proliferating cell nuclear antigen.Int J Oncol. 2019 Jun;54(6):2019-2029. doi: 10.3892/ijo.2019.4764. Epub 2019 Mar 27.
• [477] MT2A is an early predictive biomarker of response to chemotherapy and a potential therapeutic target in osteosarcoma.Sci Rep. 2019 Aug 23;9(1):12301. doi: 10.1038/s41598-019-48846-2.
• [478] Circular RNA circ-NT5C2 acts as a potential novel biomarker for prognosis of osteosarcoma.Eur Rev Med Pharmacol Sci. 2018 Oct;22(19):6239-6244. doi: 10.26355/eurrev_201810_16030.
• [479] Proteomic profiling of osteosarcoma cells identifies ALDOA and SULT1A3 as negative survival markers of human osteosarcoma.Mol Carcinog. 2014 Feb;53(2):138-44. doi: 10.1002/mc.21957. Epub 2012 Sep 4.
• [480] Linc00460 promotes osteosarcoma progression via miR-1224-5p/FADS1 axis.Life Sci. 2019 Sep 15;233:116757. doi: 10.1016/j.lfs.2019.116757. Epub 2019 Aug 13.
• [481] Actin-like protein 6A is a novel prognostic indicator promoting invasion and metastasis in osteosarcoma.Oncol Rep. 2017 Apr;37(4):2405-2417. doi: 10.3892/or.2017.5473. Epub 2017 Feb 23.
• [482] Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma.Pharmacogenet Genomics. 2016 May;26(5):243-7. doi: 10.1097/FPC.0000000000000212.
• [483] Genome-wide association study identifies two susceptibility loci for osteosarcoma.Nat Genet. 2013 Jul;45(7):799-803. doi: 10.1038/ng.2645. Epub 2013 Jun 2.
• [484] Epigenetic silencing of the Wnt antagonist APCDD1 by promoter DNA hyper-methylation contributes to osteosarcoma cell invasion and metastasis.Biochem Biophys Res Commun. 2017 Sep 9;491(1):91-97. doi: 10.1016/j.bbrc.2017.07.049. Epub 2017 Jul 8.
• [485] LncRNA TUG1 promotes cell proliferation and suppresses apoptosis in osteosarcoma by regulating miR-212-3p/FOXA1 axis.Biomed Pharmacother. 2018 Jan;97:1645-1653. doi: 10.1016/j.biopha.2017.12.004. Epub 2017 Dec 8.
• [486] Inhibition of LCMR1 and ATG12 by demethylation-activated miR-570-3p is involved in the anti-metastasis effects of metformin on human osteosarcoma.Cell Death Dis. 2018 May 23;9(6):611. doi: 10.1038/s41419-018-0620-z.
• [487] MicroRNA-410 regulates autophagy-related gene ATG16L1 expression and enhances chemosensitivity via autophagy inhibition in osteosarcoma.Mol Med Rep. 2017 Mar;15(3):1326-1334. doi: 10.3892/mmr.2017.6149. Epub 2017 Jan 26.
• [488] MicroRNA-1301 inhibits migration and invasion of osteosarcoma cells by targeting BCL9.Gene. 2018 Dec 30;679:100-107. doi: 10.1016/j.gene.2018.08.078. Epub 2018 Aug 30.
• [489] The role of GPCRs in bone diseases and dysfunctions.Bone Res. 2019 Jul 8;7:19. doi: 10.1038/s41413-019-0059-6. eCollection 2019.
• [490] The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/III-Tubulin Axis.Mol Cancer Res. 2017 Jul;15(7):953-964. doi: 10.1158/1541-7786.MCR-16-0372. Epub 2017 Mar 8.
• [491] MicroRNA-3200-5p Promotes Osteosarcoma Cell Invasion via Suppression of BRMS1.Mol Cells. 2018 Jun;41(6):523-531. doi: 10.14348/molcells.2018.2200. Epub 2018 Jun 11.
• [492] Long non-coding RNA ASBEL promotes osteosarcoma cell proliferation, migration, and invasion by regulating microRNA-21.J Cell Biochem. 2018 Aug;119(8):6461-6469. doi: 10.1002/jcb.26671. Epub 2018 May 9.
• [493] Downregulation of BZW2 inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.Oncol Rep. 2017 Oct;38(4):2116-2122. doi: 10.3892/or.2017.5890. Epub 2017 Aug 8.
• [494] Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells.Tumour Biol. 2016 Jun;37(6):7989-8005. doi: 10.1007/s13277-015-4661-y. Epub 2015 Dec 28.
• [495] Circular RNA hsa_circ_0001564 regulates osteosarcoma proliferation and apoptosis by acting miRNA sponge.Biochem Biophys Res Commun. 2018 Jan 15;495(3):2369-2375. doi: 10.1016/j.bbrc.2017.12.050. Epub 2017 Dec 9.
• [496] Melatonin attenuates osteosarcoma cell invasion by suppression of C-C motif chemokine ligand 24 through inhibition of the c-Jun N-terminal kinase pathway.J Pineal Res. 2018 Oct;65(3):e12507. doi: 10.1111/jpi.12507. Epub 2018 May 28.
• [497] Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.Clin Cancer Res. 2017 Oct 1;23(19):5824-5835. doi: 10.1158/1078-0432.CCR-17-0075. Epub 2017 Jun 28.
• [498] Integrated analysis of gene expression and copy number variations in MET protooncogenetransformed human primary osteoblasts.Mol Med Rep. 2018 Feb;17(2):2543-2548. doi: 10.3892/mmr.2017.8135. Epub 2017 Nov 22.
• [499] CpG methylation patterns are associated with gene expression variation in osteosarcoma.Mol Med Rep. 2017 Jul;16(1):901-907. doi: 10.3892/mmr.2017.6635. Epub 2017 May 26.
• [500] Genetic determinants of childhood and adult height associated with osteosarcoma risk.Cancer. 2018 Sep 15;124(18):3742-3752. doi: 10.1002/cncr.31645. Epub 2018 Oct 12.
• [501] Silencing of cytoskeleton-associated protein 2 represses cell proliferation and induces cell cycle arrest and cell apoptosis in osteosarcoma cells.Biomed Pharmacother. 2018 Oct;106:1396-1403. doi: 10.1016/j.biopha.2018.07.104. Epub 2018 Jul 23.
• [502] CLDN2 inhibits the metastasis of osteosarcoma cells via down-regulating the afadin/ERK signaling pathway.Cancer Cell Int. 2018 Oct 17;18:160. doi: 10.1186/s12935-018-0662-4. eCollection 2018.
• [503] Deep RNA sequencing reveals the dynamic regulation of miRNA, lncRNAs, and mRNAs in osteosarcoma tumorigenesis and pulmonary metastasis.Cell Death Dis. 2018 Jul 10;9(7):772. doi: 10.1038/s41419-018-0813-5.
• [504] ChondromodulinI suppresses tumorigenesis of human osteosarcoma cells.Mol Med Rep. 2017 Dec;16(6):8542-8548. doi: 10.3892/mmr.2017.7629. Epub 2017 Sep 26.
• [505] Long noncoding RNA HOXD-AS1 aggravates osteosarcoma carcinogenesis through epigenetically inhibiting p57 via EZH2.Biomed Pharmacother. 2018 Oct;106:890-895. doi: 10.1016/j.biopha.2018.06.173. Epub 2018 Jul 12.
• [506] Identification of miRNA and genes involving in osteosarcoma by comprehensive analysis of microRNA and copy number variation data.Oncol Lett. 2017 Nov;14(5):5427-5433. doi: 10.3892/ol.2017.6845. Epub 2017 Aug 28.
• [507] Cyclooxygenase-2 expression correlates with development, progression, metastasis, and prognosis of osteosarcoma: a meta-analysis and trial sequential analysis.FEBS Open Bio. 2019 Jan 7;9(2):226-240. doi: 10.1002/2211-5463.12560. eCollection 2019 Feb.
• [508] CPNE1 silencing inhibits the proliferation, invasion and migration of human osteosarcoma cells.Oncol Rep. 2018 Feb;39(2):643-650. doi: 10.3892/or.2017.6128. Epub 2017 Dec 4.
• [509] Thrombospondin-1 promotes cell migration, invasion and lung metastasis of osteosarcoma through FAK dependent pathway.Oncotarget. 2017 Apr 26;8(44):75881-75892. doi: 10.18632/oncotarget.17427. eCollection 2017 Sep 29.
• [510] Lentivirus-Mediated Knockdown of CTHRC1 Inhibits Osteosarcoma Cell Proliferation and Migration.Cancer Biother Radiopharm. 2016 Apr;31(3):91-8. doi: 10.1089/cbr.2014.1758. Epub 2016 Apr 4.
• [511] MicroRNA-409-3p inhibits osteosarcoma cell migration and invasion by targeting catenin-1.Gene. 2016 Jun 10;584(1):83-89. doi: 10.1016/j.gene.2016.03.021. Epub 2016 Mar 15.
• [512] Cullin-1 regulates MG63 cell proliferation and metastasis and is a novel prognostic marker of osteosarcoma.Int J Biol Markers. 2017 May 4;32(2):e202-e209. doi: 10.5301/jbm.5000247.
• [513] CXCL5 Plays a Promoting Role in Osteosarcoma Cell Migration and Invasion in Autocrine- and Paracrine-Dependent Manners.Oncol Res. 2017 Jan 26;25(2):177-186. doi: 10.3727/096504016X14732772150343.
• [514] Novel lymphoid enhancer-binding factor 1-cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs.Cancer Sci. 2018 Sep;109(9):2746-2756. doi: 10.1111/cas.13702. Epub 2018 Jul 24.
• [515] Disabled homolog 2 interactive protein functions as a tumor suppressor in osteosarcoma cells.Oncol Lett. 2018 Jul;16(1):703-712. doi: 10.3892/ol.2018.8776. Epub 2018 May 22.
• [516] Knockdown of DDX46 Inhibits the Invasion and Tumorigenesis in Osteosarcoma Cells.Oncol Res. 2017 Mar 13;25(3):417-425. doi: 10.3727/096504016X14747253292210. Epub 2016 Sep 30.
• [517] Minichromosome maintenance protein 2 and 3 promote osteosarcoma progression via DHX9 and predict poor patient prognosis.Oncotarget. 2017 Apr 18;8(16):26380-26393. doi: 10.18632/oncotarget.15474.
• [518] Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.Int J Oncol. 2017 May;50(5):1513-1530. doi: 10.3892/ijo.2017.3921. Epub 2017 Mar 21.
• [519] Silencing of translation initiation factor eIF3b promotes apoptosis in osteosarcoma cells.Bone Joint Res. 2017 Mar;6(3):186-193. doi: 10.1302/2046-3758.63.BJR-2016-0151.R2.
• [520] LncRNA FAL1 is a negative prognostic biomarker and exhibits pro-oncogenic function in osteosarcoma.J Cell Biochem. 2018 Nov;119(10):8481-8489. doi: 10.1002/jcb.27074. Epub 2018 Jul 10.
• [521] MiR-409-3p regulates cell proliferation and tumor growth by targeting E74-like factor 2 in osteosarcoma.FEBS Open Bio. 2017 Jan 27;7(3):348-357. doi: 10.1002/2211-5463.12177. eCollection 2017 Mar.
• [522] ERCC polymorphisms and risk of osteosarcoma: a meta-analysis.Eur Rev Med Pharmacol Sci. 2018 Oct;22(20):6658-6666. doi: 10.26355/eurrev_201810_16142.
• [523] Functional Requirements for Heparan Sulfate Biosynthesis in Morphogenesis and Nervous System Development in C. elegans.PLoS Genet. 2017 Jan 9;13(1):e1006525. doi: 10.1371/journal.pgen.1006525. eCollection 2017 Jan.
• [524] Knockdown of FBXO39 inhibits proliferation and promotes apoptosis of human osteosarcoma U-2OS cells.Oncol Lett. 2018 Aug;16(2):1849-1854. doi: 10.3892/ol.2018.8876. Epub 2018 Jun 1.
• [525] Prognostic implications of Kindlin proteins in human osteosarcoma.Onco Targets Ther. 2017 Feb 7;10:657-665. doi: 10.2147/OTT.S125418. eCollection 2017.
• [526] Skeletal-specific expression of Fgd1 during bone formation and skeletal defects in faciogenital dysplasia (FGDY; Aarskog syndrome).Dev Dyn. 2000 Aug;218(4):573-86. doi: 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1015>3.0.CO;2-F.
• [527] miR-210 promotes human osteosarcoma cell migration and invasion by targeting FGFRL1.Oncol Lett. 2018 Aug;16(2):2229-2236. doi: 10.3892/ol.2018.8939. Epub 2018 Jun 11.
• [528] FHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo.PLoS One. 2013;8(1):e55034. doi: 10.1371/journal.pone.0055034. Epub 2013 Jan 28.
• [529] A novel prognostic model for osteosarcoma using circulating CXCL10 and FLT3LG.Cancer. 2017 Jan 1;123(1):144-154. doi: 10.1002/cncr.30272. Epub 2016 Aug 16.
• [530] MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1.Biochem Biophys Res Commun. 2018 Sep 5;503(2):1092-1097. doi: 10.1016/j.bbrc.2018.06.121. Epub 2018 Aug 2.
• [531] The CtBP1-p300-FOXO3a transcriptional complex represses the expression of the apoptotic regulators Bax and Bim in human osteosarcoma cells.J Cell Physiol. 2019 Dec;234(12):22365-22377. doi: 10.1002/jcp.28802. Epub 2019 May 9.
• [532] Loss of miR-198 and -206 during primary tumor progression enables metastatic dissemination in human osteosarcoma.Oncotarget. 2018 Nov 6;9(87):35726-35741. doi: 10.18632/oncotarget.26284. eCollection 2018 Nov 6.
• [533] MicroRNA-520b Suppresses Proliferation, Migration, and Invasion of Spinal Osteosarcoma Cells via Downregulation of Frizzled-8.Oncol Res. 2017 Sep 21;25(8):1297-1304. doi: 10.3727/096504017X14873430389189. Epub 2017 Feb 28.
• [534] Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9.PLoS One. 2017 Jun 30;12(6):e0180558. doi: 10.1371/journal.pone.0180558. eCollection 2017.
• [535] Analysis of the Expression of Repetitive DNA Elements in Osteosarcoma.Front Genet. 2017 Nov 30;8:193. doi: 10.3389/fgene.2017.00193. eCollection 2017.
• [536] Inhibiting GIT1 reduces the growth, invasion, and angiogenesis of osteosarcoma.Cancer Manag Res. 2018 Nov 29;10:6445-6455. doi: 10.2147/CMAR.S181066. eCollection 2018.
• [537] Silencing of HAS2-AS1 mediates PI3K/AKT signaling pathway to inhibit cell proliferation, migration, and invasion in glioma.J Cell Biochem. 2019 Jul;120(7):11510-11516. doi: 10.1002/jcb.28430. Epub 2019 Feb 20.
• [538] Ras-ERK1/2 signalling promotes the development of osteosarcoma through regulation of H4K12ac through HAT1.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1207-1215. doi: 10.1080/21691401.2019.1593857.
• [539] Hes4: A potential prognostic biomarker for newly diagnosed patients with high-grade osteosarcoma.Pediatr Blood Cancer. 2017 May;64(5):10.1002/pbc.26318. doi: 10.1002/pbc.26318. Epub 2016 Oct 27.
• [540] Circular RNA circ_HIPK3 is down-regulated and suppresses cell proliferation, migration and invasion in osteosarcoma.J Cancer. 2018 Apr 26;9(10):1856-1862. doi: 10.7150/jca.24619. eCollection 2018.
• [541] Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.J Clin Invest. 2013 Nov;123(11):4681-94. doi: 10.1172/JCI65764.
• [542] Effects of the overexpression of IFITM5 and IFITM5 c.-14C>T mutation on human osteosarcoma cells.Oncol Lett. 2017 Jan;13(1):111-118. doi: 10.3892/ol.2016.5426. Epub 2016 Nov 23.
• [543] Analyzing the disease module associated with osteosarcoma via a network- and pathway-based approach.Exp Ther Med. 2018 Sep;16(3):2584-2592. doi: 10.3892/etm.2018.6506. Epub 2018 Jul 23.
• [544] Inositol polyphosphate-4-phosphatase type II and rucaparib treatment inhibit the growth of osteosarcoma cells dependent on phosphoinositide 3-kinase/protein kinase B pathway.J Cell Biochem. 2018 Dec;119(12):9899-9909. doi: 10.1002/jcb.27311. Epub 2018 Aug 21.
• [545] miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2.Oncol Lett. 2018 Sep;16(3):3150-3156. doi: 10.3892/ol.2018.9032. Epub 2018 Jun 27.
• [546] Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.Med Oncol. 2015 Mar;32(3):53. doi: 10.1007/s12032-015-0503-4. Epub 2015 Jan 31.
• [547] Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma.Int J Oncol. 2016 Sep;49(3):903-12. doi: 10.3892/ijo.2016.3601. Epub 2016 Jul 4.
• [548] LDOC1 regulates Wnt5a expression and osteosarcoma cell metastasis and is correlated with the survival of osteosarcoma patients.Tumour Biol. 2017 Feb;39(2):1010428317691188. doi: 10.1177/1010428317691188.
• [549] CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/RUVBL1 axis to enhance the transcriptional activity of -catenin/LEF1 complex via effects on chromatin remodeling.Mol Cancer. 2019 Oct 29;18(1):150. doi: 10.1186/s12943-019-1076-1.
• [550] The prognostic value of PCNA expression in patients with osteosarcoma: A meta-analysis of 16 studies.Medicine (Baltimore). 2017 Oct;96(41):e8254. doi: 10.1097/MD.0000000000008254.
• [551] Targeted cancer cell ablation in mice by an -particle-emitting astatine-211-labeled antibody against major histocompatibility complex class I chain-related protein A and B.Biochem Biophys Res Commun. 2018 Dec 2;506(4):1078-1084. doi: 10.1016/j.bbrc.2018.10.157. Epub 2018 Nov 5.
• [552] Novel Triazole-Piperazine Hybrid Molecules Induce Apoptosis via Activation of the Mitochondrial Pathway and Exhibit Antitumor Efficacy in Osteosarcoma Xenograft Nude Mice Model.ACS Chem Biol. 2017 Mar 17;12(3):753-768. doi: 10.1021/acschembio.6b01007. Epub 2017 Jan 26.
• [553] Ezrin and moesin expression in canine and feline osteosarcoma.Histol Histopathol. 2017 Aug;32(8):805-816. doi: 10.14670/HH-11-848. Epub 2016 Nov 30.
• [554] MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4.Oncogene. 2013 Jan 24;32(4):462-70. doi: 10.1038/onc.2012.69. Epub 2012 Feb 27.
• [555] N--acetyltransferase 10 protein promotes metastasis by stabilizing matrix metalloproteinase-2 protein in human osteosarcomas.Cancer Lett. 2018 Oct 1;433:86-98. doi: 10.1016/j.canlet.2018.06.033. Epub 2018 Jun 27.
• [556] MicroRNA-210 is increased and it is required for dedifferentiation of osteosarcoma cell line.Cell Biol Int. 2017 Mar;41(3):267-275. doi: 10.1002/cbin.10721. Epub 2017 Jan 6.
• [557] miR-130b targets NKD2 and regulates the Wnt signaling to promote proliferation and inhibit apoptosis in osteosarcoma cells. Biochem Biophys Res Commun. 2016 Mar 18;471(4):479-85.
• [558] NKX2-2 Suppresses Osteosarcoma Metastasis and Proliferation by Downregulating Multiple Target Genes.J Cancer. 2018 Aug 6;9(17):3067-3077. doi: 10.7150/jca.26382. eCollection 2018.
• [559] miRNA-20a upregulates TAK1 and increases proliferation in osteosarcoma cells.Future Oncol. 2018 Feb;14(5):461-469. doi: 10.2217/fon-2017-0490. Epub 2018 Jan 12.
• [560] Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.Oncol Rep. 2017 Nov;38(5):2796-2802. doi: 10.3892/or.2017.5936. Epub 2017 Sep 4.
• [561] MMP-1 Over-expression Promotes Malignancy and Stem-Like Properties of Human Osteosarcoma MG-63 Cells In Vitro.Curr Med Sci. 2018 Oct;38(5):809-817. doi: 10.1007/s11596-018-1947-5. Epub 2018 Dec 29.
• [562] The miR-15b-5p/PDK4 axis regulates osteosarcoma proliferation through modulation of the Warburg effect.Biochem Biophys Res Commun. 2018 Sep 18;503(4):2749-2757. doi: 10.1016/j.bbrc.2018.08.035. Epub 2018 Aug 6.
• [563] Significance of NF-kappaB signaling and PARP1 activity in the TNF-induced inhibition of PHEX gene expression in human osteoblasts.Acta Biochim Pol. 2018 Nov 15;65(4):573-571. doi: 10.18388/abp.2018_2633.
• [564] MicroRNA-199a-5p promotes tumour growth by dual-targeting PIAS3 and p27 in human osteosarcoma.Sci Rep. 2017 Jan 25;7:41456. doi: 10.1038/srep41456.
• [565] The Function of the Novel Mechanical Activated Ion Channel Piezo1 in the Human Osteosarcoma Cells.Med Sci Monit. 2017 Oct 24;23:5070-5082. doi: 10.12659/msm.906959.
• [566] Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome.Oncol Lett. 2018 Oct;16(4):4953-4960. doi: 10.3892/ol.2018.9239. Epub 2018 Jul 31.
• [567] miR-142-5p suppresses proliferation and promotes apoptosis of human osteosarcoma cell line, HOS, by targeting PLA2G16 through the ERK1/2 signaling pathway.Oncol Lett. 2019 Jan;17(1):1363-1371. doi: 10.3892/ol.2018.9712. Epub 2018 Nov 15.
• [568] ONZIN Upregulation by Mutant p53 Contributes to Osteosarcoma Metastasis Through the CXCL5-MAPK Signaling Pathway.Cell Physiol Biochem. 2018;48(3):1099-1111. doi: 10.1159/000491976. Epub 2018 Jul 24.
• [569] Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma.Oncol Rep. 2017 Jan;37(1):622-630. doi: 10.3892/or.2016.5233. Epub 2016 Nov 8.
• [570] Expression level of CDC2 gene in osteosarcoma and its clinical significance.Oncol Lett. 2018 May;15(5):7884-7888. doi: 10.3892/ol.2018.8307. Epub 2018 Mar 20.
• [571] CYP genes in osteosarcoma: Their role in tumorigenesis, pulmonary metastatic microenvironment and treatment response.Oncotarget. 2017 Jun 13;8(24):38530-38540. doi: 10.18632/oncotarget.15869.
• [572] MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1 protein.Oncotarget. 2017 Jan 10;8(2):2342-2355. doi: 10.18632/oncotarget.13672.
• [573] Modeling osteosarcoma progression by measuring the connectivity dynamics using an inference of multiple differential modules algorithm.Mol Med Rep. 2017 Aug;16(2):1047-1054. doi: 10.3892/mmr.2017.6703. Epub 2017 Jun 6.
• [574] RNA-binding protein PUM2 suppresses osteosarcoma progression via partly and competitively binding to STARD13 3'UTR with miRNAs.Cell Prolif. 2018 Dec;51(6):e12508. doi: 10.1111/cpr.12508. Epub 2018 Aug 7.
• [575] Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.Oncol Lett. 2018 May;15(5):7312-7318. doi: 10.3892/ol.2018.8228. Epub 2018 Mar 9.
• [576] Long non-coding RNA RAB11B-AS1 prevents osteosarcoma development and progression via its natural antisense transcript RAB11B.Oncotarget. 2018 Jan 13;9(42):26770-26786. doi: 10.18632/oncotarget.24247. eCollection 2018 Jun 1.
• [577] MicroRNA-16 suppressed the invasion and migration of osteosarcoma by directly inhibiting RAB23.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2598-2605. doi: 10.26355/eurrev_201805_14953.
• [578] New 2-Oxoindolin Phosphonates as Novel Agents to Treat Cancer: A Green Synthesis and Molecular Modeling.Molecules. 2018 Aug 8;23(8):1981. doi: 10.3390/molecules23081981.
• [579] RBEL1 is required for osteosarcoma cell proliferation via inhibiting retinoblastoma 1.Mol Med Rep. 2016 Feb;13(2):1275-80. doi: 10.3892/mmr.2015.4670. Epub 2015 Dec 10.
• [580] RANBP9 suppresses tumor proliferation in colorectal cancer.Oncol Lett. 2019 May;17(5):4409-4416. doi: 10.3892/ol.2019.10134. Epub 2019 Mar 8.
• [581] A new subtype of high-grade mandibular osteosarcoma with RASAL1/MDM2 amplification.Hum Pathol. 2016 Apr;50:70-8. doi: 10.1016/j.humpath.2015.11.012. Epub 2015 Dec 9.
• [582] RASSF4 Overexpression Inhibits the Proliferation, Invasion, EMT, and Wnt Signaling Pathway in Osteosarcoma Cells.Oncol Res. 2017 Jan 2;25(1):83-91. doi: 10.3727/096504016X14719078133447.
• [583] Elevated circulating macrophage inhibitory cytokine 1 is a biological marker for the diagnosis and prognosis of osteosarcoma.Exp Ther Med. 2018 Dec;16(6):4803-4809. doi: 10.3892/etm.2018.6786. Epub 2018 Sep 21.
• [584] Targeting the Wnt/-catenin pathway in human osteosarcoma cells.Oncotarget. 2018 Dec 4;9(95):36780-36792. doi: 10.18632/oncotarget.26377. eCollection 2018 Dec 4.
• [585] Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control.Sci Rep. 2016 Nov 24;6:37690. doi: 10.1038/srep37690.
• [586] Down-regulation of RPS9 Inhibits Osteosarcoma Cell Growth through Inactivation of MAPK Signaling Pathway.J Cancer. 2017 Aug 22;8(14):2720-2728. doi: 10.7150/jca.19130. eCollection 2017.
• [587] RRP12 is a crucial nucleolar protein that regulates p53 activity in osteosarcoma cells.Tumour Biol. 2016 Apr;37(4):4351-8. doi: 10.1007/s13277-015-4062-2. Epub 2015 Oct 23.
• [588] Rhotekin 2 silencing inhibits proliferation and induces apoptosis in human osteosarcoma cells.Biosci Rep. 2018 Nov 20;38(6):BSR20181384. doi: 10.1042/BSR20181384. Print 2018 Dec 21.
• [589] P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.Tumour Biol. 2016 Mar;37(3):3879-86. doi: 10.1007/s13277-015-3838-8. Epub 2015 Oct 17.
• [590] Overexpression of SCARA5 inhibits tumor proliferation and invasion in osteosarcoma via suppression of the FAK signaling pathway.Mol Med Rep. 2016 Mar;13(3):2885-91. doi: 10.3892/mmr.2016.4857. Epub 2016 Feb 3.
• [591] 2-Methoxyestradiol Affects Mitochondrial Biogenesis Pathway and Succinate Dehydrogenase Complex Flavoprotein Subunit A in Osteosarcoma Cancer Cells.Cancer Genomics Proteomics. 2018 Jan-Feb;15(1):73-89. doi: 10.21873/cgp.20067.
• [592] SUMO-specific protease 2 (SENP2) functions as a tumor suppressor in osteosarcoma via SOX9 degradation.Exp Ther Med. 2018 Dec;16(6):5359-5365. doi: 10.3892/etm.2018.6838. Epub 2018 Oct 9.
• [593] LncRNA SNHG5 promotes the progression of osteosarcoma by sponging the miR-212-3p/SGK3 axis.Cancer Cell Int. 2018 Sep 18;18:141. doi: 10.1186/s12935-018-0641-9. eCollection 2018.
• [594] Siva 1 inhibits proliferation, migration and invasion by phosphorylating Stathmin in ovarian cancer cells.Oncol Lett. 2017 Aug;14(2):1512-1518. doi: 10.3892/ol.2017.6307. Epub 2017 Jun 2.
• [595] Integrated bioinformatics analysis of miRNA expression in osteosarcoma.Artif Cells Nanomed Biotechnol. 2017 Aug;45(5):936-943. doi: 10.1080/21691401.2016.1196456. Epub 2016 Jun 17.
• [596] SPC24 Regulates breast cancer progression by PI3K/AKT signaling.Gene. 2018 Oct 30;675:272-277. doi: 10.1016/j.gene.2018.07.017. Epub 2018 Jul 6.
• [597] A genome landscape of SRSF3-regulated splicing events and gene expression in human osteosarcoma U2OS cells.Nucleic Acids Res. 2016 Feb 29;44(4):1854-70. doi: 10.1093/nar/gkv1500. Epub 2015 Dec 23.
• [598] DEAD-Box Helicase 5 Interacts With Transcription Factor 12 and Promotes the Progression of Osteosarcoma by Stimulating Cell Cycle Progression.Front Pharmacol. 2019 Jan 24;9:1558. doi: 10.3389/fphar.2018.01558. eCollection 2018.
• [599] TEAD1 mediates the oncogenic activities of Hippo-YAP1 signaling in osteosarcoma.Biochem Biophys Res Commun. 2017 Jun 24;488(2):297-302. doi: 10.1016/j.bbrc.2017.05.032. Epub 2017 May 5.
• [600] Estrogen-related receptor participates transforming growth factor- (TGF-) induced epithelial-mesenchymal transition of osteosarcoma cells.Cell Adh Migr. 2017 Jul 4;11(4):338-346. doi: 10.1080/19336918.2016.1221567. Epub 2016 Aug 17.
• [601] The adaptor protein ARA55 and the nuclear kinase HIPK1 assist c-Myb in recruiting p300 to chromatin.Biochim Biophys Acta Gene Regul Mech. 2017 Jul;1860(7):751-760. doi: 10.1016/j.bbagrm.2017.05.001. Epub 2017 May 8.
• [602] miR-34 inhibits growth and promotes apoptosis of osteosarcoma in nude mice through targetly regulating TGIF2 expression.Biosci Rep. 2018 Jun 12;38(3):BSR20180078. doi: 10.1042/BSR20180078. Print 2018 Jun 29.
• [603] MicroRNA-552 promotes migration and invasion of osteosarcoma through targeting TIMP2.Biochem Biophys Res Commun. 2019 Mar 26;511(1):63-68. doi: 10.1016/j.bbrc.2019.02.007. Epub 2019 Feb 11.
• [604] Upregulation and biological function of transmembrane protein 119 in osteosarcoma.Exp Mol Med. 2017 May 12;49(5):e329. doi: 10.1038/emm.2017.41.
• [605] Silencing Transmembrane Protein 45B (TNEM45B) Inhibits Proliferation, Invasion, and Tumorigenesis in Osteosarcoma Cells.Oncol Res. 2017 Jul 5;25(6):1021-1026. doi: 10.3727/096504016X14821477992177. Epub 2016 Dec 21.
• [606] MicroRNA-138 directly targets TNFAIP8 and acts as a tumor suppressor in osteosarcoma.Exp Ther Med. 2017 Oct;14(4):3665-3673. doi: 10.3892/etm.2017.4947. Epub 2017 Aug 16.
• [607] TIPE2 sensitizes osteosarcoma cells to cis-platin by down-regulating MDR1 via the TAK1- NF-B and - AP-1 pathways.Mol Immunol. 2018 Sep;101:471-478. doi: 10.1016/j.molimm.2018.08.010. Epub 2018 Aug 14.
• [608] Identification of a p53 target, CD137L, that mediates growth suppression and immune response of osteosarcoma cells.Sci Rep. 2017 Sep 6;7(1):10739. doi: 10.1038/s41598-017-11208-x.
• [609] Analysis of Minerals Produced by hFOB 1.19 and Saos-2 Cells Using Transmission Electron Microscopy with Energy Dispersive X-ray Microanalysis.J Vis Exp. 2018 Jun 24;(136):57423. doi: 10.3791/57423.
• [610] TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4022-4031.
• [611] Migration-inducing gene-7 independently predicts poor prognosis of human osteosarcoma and is associated with vasculogenic mimicry.Exp Cell Res. 2018 Aug 1;369(1):80-89. doi: 10.1016/j.yexcr.2018.05.008. Epub 2018 May 8.
• [612] MicroRNA-107 Promotes Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting Tropomyosin 1.Oncol Res. 2017 Sep 21;25(8):1409-1419. doi: 10.3727/096504017X14882829077237. Epub 2017 Mar 8.
• [613] MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3.Eur Rev Med Pharmacol Sci. 2018 Aug;22(16):5156-5164. doi: 10.26355/eurrev_201808_15711.
• [614] TRIM2 regulates the development and metastasis of tumorous cells of osteosarcoma.Int J Oncol. 2018 Oct;53(4):1643-1656. doi: 10.3892/ijo.2018.4494. Epub 2018 Jul 20.
• [615] High expression of TRIM29(ATDC) contributes to poor prognosis and tumor metastasis by inducing epithelialmesenchymal transition in osteosarcoma.Oncol Rep. 2017 Sep;38(3):1645-1654. doi: 10.3892/or.2017.5842. Epub 2017 Jul 21.
• [616] miR-491-3p suppresses the growth and invasion of osteosarcoma cells by targeting TSPAN1.Mol Med Rep. 2017 Oct;16(4):5568-5574. doi: 10.3892/mmr.2017.7256. Epub 2017 Aug 16.
• [617] hTERT promotes tumor progression by enhancing TSPAN13 expression in osteosarcoma cells.Mol Carcinog. 2018 Aug;57(8):1038-1054. doi: 10.1002/mc.22824. Epub 2018 May 18.
• [618] CEP55 promotes the proliferation and invasion of tumour cells via the AKT signalling pathway in osteosarcoma.Carcinogenesis. 2018 Apr 5;39(4):623-631. doi: 10.1093/carcin/bgy017.
• [619] Effects of Dermatopontin gene silencing on apoptosis and proliferation of osteosarcoma MG?3 cells.Mol Med Rep. 2018 Jan;17(1):422-427. doi: 10.3892/mmr.2017.7866. Epub 2017 Oct 25.
• [620] Effects of Grb2-associated binding protein 2-specific siRNA on the migration and invasion of MG-63 osteosarcoma cells.Oncol Lett. 2018 Jan;15(1):926-930. doi: 10.3892/ol.2017.7375. Epub 2017 Nov 9.
• [621] MiR-378 promotes the cell proliferation of osteosarcoma through down-regulating the expression of Kruppel-like factor 9.Biochem Cell Biol. 2018 Oct;96(5):515-521. doi: 10.1139/bcb-2017-0186. Epub 2018 Feb 28.
• [622] MicroRNA-18a inhibits cell growth and induces apoptosis in osteosarcoma by targeting MED27.Int J Oncol. 2018 Jul;53(1):329-338. doi: 10.3892/ijo.2018.4374. Epub 2018 Apr 16.
• [623] Association between expression of nuclear receptor co-activator 5 protein and prognosis in postoperative patients with osteosarcoma.Oncol Lett. 2018 Feb;15(2):1888-1892. doi: 10.3892/ol.2017.7513. Epub 2017 Dec 5.
• [624] Anticancer effect of (S)-crizotinib on osteosarcoma cells by targeting MTH1 and activating reactive oxygen species.Anticancer Drugs. 2018 Apr;29(4):341-352. doi: 10.1097/CAD.0000000000000602.
• [625] Long Noncoding RNA XIST Promotes Osteosarcoma Progression by Targeting Ras-Related Protein RAP2B via miR-320b.Oncol Res. 2018 Jul 5;26(6):837-846. doi: 10.3727/096504017X14920318811721. Epub 2017 Apr 12.
• [626] Downregulation of lncRNA CASC2 facilitates osteosarcoma growth and invasion through miR-181a.Cell Prolif. 2018 Feb;51(1):e12409. doi: 10.1111/cpr.12409. Epub 2017 Nov 30.
• [627] MicroRNA?2 inhibits the proliferation and migration, and increases the cisplatin sensitivity, of osteosarcoma cells.Mol Med Rep. 2018 May;17(5):7209-7217. doi: 10.3892/mmr.2018.8790. Epub 2018 Mar 20.
• [628] miR-19 promotes osteosarcoma progression by targeting SOCS6.Biochem Biophys Res Commun. 2018 Jan 1;495(1):1363-1369. doi: 10.1016/j.bbrc.2017.10.002. Epub 2017 Oct 3.
• [629] SOX6 is downregulated in osteosarcoma and suppresses the migration, invasion and epithelial-mesenchymal transition via TWIST1 regulation.Mol Med Rep. 2018 May;17(5):6803-6811. doi: 10.3892/mmr.2018.8681. Epub 2018 Mar 6.
• [630] SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/-catenin signaling through stabilization of the WNT-receptor complex.Oncogene. 2018 Feb 22;37(8):1049-1061. doi: 10.1038/onc.2017.403. Epub 2017 Oct 30.
• [631] CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity.Oncogene. 2014 Apr 10;33(15):1912-21. doi: 10.1038/onc.2013.152. Epub 2013 May 6.
• [632] Depletion of ALX1 causes inhibition of migration and induction of apoptosis in human osteosarcoma.Tumour Biol. 2015 Aug;36(8):5965-70. doi: 10.1007/s13277-015-3271-z. Epub 2015 Mar 4.
• [633] Armadillo Repeat-Containing Protein 8 (ARMC8) Silencing Inhibits Proliferation and Invasion in Osteosarcoma Cells.Oncol Res. 2016;24(5):381-389. doi: 10.3727/096504016X14685034103392.
• [634] Silencing of Barkor/ATG14 sensitizes osteosarcoma cells to cisplatininduced apoptosis.Int J Mol Med. 2014 Feb;33(2):271-6. doi: 10.3892/ijmm.2013.1578. Epub 2013 Dec 9.
• [635] Identification of key biomarkers involved in osteosarcoma using altered modules.Genet Mol Res. 2016 Aug 26;15(3). doi: 10.4238/gmr.15038277.
• [636] miR-27a and miR-27a* contribute to metastatic properties of osteosarcoma cells.Oncotarget. 2015 Mar 10;6(7):4920-35. doi: 10.18632/oncotarget.3025.
• [637] miR-9 Modulates Osteosarcoma Cell Growth by Targeting the GCIP Tumor Suppressor.Asian Pac J Cancer Prev. 2015;16(11):4509-13. doi: 10.7314/apjcp.2015.16.11.4509.
• [638] Whole exome sequencing of a single osteosarcoma case--integrative analysis with whole transcriptome RNA-seq data.Hum Genomics. 2014 Dec 11;8(1):20. doi: 10.1186/s40246-014-0020-0.
• [639] Clinicopathologic significance of S100A4 expression in osteosarcoma.Eur Rev Med Pharmacol Sci. 2014;18(6):833-9.
• [640] CIP2A is overexpressed in osteosarcoma and regulates cell proliferation and invasion.Tumour Biol. 2014 Feb;35(2):1123-8. doi: 10.1007/s13277-013-1150-z. Epub 2013 Sep 8.
• [641] Focal chromosomal copy number aberrations identify CMTM8 and GPR177 as new candidate driver genes in osteosarcoma.PLoS One. 2014 Dec 31;9(12):e115835. doi: 10.1371/journal.pone.0115835. eCollection 2014.
• [642] Tumstatin induces apoptosis and stimulates phosphorylation of p65NF-B in human osteoblastic osteosarcoma Saos-2 cells.Oncol Rep. 2016 Jun;35(6):3403-8. doi: 10.3892/or.2016.4762. Epub 2016 Apr 20.
• [643] The Expression of HSPD1, SCUBE3, CXCL14 and Its Relations with the Prognosis in Osteosarcoma.Cell Biochem Biophys. 2015 Dec;73(3):763-8. doi: 10.1007/s12013-015-0579-7.
• [644] MiR-451 inhibits cell growth and invasion by targeting CXCL16 and is associated with prognosis of osteosarcoma patients.Tumour Biol. 2015 Mar;36(3):2041-8. doi: 10.1007/s13277-014-2811-2. Epub 2014 Nov 13.
• [645] Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.Mol Cell Biol. 2015 Sep;35(18):3145-62. doi: 10.1128/MCB.00332-15. Epub 2015 Jul 6.
• [646] Zebularine enhances apoptosis of human osteosarcoma cells by suppressing methylation of ARHI.Cancer Sci. 2016 Dec;107(12):1851-1857. doi: 10.1111/cas.13088. Epub 2016 Dec 19.
• [647] Acute dyskerin depletion triggers cellular senescence and renders osteosarcoma cells resistant to genotoxic stress-induced apoptosis.Biochem Biophys Res Commun. 2014 Apr 18;446(4):1268-75. doi: 10.1016/j.bbrc.2014.03.114. Epub 2014 Mar 29.
• [648] Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.Cancer. 2015 Mar 1;121(5):697-707. doi: 10.1002/cncr.29090. Epub 2014 Nov 11.
• [649] Regulation of interferon pathway in 2-methoxyestradiol-treated osteosarcoma cells.BMC Cancer. 2012 Mar 19;12:93. doi: 10.1186/1471-2407-12-93.
• [650] Role of ezrin in osteosarcoma metastasis.Adv Exp Med Biol. 2014;804:181-201. doi: 10.1007/978-3-319-04843-7_10.
• [651] Inhibitory effects of forkhead box L1 gene on osteosarcoma growth through the induction of cell cycle arrest and apoptosis.Oncol Rep. 2015 Jul;34(1):265-71. doi: 10.3892/or.2015.3969. Epub 2015 May 11.
• [652] WT1 is involved in the Akt-JNK pathway dependent autophagy through directly regulating Gas1 expression in human osteosarcoma cells.Biochem Biophys Res Commun. 2016 Sep 9;478(1):74-80. doi: 10.1016/j.bbrc.2016.07.090. Epub 2016 Jul 21.
• [653] The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis.Eur J Cancer Care (Engl). 2015 May;24(3):417-24. doi: 10.1111/ecc.12197. Epub 2014 Apr 1.
• [654] TIM-3 expression and its association with overall survival in primary osteosarcoma.Oncol Lett. 2019 Nov;18(5):5294-5300. doi: 10.3892/ol.2019.10855. Epub 2019 Sep 12.
• [655] Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.Br J Cancer. 2015 Mar 31;112(7):1232-40. doi: 10.1038/bjc.2015.84.
• [656] Nucleosome-binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2-OS osteosarcoma cell lines.Oncol Rep. 2015 Mar;33(3):1300-6. doi: 10.3892/or.2014.3689. Epub 2014 Dec 22.
• [657] The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.Tumour Biol. 2016 Nov;37(11):14961-14967. doi: 10.1007/s13277-016-5384-4. Epub 2016 Sep 20.
• [658] MiR-542-5p is a negative prognostic factor and promotes osteosarcoma tumorigenesis by targeting HUWE1.Oncotarget. 2015 Dec 15;6(40):42761-72. doi: 10.18632/oncotarget.6199.
• [659] RUNX2 controls human IPO8 basal transcription in Saos-2 cells.Mol Med Rep. 2016 Aug;14(2):1418-24. doi: 10.3892/mmr.2016.5356. Epub 2016 Jun 1.
• [660] IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-B signaling.J Clin Invest. 2015 May;125(5):1839-56. doi: 10.1172/JCI78437. Epub 2015 Mar 30.
• [661] Association of ITGA3 gene polymorphisms with susceptibility and clinicopathological characteristics of osteosarcoma.Med Oncol. 2014 Feb;31(2):826. doi: 10.1007/s12032-013-0826-y. Epub 2014 Jan 1.
• [662] MSP-4, an antimicrobial peptide, induces apoptosis via activation of extrinsic Fas/FasL- and intrinsic mitochondria-mediated pathways in one osteosarcoma cell line. Mar Drugs. 2018 Jan 2;16(1).
• [663] miR-214 promotes the proliferation and invasion of osteosarcoma cells through direct suppression of LZTS1.Biochem Biophys Res Commun. 2014 Jun 27;449(2):190-5. doi: 10.1016/j.bbrc.2014.04.140. Epub 2014 May 4.
• [664] MicroRNA-1 functions as a potential tumor suppressor in osteosarcoma by targeting Med1 and Med31.Oncol Rep. 2014 Sep;32(3):1249-56. doi: 10.3892/or.2014.3274. Epub 2014 Jun 20.
• [665] Meteorin-Like Shows Unique Expression Pattern in Bone and Its Overexpression Inhibits Osteoblast Differentiation.PLoS One. 2016 Oct 7;11(10):e0164446. doi: 10.1371/journal.pone.0164446. eCollection 2016.
• [666] MicroRNA-19b targets Mfn1 to inhibit Mfn1-induced apoptosis in osteosarcoma cells.Neoplasma. 2014;61(3):265-73. doi: 10.4149/neo_2014_034.
• [667] Identification of CD20, ECM, and ITGA as Biomarkers for Osteosarcoma by Integrating Transcriptome Analysis.Med Sci Monit. 2016 Jun 17;22:2075-85. doi: 10.12659/msm.898852.
• [668] Targeting DNA-PKcs and telomerase in brain tumour cells.Mol Cancer. 2014 Oct 13;13:232. doi: 10.1186/1476-4598-13-232.
• [669] MicroRNA-135b promotes proliferation, invasion and migration of osteosarcoma cells by degrading myocardin.Int J Oncol. 2014 Nov;45(5):2024-32. doi: 10.3892/ijo.2014.2641. Epub 2014 Sep 4.
• [670] NAIF1 suppresses osteosarcoma progression and is regulated by miR-128.Cell Biochem Funct. 2018 Dec;36(8):443-449. doi: 10.1002/cbf.3365. Epub 2018 Nov 8.
• [671] Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment.Hum Mol Genet. 2014 Mar 15;23(6):1453-66. doi: 10.1093/hmg/ddt533. Epub 2013 Oct 24.
• [672] Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.Invest New Drugs. 2014 Dec;32(6):1167-80. doi: 10.1007/s10637-014-0158-6. Epub 2014 Sep 7.
• [673] NRSN2 promotes osteosarcoma cell proliferation and growth through PI3K/Akt/MTOR and Wnt/-catenin signaling.Am J Cancer Res. 2017 Mar 1;7(3):565-573. eCollection 2017.
• [674] High Relative Expression of Pannexin 3 (PANX3) in an Axillary Sweat Gland Carcinoma With Osteosarcomatous Transformation.Am J Dermatopathol. 2016 Nov;38(11):846-851. doi: 10.1097/DAD.0000000000000583.
• [675] The tumor suppressor role of PAQR3 in osteosarcoma.Tumour Biol. 2015 May;36(5):3319-24. doi: 10.1007/s13277-014-2964-z. Epub 2014 Dec 17.
• [676] PDCD5 inhibits osteosarcoma cell metastasis via targeting TGF-1/Smad signaling pathway and is associated with good prognosis.Am J Transl Res. 2019 Feb 15;11(2):1116-1128. eCollection 2019.
• [677] Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.Oncotarget. 2015 Oct 6;6(30):29469-81. doi: 10.18632/oncotarget.5177.
• [678] Polymeric immunoglobulin receptor expression is correlated with poor prognosis in patients with osteosarcoma.Mol Med Rep. 2014 Jun;9(6):2105-10. doi: 10.3892/mmr.2014.2110. Epub 2014 Apr 2.
• [679] Silencing of phosphoinositide-specific phospholipase C remodulates the expression of the phosphoinositide signal transduction pathway in human osteosarcoma cell lines.Anticancer Res. 2014 Aug;34(8):4069-75.
• [680] NOV inhibits proliferation while promoting apoptosis and migration in osteosarcoma cell lines through p38/MAPK and JNK/MAPK pathways.Oncol Rep. 2015 Oct;34(4):2011-21. doi: 10.3892/or.2015.4153. Epub 2015 Jul 24.
• [681] Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis.PLoS One. 2015 Aug 28;10(8):e0133592. doi: 10.1371/journal.pone.0133592. eCollection 2015.
• [682] Peroxiredoxin-1 promotes cell proliferation and metastasis through enhancing Akt/mTOR in human osteosarcoma cells.Oncotarget. 2017 Dec 23;9(9):8290-8302. doi: 10.18632/oncotarget.23662. eCollection 2018 Feb 2.
• [683] Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells.Oncol Rep. 2015 Aug;34(2):787-94. doi: 10.3892/or.2015.4011. Epub 2015 May 28.
• [684] Increased cathepsin D protein expression is a biomarker for osteosarcomas, pulmonary metastases and other bone malignancies.Oncotarget. 2015 Jun 30;6(18):16517-26. doi: 10.18632/oncotarget.4140.
• [685] RASSF5 inhibits growth and invasion and induces apoptosis in osteosarcoma cells through activation of MST1/LATS1 signaling.Oncol Rep. 2014 Oct;32(4):1505-12. doi: 10.3892/or.2014.3387. Epub 2014 Aug 7.
• [686] Prognostic implications of RB1 tumour suppressor gene alterations in the clinical outcome of human osteosarcoma: a meta-analysis.Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12401. Epub 2015 Oct 27.
• [687] Translesion polymerase genes polymorphisms and haplotypes influence survival of osteosarcoma patients.OMICS. 2015 Mar;19(3):180-5. doi: 10.1089/omi.2014.0159.
• [688] Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.Int J Oncol. 2004 Mar;24(3):647-55.
• [689] RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance.Biomed Res Int. 2015;2015:147468. doi: 10.1155/2015/147468. Epub 2015 Jul 1.
• [690] MEF2D overexpression contributes to the progression of osteosarcoma.Gene. 2015 Jun 1;563(2):130-5. doi: 10.1016/j.gene.2015.03.046. Epub 2015 Mar 23.
• [691] Ribosomal protein S15A augments human osteosarcoma cell proliferation in vitro.Cancer Biother Radiopharm. 2014 Dec;29(10):451-6. doi: 10.1089/cbr.2014.1698.
• [692] Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion.Cancer Lett. 2015 Jan 28;356(2 Pt B):855-61. doi: 10.1016/j.canlet.2014.10.042. Epub 2014 Nov 11.
• [693] Polymorphisms in miRNA processing genes and their role in osteosarcoma risk.Pediatr Blood Cancer. 2015 May;62(5):766-9. doi: 10.1002/pbc.25416. Epub 2015 Feb 7.
• [694] SerpinE2 promotes multiple cell proliferation and drug resistance in osteosarcoma.Mol Med Rep. 2016 Jul;14(1):881-7. doi: 10.3892/mmr.2016.5316. Epub 2016 May 19.
• [695] SPOCD1 promotes cell proliferation and inhibits cell apoptosis in human osteosarcoma.Mol Med Rep. 2018 Feb;17(2):3218-3225. doi: 10.3892/mmr.2017.8263. Epub 2017 Dec 12.
• [696] Spondin 1 promotes metastatic progression through Fak and Src dependent pathway in human osteosarcoma.Biochem Biophys Res Commun. 2015 Aug 14;464(1):45-50. doi: 10.1016/j.bbrc.2015.05.092. Epub 2015 May 29.
• [697] Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells.PLoS One. 2014 Apr 30;9(4):e95136. doi: 10.1371/journal.pone.0095136. eCollection 2014.
• [698] Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.Anticancer Res. 1995 Nov-Dec;15(6B):2461-8.
• [699] Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.Cancer Res. 2019 Mar 15;79(6):1054-1068. doi: 10.1158/0008-5472.CAN-18-1255. Epub 2018 Dec 28.
• [700] Che-1 gene silencing induces osteosarcoma cell apoptosis by inhibiting mutant p53 expression.Biochem Biophys Res Commun. 2016 Apr 22;473(1):168-173. doi: 10.1016/j.bbrc.2016.03.073. Epub 2016 Mar 21.
• [701] IL-6 upregulates a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS-2) in human osteosarcoma cells mediated by JNK pathway.Mol Cell Biochem. 2014 Aug;393(1-2):165-75. doi: 10.1007/s11010-014-2056-9. Epub 2014 Apr 22.
• [702] SP1-mediated downregulation of ADAMTS3 gene expression in osteosarcoma models.Gene. 2018 Jun 15;659:1-10. doi: 10.1016/j.gene.2018.03.009. Epub 2018 Mar 5.
• [703] Clinical Significance of G Protein-Coupled Receptor 110 (GPR110) as a Novel Prognostic Biomarker in Osteosarcoma.Med Sci Monit. 2018 Jul 27;24:5216-5224. doi: 10.12659/MSM.909555.
• [704] Clinicopathological and immunohistochemical analysis of autoimmune regulator expression in patients with osteosarcoma.Clin Exp Metastasis. 2018 Oct;35(7):641-648. doi: 10.1007/s10585-018-9928-4. Epub 2018 Aug 18.
• [705] Silencing of Cited2 and Akap12 genes in radiation-induced rat osteosarcomas.Biochem Biophys Res Commun. 2009 Dec 18;390(3):654-8. doi: 10.1016/j.bbrc.2009.10.022. Epub 2009 Oct 13.
• [706] Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.Sci Rep. 2017 Jan 5;7:40187. doi: 10.1038/srep40187.
• [707] Angiopoietin-like protein 2 is an important facilitator of tumor proliferation, metastasis, angiogenesis and glycolysis in osteosarcoma.Am J Transl Res. 2019 Oct 15;11(10):6341-6355. eCollection 2019.
• [708] Circ_ANKIB1 stabilizes the regulation of miR-19b on SOCS3/STAT3 pathway to promote osteosarcoma cell growth and invasion.Hum Cell. 2020 Jan;33(1):252-260. doi: 10.1007/s13577-019-00298-6. Epub 2019 Oct 30.
• [709] p53 family members regulate the expression of the apolipoprotein D gene.J Biol Chem. 2009 Jan 9;284(2):872-83. doi: 10.1074/jbc.M807185200. Epub 2008 Nov 11.
• [710] Panobinostat mediated cell death: a novel therapeutic approach for osteosarcoma.Oncotarget. 2018 Aug 31;9(68):32997-33010. doi: 10.18632/oncotarget.26038. eCollection 2018 Aug 31.
• [711] Glucocorticoid receptor DNA binding factor 1 expression and osteosarcoma prognosis.Tumour Biol. 2014 Dec;35(12):12449-58. doi: 10.1007/s13277-014-2563-z. Epub 2014 Sep 4.
• [712] Expression of miR?42?p in osteosarcoma with miRNA microarray data, and its potential signaling pathways.Mol Med Rep. 2019 Feb;19(2):974-983. doi: 10.3892/mmr.2018.9761. Epub 2018 Dec 13.
• [713] Reduced argininosuccinate synthetase expression in refractory sarcomas: Impacts on therapeutic potential and drug resistance.Oncotarget. 2016 Oct 25;7(43):70832-70844. doi: 10.18632/oncotarget.12225.
• [714] Human FRAG1 encodes a novel membrane-spanning protein that localizes to chromosome 11p15.5, a region of frequent loss of heterozygosity in cancer.Genomics. 1999 Nov 15;62(1):59-66. doi: 10.1006/geno.1999.5980.
• [715] ATF6 Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma.Neoplasia. 2019 Jun;21(6):516-532. doi: 10.1016/j.neo.2019.02.004. Epub 2019 Apr 25.
• [716] Mutations in the mitochondrial ATPase6 gene are frequent in human osteosarcoma.Exp Mol Pathol. 2013 Feb;94(1):285-8. doi: 10.1016/j.yexmp.2012.04.015. Epub 2012 Apr 19.
• [717] Down-regulation of microRNA-31-5p inhibits proliferation and invasion of osteosarcoma cells through Wnt/-catenin signaling pathway by enhancing AXIN1.Exp Mol Pathol. 2019 Jun;108:32-41. doi: 10.1016/j.yexmp.2019.03.001. Epub 2019 Mar 4.
• [718] The retinoblastoma protein (Rb) as an anti-apoptotic factor: expression of Rb is required for the anti-apoptotic function of BAG-1 protein in colorectal tumour cells.Cell Death Dis. 2012 Oct 11;3(10):e408. doi: 10.1038/cddis.2012.142.
• [719] Scythe/BAT3 regulates apoptotic cell death induced by papillomavirus binding factor in human osteosarcoma.Cancer Sci. 2009 Jan;100(1):47-53. doi: 10.1111/j.1349-7006.2008.00991.x. Epub 2008 Oct 29.
• [720] Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation.J Pediatr Hematol Oncol. 2019 Mar;41(2):e94-e96. doi: 10.1097/MPH.0000000000001264.
• [721] Up-regulation of microRNA-340 promotes osteosarcoma cell apoptosis while suppressing proliferation, migration, and invasion by inactivating the CTNNB1-mediated Notch signaling pathway.Biosci Rep. 2018 Aug 31;38(4):BSR20171615. doi: 10.1042/BSR20171615. Print 2018 Aug 31.
• [722] BCOR-CCNB3 (Ewing-like) sarcoma: a clinicopathologic analysis of 10 cases, in comparison with conventional Ewing sarcoma.Am J Surg Pathol. 2014 Oct;38(10):1307-18. doi: 10.1097/PAS.0000000000000223.
• [723] MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2.J Exp Clin Cancer Res. 2016 Apr 19;35:69. doi: 10.1186/s13046-016-0348-5.
• [724] Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
• [725] Immunoexpression analysis and prognostic value of BLCAP in breast cancer.PLoS One. 2012;7(9):e45967. doi: 10.1371/journal.pone.0045967. Epub 2012 Sep 25.
• [726] MicroRNA-603 functions as an oncogene by suppressing BRCC2 protein translation in osteosarcoma.Oncol Rep. 2016 Jun;35(6):3257-64. doi: 10.3892/or.2016.4718. Epub 2016 Mar 30.
• [727] Sequence and expression of bone morphogenetic protein 3 mRNA in prolonged cultures of fetal rat calvarial osteoblasts and in rat prostate adenocarcinoma PA III cells.DNA Cell Biol. 1995 Mar;14(3):235-9. doi: 10.1089/dna.1995.14.235.
• [728] Allelic loss at 10q26 in osteosarcoma in the region of the BUB3 and FGFR2 genes.Cancer Genet Cytogenet. 2005 Apr 15;158(2):142-7. doi: 10.1016/j.cancergencyto.2004.08.035.
• [729] Differential stimulation of signaling pathways initiated by Edg-2 in response to lysophosphatidic acid or sphingosine-1-phosphate.Cell Mol Life Sci. 2000 Jul;57(7):1109-16. doi: 10.1007/PL00000747.
• [730] The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line.Int J Oncol. 2007 Oct;31(4):915-22.
• [731] Inhibition of CaMKII Activity Enhances Antitumor Effect of Fullerene C60 Nanocrystals by Suppression of Autophagic Degradation.Adv Sci (Weinh). 2019 Feb 10;6(8):1801233. doi: 10.1002/advs.201801233. eCollection 2019 Apr 17.
• [732] MicroRNA profiling with correlation to gene expression revealed the oncogenic miR-17-92 cluster to be up-regulated in osteosarcoma.Cancer Genet. 2012 May;205(5):212-9. doi: 10.1016/j.cancergen.2012.03.001.
• [733] Upregulation of caprin1 expression is associated with poor prognosis in hepatocellular carcinoma.Pathol Res Pract. 2017 Dec;213(12):1563-1567. doi: 10.1016/j.prp.2017.07.014. Epub 2017 Jul 15.
• [734] Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells.Gene Ther. 2006 Mar;13(5):389-99. doi: 10.1038/sj.gt.3302674.
• [735] CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.Mol Med Rep. 2019 May;19(5):4205-4212. doi: 10.3892/mmr.2019.10104. Epub 2019 Mar 28.
• [736] Clinical impact of the methotrexate resistance-associated genes C-MYC and dihydrofolate reductase (DHFR) in high-grade osteosarcoma.Ann Oncol. 2008 Aug;19(8):1500-1508. doi: 10.1093/annonc/mdn148. Epub 2008 Apr 2.
• [737] Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1.J Mol Med (Berl). 2019 Jan;97(1):49-61. doi: 10.1007/s00109-018-1711-0. Epub 2018 Nov 13.
• [738] WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma.Cell Death Dis. 2017 Apr 13;8(4):e2750. doi: 10.1038/cddis.2016.421.
• [739] Retroviral cyclin enhances cyclin-dependent kinase-8 activity.J Virol. 2012 May;86(10):5742-51. doi: 10.1128/JVI.07006-11. Epub 2012 Feb 29.
• [740] MicroRNA-27a functions as an oncogene in human osteosarcoma by targeting CCNG1.Oncol Lett. 2018 Jan;15(1):1067-1071. doi: 10.3892/ol.2017.7389. Epub 2017 Nov 10.
• [741] CD151 knockdown inhibits osteosarcoma metastasis through the GSK-3/-catenin/MMP9 pathway.Oncol Rep. 2016 Mar;35(3):1764-70. doi: 10.3892/or.2015.4517. Epub 2015 Dec 24.
• [742] Targeting Tumor Vascular CD99 Inhibits Tumor Growth.Front Immunol. 2019 Apr 2;10:651. doi: 10.3389/fimmu.2019.00651. eCollection 2019.
• [743] Cell cycle regulator gene CDC5L, a potential target for 6p12-p21 amplicon in osteosarcoma.Mol Cancer Res. 2008 Jun;6(6):937-46. doi: 10.1158/1541-7786.MCR-07-2115.
• [744] CDH4 is a novel determinant of osteosarcoma tumorigenesis and metastasis.Oncogene. 2018 Jul;37(27):3617-3630. doi: 10.1038/s41388-018-0231-2. Epub 2018 Apr 3.
• [745] Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.Clin Cancer Res. 2012 Sep 1;18(17):4580-8. doi: 10.1158/1078-0432.CCR-12-1157. Epub 2012 Jul 12.
• [746] Structure of human cyclin-dependent kinase inhibitor p19INK4d: comparison to known ankyrin-repeat-containing structures and implications for the dysfunction of tumor suppressor p16INK4a.Structure. 1998 Oct 15;6(10):1279-90. doi: 10.1016/s0969-2126(98)00128-2.
• [747] Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase.Mol Cell Biol. 2005 Dec;25(24):10875-94. doi: 10.1128/MCB.25.24.10875-10894.2005.
• [748] Construction of a novel oncolytic adenoviral vector and its biological characteristics.Oncol Rep. 2013 Feb;29(2):798-804. doi: 10.3892/or.2012.2140. Epub 2012 Nov 15.
• [749] TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma.Int J Mol Med. 2018 Oct;42(4):1799-1808. doi: 10.3892/ijmm.2018.3753. Epub 2018 Jul 4.
• [750] CLDN10 promotes a malignant phenotype of osteosarcoma cells via JAK1/Stat1 signaling.J Cell Commun Signal. 2019 Sep;13(3):395-405. doi: 10.1007/s12079-019-00509-7. Epub 2019 Feb 22.
• [751] The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma.Cancer Manag Res. 2019 Nov 1;11:9339-9351. doi: 10.2147/CMAR.S229441. eCollection 2019.
• [752] Transcription Factor SOX9 Promotes Osteosarcoma Cell Growth by Repressing Claudin-8 Expression.Tohoku J Exp Med. 2017 Jan;241(1):55-63. doi: 10.1620/tjem.241.55.
• [753] Antisense suppression of the chloride intracellular channel family induces apoptosis, enhances tumor necrosis factor {alpha}-induced apoptosis, and inhibits tumor growth.Cancer Res. 2005 Jan 15;65(2):562-71.
• [754] Identification of CLUAP1 as a human osteosarcoma tumor-associated antigen recognized by the humoral immune system.Int J Oncol. 2007 Feb;30(2):461-7.
• [755] Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis.Int J Cancer. 1998 Jun 19;79(3):245-50. doi: 10.1002/(sici)1097-0215(19980619)79:3<245::aid-ijc6>3.0.co;2-p.
• [756] CNOT1 cooperates with LMNA to aggravate osteosarcoma tumorigenesis through the Hedgehog signaling pathway.Mol Oncol. 2017 Apr;11(4):388-404. doi: 10.1002/1878-0261.12043. Epub 2017 Mar 6.
• [757] Competitive PCR demonstrates that 9-cis retinoic acid induces cellular retinoic acid-binding protein-II more efficiently than all-trans retinoic acid in human osteosarcoma cells.Biochem Biophys Res Commun. 1994 Apr 29;200(2):1125-9. doi: 10.1006/bbrc.1994.1567.
• [758] RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.Cancer Chemother Pharmacol. 2009 Aug;64(3):607-14. doi: 10.1007/s00280-008-0912-6. Epub 2009 Jan 6.
• [759] Circular RNA circTADA2A promotes osteosarcoma progression and metastasis by sponging miR-203a-3p and regulating CREB3 expression.Mol Cancer. 2019 Apr 2;18(1):73. doi: 10.1186/s12943-019-1007-1.
• [760] CRIP1 expression is correlated with a favorable outcome and less metastases in osteosarcoma patients.Oncotarget. 2011 Dec;2(12):970-5. doi: 10.18632/oncotarget.398.
• [761] Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells.Cancer Chemother Pharmacol. 2012 May;69(5):1173-80. doi: 10.1007/s00280-011-1810-x. Epub 2012 Jan 12.
• [762] Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival.Cancer Biomark. 2011-2012;10(1):35-41. doi: 10.3233/CBM-2012-0227.
• [763] CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.Tumour Biol. 2016 Jun;37(6):8139-44. doi: 10.1007/s13277-015-4715-1. Epub 2015 Dec 29.
• [764] Small molecule TSC01682 inhibits osteosarcoma cell growth by specifically disrupting the CUL4B-DDB1 interaction and decreasing the ubiquitination of CRL4B E3 ligase substrates.Am J Cancer Res. 2019 Sep 1;9(9):1857-1870. eCollection 2019.
• [765] Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties.Biochemistry. 1997 Mar 4;36(9):2716-23. doi: 10.1021/bi961999z.
• [766] MicroRNA-661 Enhances TRAIL or STS Induced Osteosarcoma Cell Apoptosis by Modulating the Expression of Cytochrome c1.Cell Physiol Biochem. 2017;41(5):1935-1946. doi: 10.1159/000472380. Epub 2017 Apr 7.
• [767] LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma.Anticancer Res. 2007 Mar-Apr;27(2):761-8.
• [768] Rapid and reversible suppression of ALT by DAXX in osteosarcoma cells.Sci Rep. 2019 Mar 14;9(1):4544. doi: 10.1038/s41598-019-41058-8.
• [769] Caprin-1, a novel Cyr61-interacting protein, promotes osteosarcoma tumor growth and lung metastasis in mice.Biochim Biophys Acta. 2013 Aug;1832(8):1173-82. doi: 10.1016/j.bbadis.2013.03.014. Epub 2013 Mar 23.
• [770] Phenotypic changes associated with DYNACTIN-2 (DCTN2) over expression characterise SJSA-1 osteosarcoma cells.Mol Carcinog. 2006 Mar;45(3):157-63. doi: 10.1002/mc.20151.
• [771] DDX10 overexpression predicts worse prognosis in osteosarcoma and its deletion prohibits cell activities modulated by MAPK pathway.Biochem Biophys Res Commun. 2019 Mar 19;510(4):525-529. doi: 10.1016/j.bbrc.2019.01.114. Epub 2019 Feb 6.
• [772] Cross-species genomics identifies DLG2 as a tumor suppressor in osteosarcoma.Oncogene. 2019 Jan;38(2):291-298. doi: 10.1038/s41388-018-0444-4. Epub 2018 Aug 9.
• [773] Long noncoding RNA DNAJC3-AS1 promotes osteosarcoma progression via its sense-cognate gene DNAJC3.Cancer Med. 2019 Feb;8(2):761-772. doi: 10.1002/cam4.1955. Epub 2019 Jan 16.
• [774] The Poly(ADP-ribose) polymerase-1-regulated endonuclease DNAS1L3 is required for etoposide-induced internucleosomal DNA fragmentation and increases etoposide cytotoxicity in transfected osteosarcoma cells.Cancer Res. 2002 Aug 1;62(15):4439-44.
• [775] DOCK4, a GTPase activator, is disrupted during tumorigenesis.Cell. 2003 Mar 7;112(5):673-84. doi: 10.1016/s0092-8674(03)00155-7.
• [776] Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells.Mol Cancer Ther. 2013 Mar;12(3):314-25. doi: 10.1158/1535-7163.MCT-12-0869. Epub 2013 Jan 11.
• [777] Regulation of NOTCH signaling by reciprocal inhibition of HES1 and Deltex 1 and its role in osteosarcoma invasiveness.Oncogene. 2010 May 20;29(20):2916-26. doi: 10.1038/onc.2010.62. Epub 2010 Mar 8.
• [778] PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors.Oncogene. 2007 Mar 15;26(12):1714-22. doi: 10.1038/sj.onc.1209988. Epub 2006 Sep 25.
• [779] Potential Regulatory Effects of miR-182-3p in Osteosarcoma via Targeting EBF2.Biomed Res Int. 2019 Mar 12;2019:4897905. doi: 10.1155/2019/4897905. eCollection 2019.
• [780] Antimetastatic effects of calycosin on osteosarcoma and the underlying mechanism.Biofactors. 2019 Nov;45(6):975-982. doi: 10.1002/biof.1545. Epub 2019 Jul 19.
• [781] EEF1D overexpression promotes osteosarcoma cell proliferation by facilitating Akt-mTOR and Akt-bad signaling.J Exp Clin Cancer Res. 2018 Mar 6;37(1):50. doi: 10.1186/s13046-018-0715-5.
• [782] Fibulin-3 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition and activating the Wnt/-catenin signaling pathway.Sci Rep. 2017 Jul 24;7(1):6215. doi: 10.1038/s41598-017-06353-2.
• [783] De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway.Histopathology. 2010 Dec;57(6):836-50. doi: 10.1111/j.1365-2559.2010.03713.x.
• [784] Human osteosarcoma expresses specific ephrin profiles: implications for tumorigenicity and prognosis.Cancer. 2002 Aug 15;95(4):862-9. doi: 10.1002/cncr.10749.
• [785] The cyclooxygenase-2 inhibitor NS-398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway.Oncol Rep. 2012 Nov;28(5):1693-700. doi: 10.3892/or.2012.1992. Epub 2012 Aug 24.
• [786] IL-10 inhibits cysteinyl leukotriene-induced activation of human monocytes and monocyte-derived dendritic cells.J Immunol. 2008 Jun 1;180(11):7597-603. doi: 10.4049/jimmunol.180.11.7597.
• [787] The expression of Eps15 homology domain 1 is negatively correlated with disease-free survival and overall survival of osteosarcoma patients.J Orthop Surg Res. 2019 Apr 11;14(1):103. doi: 10.1186/s13018-019-1137-6.
• [788] Knockdown of EIF3C promotes human U-2OS cells apoptosis through increased CASP3/7 and Chk1/2 by upregulating SAPK/JNK.Onco Targets Ther. 2019 Feb 14;12:1225-1235. doi: 10.2147/OTT.S187209. eCollection 2019.
• [789] Distinct profiles of oxidative stress-related and matrix proteins in adult bone and soft tissue osteosarcoma and desmoid tumors: a proteomics study.Hum Pathol. 2013 May;44(5):725-33. doi: 10.1016/j.humpath.2012.06.023. Epub 2012 Oct 11.
• [790] Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.Mol Pharmacol. 2007 Jan;71(1):333-43. doi: 10.1124/mol.106.028837. Epub 2006 Oct 18.
• [791] Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population.Mamm Genome. 2017 Jun;28(5-6):227-233. doi: 10.1007/s00335-017-9693-8. Epub 2017 May 4.
• [792] Genetic variability of genes involved in DNA repair influence treatment outcome in osteosarcoma.Genet Mol Res. 2015 Sep 28;14(3):11652-7. doi: 10.4238/2015.September.28.17.
• [793] Letter regarding Li JS et al. entitled "ERCC polymorphisms and prognosis of patients with osteosarcoma".Tumour Biol. 2015 May;36(5):3195-6. doi: 10.1007/s13277-015-3345-y. Epub 2015 Apr 1.
• [794] The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.Transl Oncol. 2019 Jan;12(1):134-142. doi: 10.1016/j.tranon.2018.09.001. Epub 2018 Oct 5.
• [795] Endoplasmic reticulum protein 29 (ERp29) as a novel prognostic marker and tumor suppressor in osteosarcoma.J Bone Oncol. 2019 Mar 19;16:100233. doi: 10.1016/j.jbo.2019.100233. eCollection 2019 Jun.
• [796] Chromosome 13 instability and esterase D expression in an osteosarcoma cell line.Cancer Genet Cytogenet. 1987 Feb;24(2):327-34. doi: 10.1016/0165-4608(87)90115-4.
• [797] Overexpression and mislocalization of the chromosomal segregation protein separase in multiple human cancers.Clin Cancer Res. 2009 Apr 15;15(8):2703-10. doi: 10.1158/1078-0432.CCR-08-2454. Epub 2009 Apr 7.
• [798] An EWS-FLI1-Induced Osteosarcoma Model Unveiled a Crucial Role of Impaired Osteogenic Differentiation on Osteosarcoma Development.Stem Cell Reports. 2016 Apr 12;6(4):592-606. doi: 10.1016/j.stemcr.2016.02.009. Epub 2016 Mar 17.
• [799] Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines.Int J Cancer. 2004 May 1;109(5):661-7. doi: 10.1002/ijc.20008.
• [800] A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma.BMC Cancer. 2011 May 29;11:209. doi: 10.1186/1471-2407-11-209.
• [801] fau and its ubiquitin-like domain (FUBI) transforms human osteogenic sarcoma (HOS) cells to anchorage-independence.Oncogene. 2003 Mar 27;22(12):1817-21. doi: 10.1038/sj.onc.1206283.
• [802] A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines.Curr Pharm Des. 2018;24(16):1821-1826. doi: 10.2174/1381612824666180406103317.
• [803] Inhibitory Effects of Indomethacin in Human MNNG/HOS Osteosarcoma Cell Line InVitro.Cancer Invest. 2020 Jan;38(1):23-36. doi: 10.1080/07357907.2019.1698592. Epub 2019 Dec 16.
• [804] Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis.Cancer Cell Int. 2018 Oct 22;18:166. doi: 10.1186/s12935-018-0651-7. eCollection 2018.
• [805] Parathyroid hormone affects the fibroblast growth factor-proteoglycan signaling axis to regulate osteosarcoma cell migration.FEBS J. 2011 Oct;278(19):3782-92. doi: 10.1111/j.1742-4658.2011.08300.x. Epub 2011 Sep 8.
• [806] FGF5 promotes osteosarcoma cells proliferation via activating MAPK signaling pathway.Cancer Manag Res. 2019 Jul 10;11:6457-6466. doi: 10.2147/CMAR.S200234. eCollection 2019.
• [807] MiR-361 inhibits osteosarcoma cell lines invasion and proliferation by targeting FKBP14.Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):79-86. doi: 10.26355/eurrev_201801_14103.
• [808] miR-145 promotes osteosarcoma growth by reducing expression of the transcription factor friend leukemia virus integration 1.Oncotarget. 2016 Jul 5;7(27):42241-42251. doi: 10.18632/oncotarget.9948.
• [809] FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma.Appl Immunohistochem Mol Morphol. 2011 May;19(3):233-8. doi: 10.1097/PAI.0b013e3181fd6697.
• [810] Silencing of long noncoding RNA SBF2-AS1 inhibits proliferation, migration and invasion and contributes to apoptosis in osteosarcoma cells by upregulating microRNA-30a to suppress FOXA1 expression.Cell Cycle. 2019 Oct;18(20):2727-2741. doi: 10.1080/15384101.2019.1656478. Epub 2019 Aug 21.
• [811] Circular RNA circNASP modulates the malignant behaviors in osteosarcoma via miR-1253/FOXF1 pathway.Biochem Biophys Res Commun. 2018 Jun 2;500(2):511-517. doi: 10.1016/j.bbrc.2018.04.131. Epub 2018 Apr 21.
• [812] miR-186-5p Functions as a Tumor Suppressor in Human Osteosarcoma by Targeting FOXK1.Cell Physiol Biochem. 2019;52(3):553-564. doi: 10.33594/000000039.
• [813] MicroRNA-139 inhibits the proliferation and migration of osteosarcoma cells via targeting forkhead-box P2.Life Sci. 2017 Dec 15;191:68-73. doi: 10.1016/j.lfs.2017.10.010. Epub 2017 Oct 7.
• [814] Up-regulation of microRNA-491-5p suppresses cell proliferation and promotes apoptosis by targeting FOXP4 in human osteosarcoma.Cell Prolif. 2017 Feb;50(1):e12308. doi: 10.1111/cpr.12308. Epub 2016 Oct 5.
• [815] Oncogenic activation of FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma.Oncogene. 2012 Mar 22;31(12):1571-81. doi: 10.1038/onc.2011.344. Epub 2011 Aug 22.
• [816] Amplification of FRS2 in atypical lipomatous tumour/well-differentiated liposarcoma and de-differentiated liposarcoma: a clinicopathological and genetic study of 146 cases.Histopathology. 2018 Jun;72(7):1145-1155. doi: 10.1111/his.13473. Epub 2018 Mar 7.
• [817] Decreased local and systemic levels of sFRP3 protein in osteosarcoma patients.Gene. 2018 Oct 20;674:1-7. doi: 10.1016/j.gene.2018.06.059. Epub 2018 Jun 19.
• [818] MiR-1 Suppresses Proliferation of Osteosarcoma Cells by Up-regulating p21 via PAX3.Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):71-79. doi: 10.21873/cgp.20113.
• [819] Decreased expression of ferritin light chain in osteosarcoma and its correlation with epithelial-mesenchymal transition.Eur Rev Med Pharmacol Sci. 2018 May;22(9):2580-2587. doi: 10.26355/eurrev_201805_14951.
• [820] MiR-372-3p inhibits the growth and metastasis of osteosarcoma cells by targeting FXYD6.Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):62-69. doi: 10.26355/eurrev_201801_14101.
• [821] Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells.Int J Clin Exp Pathol. 2014 Jul 15;7(8):4795-805. eCollection 2014.
• [822] Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells.J Orthop Res. 2007 Jul;25(7):964-71. doi: 10.1002/jor.20356.
• [823] Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression.Apoptosis. 2009 Jan;14(1):124-33. doi: 10.1007/s10495-008-0282-x.
• [824] MiR-16-1-3p and miR-16-2-3p possess strong tumor suppressive and antimetastatic properties in osteosarcoma.Int J Cancer. 2019 Dec 1;145(11):3052-3063. doi: 10.1002/ijc.32368. Epub 2019 May 9.
• [825] Purification and partial identification of bone-inducing protein from a murine osteosarcoma.Biochem J. 1992 Jun 15;284 ( Pt 3)(Pt 3):847-54. doi: 10.1042/bj2840847.
• [826] GFRA1: A Novel Molecular Target for the Prevention of Osteosarcoma Chemoresistance.Int J Mol Sci. 2018 Apr 4;19(4):1078. doi: 10.3390/ijms19041078.
• [827] The oncogenic role of GNL3 in the progression and metastasis of osteosarcoma.Cancer Manag Res. 2019 Mar 15;11:2179-2188. doi: 10.2147/CMAR.S195360. eCollection 2019.
• [828] Proton-sensing G-protein-coupled receptors. Nature. 2003 Sep 4;425(6953):93-8. doi: 10.1038/nature01905.
• [829] Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.J Cell Physiol. 2020 Mar;235(3):2911-2924. doi: 10.1002/jcp.29197. Epub 2019 Sep 18.
• [830] miR?28?p enhances the radiosensitivity of osteosarcoma and regulates apoptosis and cell viability via H2AX.Oncol Rep. 2018 Feb;39(2):545-553. doi: 10.3892/or.2017.6112. Epub 2017 Nov 27.
• [831] Concerted control of multiple histone promoter factors during cell density inhibition of proliferation in osteosarcoma cells: reciprocal regulation of cell cycle-controlled and bone-related genes.Cancer Res. 1993 May 15;53(10 Suppl):2399-409.
• [832] Absence of H3F3A mutation in a subset of malignant giant cell tumor of bone.Mod Pathol. 2019 Dec;32(12):1751-1761. doi: 10.1038/s41379-019-0318-5. Epub 2019 Jul 8.
• [833] HACE1 is a potential tumor suppressor in osteosarcoma.Cell Death Dis. 2019 Jan 8;10(1):21. doi: 10.1038/s41419-018-1276-4.
• [834] HAS3-related hyaluronan enhances biological activities necessary for metastasis of osteosarcoma cells.Int J Oncol. 2006 Jul;29(1):175-83.
• [835] Functional testing of thousands of osteoarthritis-associated variants for regulatory activity.Nat Commun. 2019 Jun 4;10(1):2434. doi: 10.1038/s41467-019-10439-y.
• [836] Scavenger chemokine (CXC motif) receptor 7 (CXCR7) is a direct target gene of HIC1 (hypermethylated in cancer 1).J Biol Chem. 2009 Jul 31;284(31):20927-35. doi: 10.1074/jbc.M109.022350. Epub 2009 Jun 12.
• [837] Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas.Tumour Biol. 2015 Jan;36(1):227-31. doi: 10.1007/s13277-014-2621-6. Epub 2014 Sep 18.
• [838] MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.Sci Rep. 2017 Mar 24;7(1):416. doi: 10.1038/s41598-017-00405-3.
• [839] MicroRNA?73 targets HOXA9 to inhibit the aggressive phenotype of osteosarcoma by deactivating the Wnt/catenin pathway.Int J Oncol. 2019 May;54(5):1809-1820. doi: 10.3892/ijo.2019.4735. Epub 2019 Feb 28.
• [840] Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway.Biomed Pharmacother. 2019 Jan;109:2335-2341. doi: 10.1016/j.biopha.2018.11.026. Epub 2018 Nov 29.
• [841] Downregulation of Homeobox B7 Inhibits the Tumorigenesis and Progression of Osteosarcoma.Oncol Res. 2017 Aug 7;25(7):1089-1095. doi: 10.3727/096504016X14784668796788. Epub 2016 Nov 8.
• [842] Knockdown of HOXB8 inhibits tumor growth and metastasis by the inactivation of Wnt/-catenin signaling pathway in osteosarcoma.Eur J Pharmacol. 2019 Jul 5;854:22-27. doi: 10.1016/j.ejphar.2019.04.004. Epub 2019 Apr 5.
• [843] Homeobox C10 knockdown suppresses cell proliferation and promotes cell apoptosis in osteosarcoma cells through regulating caspase 3.Onco Targets Ther. 2018 Jan 22;11:473-482. doi: 10.2147/OTT.S143440. eCollection 2018.
• [844] Mutations in the mitochondrial DNA D-Loop region occur frequently in human osteosarcoma.Cancer Lett. 2006 Jul 28;239(1):151-5. doi: 10.1016/j.canlet.2005.08.008. Epub 2005 Oct 20.
• [845] Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide.Clin Cancer Res. 2009 Dec 1;15(23):7161-9. doi: 10.1158/1078-0432.CCR-08-2816. Epub 2009 Nov 17.
• [846] IFI16 inhibits tumorigenicity and cell proliferation of bone and cartilage tumor cells.Front Biosci. 2007 Sep 1;12:4855-63. doi: 10.2741/2433.
• [847] miR-628-5p promotes growth and migration of osteosarcoma by targeting IFI44L.Biochem Cell Biol. 2020 Apr;98(2):99-105. doi: 10.1139/bcb-2019-0001. Epub 2019 Apr 24.
• [848] Expression of microRNA-150 and its Target Gene IGF2BP1 in Human Osteosarcoma and their Clinical Implications.Pathol Oncol Res. 2019 Apr;25(2):527-533. doi: 10.1007/s12253-018-0454-0. Epub 2018 Sep 15.
• [849] Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma.Oncol Res. 2008;17(6):269-72. doi: 10.3727/096504008786991639.
• [850] IL-17A/IL-17RA interaction promoted metastasis of osteosarcoma cells.Cancer Biol Ther. 2013 Feb;14(2):155-63. doi: 10.4161/cbt.22955. Epub 2012 Nov 28.
• [851] Adenovirus-mediated interleukin 3 beta gene transfer by isolated limb perfusion inhibits growth of limb sarcoma in rats.Hum Gene Ther. 2001 Mar 20;12(5):489-502. doi: 10.1089/104303401300042384.
• [852] Adenovirus-mediated ING4 Gene Transfer in Osteosarcoma Suppresses Tumor Growth via Induction of Apoptosis and Inhibition of Tumor Angiogenesis.Technol Cancer Res Treat. 2015 Aug;14(4):369-78. doi: 10.1177/1533034614500424. Epub 2014 Oct 16.
• [853] Up-regulated MiR-27-3p promotes the G1-S phase transition by targeting inhibitor of growth family member 5 in osteosarcoma.Biomed Pharmacother. 2018 May;101:219-227. doi: 10.1016/j.biopha.2018.02.066. Epub 2018 Feb 26.
• [854] IRX2-mediated upregulation of MMP-9 and VEGF in a PI3K/AKT-dependent manner.Mol Med Rep. 2015 Sep;12(3):4346-4351. doi: 10.3892/mmr.2015.3915. Epub 2015 Jun 11.
• [855] MiR-26a inhibits stem cell-like phenotype and tumor growth of osteosarcoma by targeting Jagged1.Oncogene. 2017 Jan 12;36(2):231-241. doi: 10.1038/onc.2016.194. Epub 2016 Jun 6.
• [856] Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.J Cell Mol Med. 2019 Sep;23(9):6154-6163. doi: 10.1111/jcmm.14497. Epub 2019 Jun 20.
• [857] The function of DREAM gene mediated by NF-kB signal pathway in the pathogenesis of osteosarcoma.J BUON. 2017 Jul-Aug;22(4):1068-1072.
• [858] Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.PLoS One. 2012;7(4):e34618. doi: 10.1371/journal.pone.0034618. Epub 2012 Apr 13.
• [859] Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.Cancer Sci. 2017 Sep;108(9):1870-1880. doi: 10.1111/cas.13316. Epub 2017 Aug 3.
• [860] Effects of Kruppel-like factor 6 on osteosarcoma cell biological behavior.Tumour Biol. 2013 Apr;34(2):1097-105. doi: 10.1007/s13277-013-0651-0. Epub 2013 Jan 16.
• [861] Upregulated miRNA-1236-3p in osteosarcoma inhibits cell proliferation and induces apoptosis via targeting KLF8.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6053-6061. doi: 10.26355/eurrev_201907_18418.
• [862] KMT2C modulates migration and invasion processes in osteosarcoma cell lines.Pathol Res Pract. 2019 Oct;215(10):152534. doi: 10.1016/j.prp.2019.152534. Epub 2019 Jul 12.
• [863] LAMP3 plays an oncogenic role in osteosarcoma cells partially by inhibiting TP53.Cell Mol Biol Lett. 2018 Jul 11;23:33. doi: 10.1186/s11658-018-0099-8. eCollection 2018.
• [864] Circular RNA LARP4 correlates with decreased Enneking stage, better histological response, and prolonged survival profiles, and it elevates chemosensitivity to cisplatin and doxorubicin via sponging microRNA-424 in osteosarcoma.J Clin Lab Anal. 2020 Feb;34(2):e23045. doi: 10.1002/jcla.23045. Epub 2019 Oct 22.
• [865] LHX2 promotes malignancy and inhibits autophagy via mTOR in osteosarcoma and is negatively regulated by miR-129-5p.Aging (Albany NY). 2019 Nov 13;11(21):9794-9810. doi: 10.18632/aging.102427. Epub 2019 Nov 13.
• [866] Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model.Mol Cancer. 2014 Apr 28;13:93. doi: 10.1186/1476-4598-13-93.
• [867] miR-421 promotes apoptosis and suppresses metastasis of osteosarcoma cells via targeting LTBP2.J Cell Biochem. 2019 Jul;120(7):10978-10987. doi: 10.1002/jcb.28144. Epub 2019 Mar 28.
• [868] Lumican regulates osteosarcoma cell adhesion by modulating TGF2 activity.Int J Biochem Cell Biol. 2011 Jun;43(6):928-35. doi: 10.1016/j.biocel.2011.03.008. Epub 2011 Mar 21.
• [869] Gene expression profiling of alpha-radiation-induced rat osteosarcomas: identification of dysregulated genes involved in radiation-induced tumorigenesis of bone.Int J Cancer. 2009 Aug 1;125(3):612-20. doi: 10.1002/ijc.24392.
• [870] MicroRNA-432 is downregulated in osteosarcoma and inhibits cell proliferation and invasion by directly targeting metastasis-associated in colon cancer-1.Exp Ther Med. 2019 Jan;17(1):919-926. doi: 10.3892/etm.2018.7029. Epub 2018 Nov 29.
• [871] DDTD, an isoflavone derivative, induces cell apoptosis through the reactive oxygen species/apoptosis signal-regulating kinase 1 pathway in human osteosarcoma cells.Eur J Pharmacol. 2008 Nov 12;597(1-3):19-26. doi: 10.1016/j.ejphar.2008.08.036. Epub 2008 Sep 16.
• [872] MicroRNA-27a promotes proliferation, migration and invasion by targeting MAP2K4 in human osteosarcoma cells.Cell Physiol Biochem. 2014;33(2):402-12. doi: 10.1159/000356679. Epub 2014 Feb 11.
• [873] Long non-coding RNA EPIC1 inhibits viability and invasion of osteosarcoma cells by promoting MEF2D ubiquitylation.Int J Biol Macromol. 2019 May 1;128:566-573. doi: 10.1016/j.ijbiomac.2019.01.156. Epub 2019 Jan 28.
• [874] Capsaicin induces apoptosis in human osteosarcoma cells through AMPK-dependent and AMPK-independent signaling pathways.Mol Cell Biochem. 2013 Dec;384(1-2):229-37. doi: 10.1007/s11010-013-1802-8. Epub 2013 Sep 5.
• [875] Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1-dependent manner.Int J Oncol. 2012 Dec;41(6):2005-12. doi: 10.3892/ijo.2012.1630. Epub 2012 Sep 18.
• [876] Osteogenic BMPs promote tumor growth of human osteosarcomas that harbor differentiation defects.Lab Invest. 2008 Dec;88(12):1264-77. doi: 10.1038/labinvest.2008.98. Epub 2008 Oct 6.
• [877] Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.Asian Pac J Cancer Prev. 2013;14(3):2049-52. doi: 10.7314/apjcp.2013.14.3.2049.
• [878] MAT1 facilitates the lung metastasis of osteosarcoma through upregulation of AKT1 expression.Life Sci. 2019 Oct 1;234:116771. doi: 10.1016/j.lfs.2019.116771. Epub 2019 Aug 14.
• [879] Hsa-miR-889-3p promotes the proliferation of osteosarcoma through inhibiting myeloid cell nuclear differentiation antigen expression.Biomed Pharmacother. 2019 Jun;114:108819. doi: 10.1016/j.biopha.2019.108819. Epub 2019 Apr 2.
• [880] Epstein-Barr virus infection induces expression in B lymphocytes of a novel gene encoding an evolutionarily conserved 55-kilodalton actin-bundling protein.J Virol. 1994 Nov;68(11):7320-8. doi: 10.1128/JVI.68.11.7320-7328.1994.
• [881] Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells. Int J Cancer. 2006 Jan 1;118(1):90-7. doi: 10.1002/ijc.21297.
• [882] Inhibitory effect of MSH6 gene silencing in combination with cisplatin on cell proliferation of human osteosarcoma cell line MG63.J Cell Physiol. 2019 Jun;234(6):9358-9369. doi: 10.1002/jcp.27620. Epub 2018 Nov 19.
• [883] Expression of osteocalcin and its transcriptional regulators core-binding factor alpha 1 and MSX2 in osteoid-forming tumours.J Orthop Res. 1999 Sep;17(5):633-8. doi: 10.1002/jor.1100170503.
• [884] Outpatient High-dose Methotrexate for Osteosarcoma: It's Safe and Feasible, If You Want It.J Pediatr Hematol Oncol. 2019 Jul;41(5):394-398. doi: 10.1097/MPH.0000000000001238.
• [885] Primary sclerosing epithelioid fibrosarcoma of bone: analysis of a series.Am J Surg Pathol. 2014 Nov;38(11):1538-44. doi: 10.1097/PAS.0000000000000265.
• [886] Expression of major vault protein gene in osteosarcoma patients.J Orthop Res. 2007 Jul;25(7):958-63. doi: 10.1002/jor.20371.
• [887] An integrative analysis of DNA methylation in osteosarcoma.J Bone Oncol. 2017 May 19;9:34-40. doi: 10.1016/j.jbo.2017.05.001. eCollection 2017 Nov.
• [888] Human smooth muscle myosin light chain-2 gene expression is repressed in ras transformed fibroblast cells.Cell Growth Differ. 1992 Jan;3(1):1-10.
• [889] Myosin-18B Promotes the Assembly of Myosin II Stacks for Maturation of Contractile Actomyosin Bundles.Curr Biol. 2019 Jan 7;29(1):81-92.e5. doi: 10.1016/j.cub.2018.11.045. Epub 2018 Dec 20.
• [890] Amplification and protein expression of chromosome 12q13-15 genes in osteosarcomas of the jaws.Oral Oncol. 2001 Oct;37(7):566-71. doi: 10.1016/s1368-8375(00)00130-5.
• [891] Evaluation of the Effects of Aminonaphthoquinone Derivatives in Combination with Curcumin Against ER-positive Breast Cancer and Related Tumours.Anticancer Res. 2017 Dec;37(12):6749-6759. doi: 10.21873/anticanres.12135.
• [892] Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma.Clin Cancer Res. 2002 Mar;8(3):788-93.
• [893] Depletion of Neuroguidin/CANu1 sensitizes human osteosarcoma U2OS cells to doxorubicin.BMB Rep. 2011 Jan;44(1):46-51. doi: 10.5483/BMBRep.2011.44.1.46.
• [894] Downregulation of NKD1 in human osteosarcoma and its clinical significance.Mol Med Rep. 2018 Jan;17(1):1111-1117. doi: 10.3892/mmr.2017.7968. Epub 2017 Nov 6.
• [895] Nucleoside diphosphate kinase B promotes osteosarcoma proliferation through c-Myc.Cancer Biol Ther. 2018 Jul 3;19(7):565-572. doi: 10.1080/15384047.2017.1416273. Epub 2018 Apr 13.
• [896] Long non-coding RNA ZFAS1 regulates NOB1 expression through interacting with miR-646 and promotes tumorigenesis in osteosarcoma.Eur Rev Med Pharmacol Sci. 2019 Apr;23(8):3206-3216. doi: 10.26355/eurrev_201904_17679.
• [897] Noninvasive Multimodal Imaging of Osteosarcoma and Lymph Nodes Using a (99m)Tc-Labeled Biomineralization Nanoprobe.Anal Chem. 2018 Apr 3;90(7):4529-4534. doi: 10.1021/acs.analchem.7b04925. Epub 2018 Mar 13.
• [898] LncSNHG16 promotes proliferation and migration of osteosarcoma cells by targeting microRNA-146a-5p.Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):96-104. doi: 10.26355/eurrev_201901_16753.
• [899] NPRL2 is an independent prognostic factor of osteosarcoma.Cancer Biomark. 2012-2013;12(1):31-6. doi: 10.3233/CBM-120290.
• [900] Long noncoding RNA NR2F1-AS1 enhances the malignant properties of osteosarcoma by increasing forkhead box A1 expression via sponging of microRNA-483-3p.Aging (Albany NY). 2019 Dec 4;11(23):11609-11623. doi: 10.18632/aging.102563. Epub 2019 Dec 4.
• [901] Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.Cell Death Dis. 2019 Jan 25;10(2):65. doi: 10.1038/s41419-019-1347-1.
• [902] p21WAF1/CIP1 gene DNA sequencing and its expression in human osteosarcoma.Chin Med J (Engl). 2004 Jun;117(6):936-40.
• [903] Comparative genomic hybridization analysis identifies gains of 1p35 approximately p36 and chromosome 19 in osteosarcoma.Cancer Genet Cytogenet. 2001 Oct 1;130(1):14-21. doi: 10.1016/s0165-4608(01)00461-7.
• [904] Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway.Cancer Manag Res. 2018 Oct 8;10:4311-4323. doi: 10.2147/CMAR.S173496. eCollection 2018.
• [905] Ovol2 induces mesenchymal-epithelial transition via targeting ZEB1 in osteosarcoma.Onco Targets Ther. 2018 May 22;11:2963-2973. doi: 10.2147/OTT.S157119. eCollection 2018.
• [906] Modulation of apoptotic signalling by 9-hydroxystearic acid in osteosarcoma cells.Biochim Biophys Acta. 2007 Feb;1771(2):139-46. doi: 10.1016/j.bbalip.2006.11.012. Epub 2006 Dec 13.
• [907] Opposite effects of oxytocin on proliferation of osteosarcoma cell lines.Regul Pept. 2008 Oct 9;150(1-3):50-4. doi: 10.1016/j.regpep.2008.02.007. Epub 2008 Mar 4.
• [908] PHD4 stimulates tumor angiogenesis in osteosarcoma cells via TGF-.Mol Cancer Res. 2013 Nov;11(11):1337-48. doi: 10.1158/1541-7786.MCR-13-0201. Epub 2013 Sep 18.
• [909] An arrayed human genomic library constructed in the PAC shuttle vector pJCPAC-Mam2 for genome-wide association studies and gene therapy.Gene. 2012 Apr 1;496(2):103-9. doi: 10.1016/j.gene.2012.01.011. Epub 2012 Jan 24.
• [910] Specific Small-Molecule NIR-II Fluorescence Imaging of Osteosarcoma and Lung Metastasis.Adv Healthc Mater. 2020 Jan;9(1):e1901224. doi: 10.1002/adhm.201901224. Epub 2019 Dec 3.
• [911] PAK5 overexpression is associated with lung metastasis in osteosarcoma.Oncol Lett. 2018 Feb;15(2):2202-2210. doi: 10.3892/ol.2017.7545. Epub 2017 Dec 7.
• [912] Altered regulation of platelet-derived growth factor receptor-alpha gene-transcription in vitro by spina bifida-associated mutant Pax1 proteins.Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14459-63. doi: 10.1073/pnas.95.24.14459.
• [913] MicroRNA-206 Reduces Osteosarcoma Cell Malignancy In Vitro by Targeting the PAX3-MET Axis.Yonsei Med J. 2019 Feb;60(2):163-173. doi: 10.3349/ymj.2019.60.2.163.
• [914] LIM mineralization protein-1 inhibits the malignant phenotypes of human osteosarcoma cells.Int J Mol Sci. 2014 Apr 23;15(4):7037-48. doi: 10.3390/ijms15047037.
• [915] Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.Blood. 2019 Nov 28;134(22):1912-1918. doi: 10.1182/blood.2019001388.
• [916] miR-363 acts as a tumor suppressor in osteosarcoma cells by inhibiting PDZD2.Oncol Rep. 2019 May;41(5):2729-2738. doi: 10.3892/or.2019.7078. Epub 2019 Mar 19.
• [917] Cloning and functional characterization of PELP1/MNAR promoter.Gene. 2004 Apr 14;330:115-22. doi: 10.1016/j.gene.2004.01.011.
• [918] Polycomb group molecule PHC3 regulates polycomb complex composition and prognosis of osteosarcoma.Cancer Sci. 2010 Jul;101(7):1646-52. doi: 10.1111/j.1349-7006.2010.01586.x. Epub 2010 Apr 7.
• [919] Upregulation of miR-214 Induced Radioresistance of Osteosarcoma by Targeting PHLDA2 via PI3K/Akt Signaling.Front Oncol. 2019 Apr 18;9:298. doi: 10.3389/fonc.2019.00298. eCollection 2019.
• [920] PKD1 negatively regulates cell invasion, migration and proliferation ability of human osteosarcoma.Int J Oncol. 2012 Jun;40(6):1839-48. doi: 10.3892/ijo.2012.1400. Epub 2012 Mar 12.
• [921] Divergent in vitro effects of recombinant interferons on human osteosarcoma cells.Bone. 1990;11(4):247-51. doi: 10.1016/8756-3282(90)90077-c.
• [922] miR-200bc/429 Inhibits Osteosarcoma Cell Proliferation and Invasion by Targeting PMP22.Med Sci Monit. 2017 Feb 24;23:1001-1008. doi: 10.12659/msm.900084.
• [923] Overexpression through amplification of genes in chromosome region 17p11.2 approximately p12 in high-grade osteosarcoma.Cancer Genet Cytogenet. 2004 Jul 1;152(1):8-14. doi: 10.1016/j.cancergencyto.2003.09.024.
• [924] Identification of valid reference housekeeping genes for gene expression analysis in tumor neovascularization studies.Clin Transl Oncol. 2013 Mar;15(3):211-8. doi: 10.1007/s12094-012-0904-1. Epub 2012 Jul 25.
• [925] LncRNA SND1-IT1 accelerates the proliferation and migration of osteosarcoma via sponging miRNA-665 to upregulate POU2F1.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9772-9780. doi: 10.26355/eurrev_201911_19540.
• [926] Overexpression of FER1L4 promotes the apoptosis and suppresses epithelial-mesenchymal transition and stemness markers via activating PI3K/AKT signaling pathway in osteosarcoma cells.Pathol Res Pract. 2019 Jun;215(6):152412. doi: 10.1016/j.prp.2019.04.004. Epub 2019 Apr 6.
• [927] Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.
• [928] Silencing of YY1 downregulates RIZ1 promoter in human osteosarcoma.Oncol Res. 2008;17(1):33-41. doi: 10.3727/096504008784046081.
• [929] Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics. 2013 Oct 8;91:393-404. doi: 10.1016/j.jprot.2013.07.022. Epub 2013 Aug 2.
• [930] Thrombospondin-1 is a transcriptional repression target of PRMT6.J Biol Chem. 2009 Aug 7;284(32):21338-46. doi: 10.1074/jbc.M109.005322. Epub 2009 Jun 9.
• [931] Prion proteins (PRNP and PRND) are over-expressed in osteosarcoma.J Orthop Res. 2012 Jun;30(6):1004-12. doi: 10.1002/jor.22034. Epub 2011 Dec 6.
• [932] miR-486 suppresses the development of osteosarcoma by regulating PKC- pathway.Int J Oncol. 2017 May;50(5):1590-1600. doi: 10.3892/ijo.2017.3928. Epub 2017 Mar 22.
• [933] A p27Kip1 mutant that does not inhibit CDK activity promotes centrosome amplification and micronucleation.Oncogene. 2012 Aug 30;31(35):3989-98. doi: 10.1038/onc.2011.550. Epub 2011 Dec 12.
• [934] Lower miR-630 expression predicts poor prognosis of osteosarcoma and promotes cell proliferation, migration and invasion by targeting PSMC2.Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):1915-1925. doi: 10.26355/eurrev_201903_17229.
• [935] Bone-targeting parathyroid hormone conjugates outperform unmodified PTH in the anabolic treatment of osteoporosis in rats.Drug Deliv Transl Res. 2017 Aug;7(4):482-496. doi: 10.1007/s13346-017-0407-2.
• [936] MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A.Biosci Rep. 2019 Jul 10;39(7):BSR20190198. doi: 10.1042/BSR20190198. Print 2019 Jul 31.
• [937] Knockdown of PTHR1 in osteosarcoma cells decreases invasion and growth and increases tumor differentiation in vivo.Oncogene. 2015 May 28;34(22):2922-33. doi: 10.1038/onc.2014.217. Epub 2014 Jul 21.
• [938] CDC20 and its downstream genes: potential prognosis factors of osteosarcoma.Int J Clin Oncol. 2019 Nov;24(11):1479-1489. doi: 10.1007/s10147-019-01500-3. Epub 2019 Jul 5.
• [939] Development of a T-cell receptor multimer with high avidity for detecting a naturally presented tumor-associated antigen on osteosarcoma cells.Cancer Sci. 2019 Jan;110(1):40-51. doi: 10.1111/cas.13854. Epub 2018 Dec 1.
• [940] Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma.Oncogene. 2005 Jul 14;24(30):4754-64. doi: 10.1038/sj.onc.1208654.
• [941] MiR-329 suppresses osteosarcoma development by downregulating Rab10. FEBS Lett. 2016 Sep;590(17):2973-81.
• [942] Effect of RAB31 silencing on osteosarcoma cell proliferation and migration through the Hedgehog signaling pathway.J Bone Miner Metab. 2019 Jul;37(4):594-606. doi: 10.1007/s00774-018-0961-9. Epub 2018 Nov 23.
• [943] The lncRNA HOXA11-AS regulates Rab3D expression by sponging miR-125a-5p promoting metastasis of osteosarcoma.Cancer Manag Res. 2019 May 16;11:4505-4518. doi: 10.2147/CMAR.S196025. eCollection 2019.
• [944] Down-regulation of RAC2 by small interfering RNA restrains the progression of osteosarcoma by suppressing the Wnt signaling pathway.Int J Biol Macromol. 2019 Sep 15;137:1221-1231. doi: 10.1016/j.ijbiomac.2019.07.016. Epub 2019 Jul 3.
• [945] Knockdown of Mad2 induces osteosarcoma cell apoptosis-involved Rad21 cleavage.J Orthop Sci. 2011 Nov;16(6):814-20. doi: 10.1007/s00776-011-0156-x. Epub 2011 Sep 7.
• [946] Altered expression and deletion of RMO1 in osteosarcoma.Int J Cancer. 2005 May 1;114(5):738-46. doi: 10.1002/ijc.20786.
• [947] Zoledronate-induced S phase arrest and apoptosis accompanied by DNA damage and activation of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells.Int J Oncol. 2007 Aug;31(2):285-91.
• [948] Preferential expression of RB1-inducible coiled-coil 1 in terminal differentiated musculoskeletal cells.Am J Pathol. 2002 Aug;161(2):359-64. doi: 10.1016/S0002-9440(10)64190-9.
• [949] Clld7, a candidate tumor suppressor on chromosome 13q14, regulates pathways of DNA damage/repair and apoptosis.Cancer Res. 2010 Nov 15;70(22):9434-43. doi: 10.1158/0008-5472.CAN-10-1960. Epub 2010 Oct 5.
• [950] Single nucleotide polymorphism in the RECQL5 gene increased osteosarcoma susceptibility in a Chinese Han population.Genet Mol Res. 2015 Mar 13;14(1):1899-902. doi: 10.4238/2015.March.13.18.
• [951] Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003 May 7;95(9):669-74. doi: 10.1093/jnci/95.9.669.
• [952] Steroid receptor co-activator-1 mediates 1,25-dihydroxyvitamin D(3)-stimulated alkaline phosphatase in human osteosarcoma cells.Calcif Tissue Int. 2000 May;66(5):370-4. doi: 10.1007/s002230010075.
• [953] Downregulated RhoBTB2 expression contributes to poor outcome in osteosarcoma patients.Cancer Biother Radiopharm. 2013 Dec;28(10):709-16. doi: 10.1089/cbr.2012.1386. Epub 2013 Jun 18.
• [954] Combined analysis of DNA methylation and gene expression profiles of osteosarcoma identified several prognosis signatures.Gene. 2018 Apr 15;650:7-14. doi: 10.1016/j.gene.2018.01.093. Epub 2018 Jan 31.
• [955] Down-regulation of ribosomal protein L7A in human osteosarcoma.J Cancer Res Clin Oncol. 2009 Aug;135(8):1025-31. doi: 10.1007/s00432-008-0538-4. Epub 2009 Jan 6.
• [956] Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines.J Cell Biochem. 2008 Feb 15;103(3):994-1004. doi: 10.1002/jcb.21472.
• [957] Regulatory mechanism of microRNA-128 in osteosarcoma tumorigenesis and evolution through targeting SASH1.Oncol Lett. 2018 Jun;15(6):8687-8694. doi: 10.3892/ol.2018.8397. Epub 2018 Mar 30.
• [958] Exosomal miR-1228 From Cancer-Associated Fibroblasts Promotes Cell Migration and Invasion of Osteosarcoma by Directly Targeting SCAI.Oncol Res. 2019 Sep 23;27(9):979-986. doi: 10.3727/096504018X15336368805108. Epub 2018 Aug 8.
• [959] Differential regulation of syndecan expression by osteosarcoma cell lines in response to cytokines but not osteotropic hormones.Bone. 1999 Jun;24(6):571-8. doi: 10.1016/s8756-3282(99)00088-5.
• [960] A 4.6 kb genomic duplication on 20p12.2-12.3 is associated with brachydactyly type A2 in a Chinese family.J Med Genet. 2011 May;48(5):312-6. doi: 10.1136/jmg.2010.084814. Epub 2011 Feb 26.
• [961] SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.Oncogene. 2020 Jan;39(5):1049-1062. doi: 10.1038/s41388-019-1041-x. Epub 2019 Oct 3.
• [962] The human homolog of yeast SEP1 is a novel candidate tumor suppressor gene in osteogenic sarcoma.Gene. 2002 Oct 2;298(2):121-7. doi: 10.1016/s0378-1119(02)00929-0.
• [963] Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.Proc Natl Acad Sci U S A. 2018 Nov 20;115(47):E11128-E11137. doi: 10.1073/pnas.1814044115. Epub 2018 Nov 1.
• [964] Histologic Response and Toxicity following Interval-Compressed Four-Drug Therapy Given Preoperatively in Children and Young Adults with Osteosarcoma: A Retrospective Study.Oncology. 2020;98(2):81-90. doi: 10.1159/000502548. Epub 2019 Sep 11.
• [965] The TGF-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.J Exp Clin Cancer Res. 2019 May 28;38(1):226. doi: 10.1186/s13046-019-1195-y.
• [966] SHOX triggers the lysosomal pathway of apoptosis via oxidative stress.Hum Mol Genet. 2014 Mar 15;23(6):1619-30. doi: 10.1093/hmg/ddt552. Epub 2013 Nov 1.
• [967] Sirtuin 7 plays an oncogenic role in human osteosarcoma via downregulating CDC4 expression.Am J Cancer Res. 2017 Sep 1;7(9):1788-1803. eCollection 2017.
• [968] miR?3b?p promotes the apoptosis and inhibits the proliferation and invasion of osteosarcoma cells by targeting SIX1.Mol Med Rep. 2018 Dec;18(6):5683-5692. doi: 10.3892/mmr.2018.9611. Epub 2018 Oct 30.
• [969] Knocking down miR-384 promotes growth and metastasis of osteosarcoma MG63 cells by targeting SLBP.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1458-1465. doi: 10.1080/21691401.2019.1601099.
• [970] The Forkhead Transcription Factor FOXP2 Is Required for Regulation of p21WAF1/CIP1 in 143B Osteosarcoma Cell Growth Arrest.PLoS One. 2015 Jun 2;10(6):e0128513. doi: 10.1371/journal.pone.0128513. eCollection 2015.
• [971] Glaucocalyxin A reverses EMT and TGF-1-induced EMT by inhibiting TGF-1/Smad2/3 signaling pathway in osteosarcoma.Chem Biol Interact. 2019 Jul 1;307:158-166. doi: 10.1016/j.cbi.2019.05.005. Epub 2019 May 4.
• [972] Sex-determining region Y-box protein 3 induces epithelial-mesenchymal transition in osteosarcoma cells via transcriptional activation of Snail1.J Exp Clin Cancer Res. 2017 Mar 23;36(1):46. doi: 10.1186/s13046-017-0515-3.
• [973] MicroRNA-124 acts as a tumor-suppressive miRNA by inhibiting the expression of Snail2 in osteosarcoma.Oncol Lett. 2018 Apr;15(4):4979-4987. doi: 10.3892/ol.2018.7994. Epub 2018 Feb 8.
• [974] SND1 promotes the proliferation of osteosarcoma cells by upregulating COX?/PGE2 expression via activation of NFB.Oncol Rep. 2019 Jan;41(1):579-589. doi: 10.3892/or.2018.6822. Epub 2018 Oct 24.
• [975] Roles of low-density lipoprotein receptor-related protein 1 in tumors.Chin J Cancer. 2016 Jan 6;35:6. doi: 10.1186/s40880-015-0064-0.
• [976] Interleukin-6 upregulates SOX18 expression in osteosarcoma.Onco Targets Ther. 2017 Nov 8;10:5329-5336. doi: 10.2147/OTT.S149905. eCollection 2017.
• [977] Downregulation of SOX3 leads to the inhibition of the proliferation, migration and invasion of osteosarcoma cells.Int J Oncol. 2018 Apr;52(4):1277-1284. doi: 10.3892/ijo.2018.4278. Epub 2018 Feb 20.
• [978] Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7. Clin Exp Med. 2017 Feb;17(1):51-58.
• [979] miR-1225-5p Functions as a Tumor Suppressor in Osteosarcoma by Targeting Sox9.DNA Cell Biol. 2020 Jan;39(1):78-91. doi: 10.1089/dna.2019.5105. Epub 2019 Nov 25.
• [980] The metastatic behavior of osteosarcoma by gene expression and cytogenetic analyses.Hum Pathol. 2013 Oct;44(10):2188-98. doi: 10.1016/j.humpath.2013.04.013. Epub 2013 Jul 8.
• [981] Characterization of 11beta-hydroxysteroid dehydrogenase activity and corticosteroid receptor expression in human osteosarcoma cell lines.J Endocrinol. 1999 Jun;161(3):455-64. doi: 10.1677/joe.0.1610455.
• [982] A novel multifunctional carbon aerogel-coated platform for osteosarcoma therapy and enhanced bone regeneration.J Mater Chem B. 2020 Jan 22;8(3):368-379. doi: 10.1039/c9tb02383f.
• [983] SPOP suppresses osteosarcoma invasion via PI3K/AKT/NF-B signaling pathway.Eur Rev Med Pharmacol Sci. 2018 Feb;22(3):609-615. doi: 10.26355/eurrev_201802_14275.
• [984] MicroRNA-330-5p promotes the development of osteosarcoma by regulating SPRY2.Eur Rev Med Pharmacol Sci. 2019 Oct;23(20):8761-8770. doi: 10.26355/eurrev_201910_19270.
• [985] miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.J Cell Biochem. 2019 Apr;120(4):5495-5504. doi: 10.1002/jcb.27832. Epub 2018 Oct 9.
• [986] MicroRNA-1908-5p contributes to the oncogenic function of the splicing factor SRSF3.Oncotarget. 2017 Jan 31;8(5):8342-8355. doi: 10.18632/oncotarget.14184.
• [987] Biological importance of a polymorphic CA sequence within intron 1 of the epidermal growth factor receptor gene (EGFR) in high grade central osteosarcomas.Genes Chromosomes Cancer. 2008 Aug;47(8):657-64. doi: 10.1002/gcc.20571.
• [988] Serine/Threonine Kinase 35, a Target Gene of STAT3, Regulates the Proliferation and Apoptosis of Osteosarcoma Cells.Cell Physiol Biochem. 2018;45(2):808-818. doi: 10.1159/000487172. Epub 2018 Jan 31.
• [989] Overexpression of SENP1 reduces the stemness capacity of osteosarcoma stem cells and increases their sensitivity to HSVtk/GCV.Int J Oncol. 2018 Nov;53(5):2010-2020. doi: 10.3892/ijo.2018.4537. Epub 2018 Aug 23.
• [990] Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma.Oncol Rep. 2019 Jan;41(1):325-332. doi: 10.3892/or.2018.6843. Epub 2018 Nov 1.
• [991] Silencing of synaptotagmin 7 regulates osteosarcoma cell proliferation, apoptosis, and migration.Histol Histopathol. 2020 Mar;35(3):303-312. doi: 10.14670/HH-18-174. Epub 2019 Oct 21.
• [992] A novel use of TAT-EGFP to validate techniques to alter osteosarcoma cell surface glycosaminoglycan expression.J Mol Histol. 2007 Oct;38(5):435-47. doi: 10.1007/s10735-007-9136-z. Epub 2007 Sep 21.
• [993] Involvement of ETS1 in thioredoxin-binding protein 2 transcription induced by a synthetic retinoid CD437 in human osteosarcoma cells.Biochem Biophys Res Commun. 2010 Jan 1;391(1):621-6. doi: 10.1016/j.bbrc.2009.11.109. Epub 2009 Nov 20.
• [994] Allelic imbalance at intragenic markers of Tbx18 is a hallmark of murine osteosarcoma.Carcinogenesis. 2003 Mar;24(3):371-6. doi: 10.1093/carcin/24.3.371.
• [995] Tbx2 represses expression of Connexin43 in osteoblastic-like cells.Calcif Tissue Int. 2004 Jun;74(6):561-73. doi: 10.1007/s00223-003-0106-5.
• [996] Role of microRNA-92a in metastasis of osteosarcoma cells in vivo and in vitro by inhibiting expression of TCF21 with the transmission of bone marrow derived mesenchymal stem cells.Cancer Cell Int. 2019 Feb 12;19:31. doi: 10.1186/s12935-019-0741-1. eCollection 2019.
• [997] Hydroxyurea promotes TET1 expression and induces apoptosis in osteosarcoma cells.Biosci Rep. 2019 May 14;39(5):BSR20190456. doi: 10.1042/BSR20190456. Print 2019 May 31.
• [998] C-terminal fragment of transforming growth factor beta-induced protein (TGFBIp) is required for apoptosis in human osteosarcoma cells.Matrix Biol. 2009 Jul;28(6):347-53. doi: 10.1016/j.matbio.2009.05.004. Epub 2009 Jun 6.
• [999] Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.BMC Cancer. 2006 Oct 5;6:237. doi: 10.1186/1471-2407-6-237.
• [1000] miR-222-3p promotes osteosarcoma cell migration and invasion through targeting TIMP3.Onco Targets Ther. 2018 Dec 3;11:8643-8653. doi: 10.2147/OTT.S175745. eCollection 2018.
• [1001] MiRNA-15a inhibits proliferation, migration and invasion by targeting TNFAIP1 in human osteosarcoma cells.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6442-9. eCollection 2015.
• [1002] TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration.Clin Transl Oncol. 2019 Mar;21(3):334-341. doi: 10.1007/s12094-018-1927-z. Epub 2018 Jul 30.
• [1003] Amplification of 17p11.2 approximately p12, including PMP22, TOP3A, and MAPK7, in high-grade osteosarcoma.Cancer Genet Cytogenet. 2002 Dec;139(2):91-6. doi: 10.1016/s0165-4608(02)00627-1.
• [1004] TNF-/miR-155 axis induces the transformation of osteosarcoma cancer stem cells independent of TP53INP1.Gene. 2020 Feb 5;726:144224. doi: 10.1016/j.gene.2019.144224. Epub 2019 Oct 26.
• [1005] The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4892-6. doi: 10.1073/pnas.88.11.4892.
• [1006] Knockdown of TRAF4 expression suppresses osteosarcoma cell growth in vitro and in vivo.Int J Mol Med. 2014 Dec;34(6):1655-60. doi: 10.3892/ijmm.2014.1948. Epub 2014 Sep 29.
• [1007] Bispecific antibody suppresses osteosarcoma aggressiveness through regulation of NF-B signaling pathway.Tumour Biol. 2017 Jun;39(6):1010428317705572. doi: 10.1177/1010428317705572.
• [1008] Target therapy of TRIM-14 inhibits osteosarcoma aggressiveness through the nuclear factor-B signaling pathway.Exp Ther Med. 2018 Mar;15(3):2365-2373. doi: 10.3892/etm.2017.5679. Epub 2017 Dec 27.
• [1009] miR-451a Inhibits the Growth and Invasion of Osteosarcoma via Targeting TRIM66.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819870209. doi: 10.1177/1533033819870209.
• [1010] Trps1 is associated with the multidrug resistance of osteosarcoma by regulating MDR1 gene expression.FEBS Lett. 2014 Mar 3;588(5):801-10. doi: 10.1016/j.febslet.2014.01.041. Epub 2014 Jan 31.
• [1011] AMPH-1 As A Critical Tumor Suppressor That Inhibits Osteosarcoma Progression.Cancer Manag Res. 2019 Nov 25;11:9913-9919. doi: 10.2147/CMAR.S220544. eCollection 2019.
• [1012] Expression and significance of Annexin A3 in the osteosarcoma cell lines HOS and U2OS.Mol Med Rep. 2019 Sep;20(3):2583-2590. doi: 10.3892/mmr.2019.10513. Epub 2019 Jul 23.
• [1013] Src and ROCK Kinases Differentially Regulate Mineralization of Human Osteosarcoma Saos-2 Cells.Int J Mol Sci. 2019 Jun 12;20(12):2872. doi: 10.3390/ijms20122872.
• [1014] SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.Biochem Biophys Res Commun. 2019 Oct 8;518(1):127-133. doi: 10.1016/j.bbrc.2019.08.019. Epub 2019 Aug 16.
• [1015] BTF3 Silencing Inhibits the Proliferation of Osteosarcoma Cells.J Cancer. 2019 Apr 21;10(8):1855-1861. doi: 10.7150/jca.28476. eCollection 2019.
• [1016] CBX2 is a functional target of miRNA let-7a and acts as a tumor promoter in osteosarcoma.Cancer Med. 2019 Jul;8(8):3981-3991. doi: 10.1002/cam4.2320. Epub 2019 May 31.
• [1017] Clear cell sarcomas of the kidney are characterised by BCOR gene abnormalities, including exon 15 internal tandem duplications and BCOR-CCNB3 gene fusion.Histopathology. 2018 Jan;72(2):320-329. doi: 10.1111/his.13366. Epub 2017 Oct 30.
• [1018] The tetraspanin CD81 mediates the growth and metastases of human osteosarcoma.Cell Oncol (Dordr). 2019 Dec;42(6):861-871. doi: 10.1007/s13402-019-00472-w. Epub 2019 Sep 7.
• [1019] miR-671-5p Inhibits Tumor Proliferation by Blocking Cell Cycle in Osteosarcoma.DNA Cell Biol. 2019 Sep;38(9):996-1004. doi: 10.1089/dna.2019.4870. Epub 2019 Aug 8.
• [1020] Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro.Biomed Pharmacother. 2019 Jul;115:108949. doi: 10.1016/j.biopha.2019.108949. Epub 2019 May 14.
• [1021] Overexpression of carboxypeptidase X M14 family member 2 predicts an unfavorable prognosis and promotes proliferation and migration of osteosarcoma.Diagn Pathol. 2019 Oct 24;14(1):118. doi: 10.1186/s13000-019-0887-0.
• [1022] C-terminal of E1A binding protein 2 promotes the malignancy of osteosarcoma cells via JAK1/Stat3 signaling.J Cell Commun Signal. 2020 Mar;14(1):67-76. doi: 10.1007/s12079-019-00523-9. Epub 2019 Jun 19.
• [1023] Analysis of telomerase activity and telomere length in bone and soft tissue tumors.Oncol Rep. 2004 Jun;11(6):1307-11.
• [1024] Adenoviral-mediated gene transfer of ectodysplasin-A2 results in induction of apoptosis and cell-cycle arrest in osteosarcoma cell lines.Cancer Gene Ther. 2007 Nov;14(11):927-33. doi: 10.1038/sj.cgt.7701078. Epub 2007 Aug 10.
• [1025] FAM83H is involved in stabilization of -catenin and progression of osteosarcomas.J Exp Clin Cancer Res. 2019 Jun 18;38(1):267. doi: 10.1186/s13046-019-1274-0.
• [1026] miR-193b Increases the Chemosensitivity of Osteosarcoma Cells by Promoting FEN1-Mediated Autophagy.Onco Targets Ther. 2019 Nov 22;12:10089-10098. doi: 10.2147/OTT.S219977. eCollection 2019.
• [1027] The study of mechanism of miR-34c-5p targeting FLOT2 to regulate proliferation, migration and invasion of osteosarcoma cells.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3559-3568. doi: 10.1080/21691401.2019.1640714.
• [1028] SP1-induced upregulation of long non-coding RNA HCP5 promotes the development of osteosarcoma.Pathol Res Pract. 2019 Mar;215(3):439-445. doi: 10.1016/j.prp.2018.12.006. Epub 2018 Dec 10.
• [1029] HELQ reverses the malignant phenotype of osteosarcoma cells via CHK1-RAD51 signaling pathway.Oncol Rep. 2017 Feb;37(2):1107-1113. doi: 10.3892/or.2016.5329. Epub 2016 Dec 20.
• [1030] AUF1 positively controls angiogenesis through mRNA stabilization-dependent up-regulation of HIF-1 and VEGF-A in human osteosarcoma.Oncotarget. 2019 Aug 6;10(47):4868-4879. doi: 10.18632/oncotarget.27115. eCollection 2019 Aug 6.
• [1031] Circular RNA 0001785 regulates the pathogenesis of osteosarcoma as a ceRNA by sponging miR-1200 to upregulate HOXB2.Cell Cycle. 2019 Jun;18(11):1281-1291. doi: 10.1080/15384101.2019.1618127. Epub 2019 May 22.
• [1032] The p33ING1b tumor suppressor cooperates with p53 to induce apoptosis in response to etoposide in human osteosarcoma cells.Life Sci. 2006 Feb 23;78(13):1469-77. doi: 10.1016/j.lfs.2005.07.044. Epub 2005 Dec 1.
• [1033] LncRNA TTN-AS1 regulates osteosarcoma cell apoptosis and drug resistance via the miR-134-5p/MBTD1 axis.Aging (Albany NY). 2019 Oct 10;11(19):8374-8385. doi: 10.18632/aging.102325. Epub 2019 Oct 10.
• [1034] The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.Biochem Biophys Res Commun. 2019 Aug 27;516(3):719-725. doi: 10.1016/j.bbrc.2019.06.128. Epub 2019 Jun 26.
• [1035] MicroRNA-765 targets MTUS1 to promote the progression of osteosarcoma via mediating ERK/EMT pathway.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4618-4628. doi: 10.26355/eurrev_201906_18040.
• [1036] A Genome-Wide Scan Identifies Variants in NFIB Associated with Metastasis in Patients with Osteosarcoma.Cancer Discov. 2015 Sep;5(9):920-31. doi: 10.1158/2159-8290.CD-15-0125. Epub 2015 Jun 17.
• [1037] Long Noncoding RNA FEZF1-AS1 Promotes Osteosarcoma Progression by Regulating the miR-4443/NUPR1 Axis.Oncol Res. 2018 Oct 17;26(9):1335-1343. doi: 10.3727/096504018X15188367859402. Epub 2018 Feb 22.
• [1038] Ras-ERK1/2 Signaling Promotes The Development Of Osteosarcoma By Regulating H2BK12ac Through CBP.Cancer Manag Res. 2019 Oct 24;11:9153-9163. doi: 10.2147/CMAR.S219535. eCollection 2019.
• [1039] Circ_ORC2 enhances the regulatory effect of miR-19a on its target gene PTEN to affect osteosarcoma cell growth.Biochem Biophys Res Commun. 2019 Jul 5;514(4):1172-1178. doi: 10.1016/j.bbrc.2019.04.188. Epub 2019 May 15.
• [1040] High Expression of PQBP1 and Low Expression of PCK2 are Associated with Metastasis and Recurrence of Osteosarcoma and Unfavorable Survival Outcomes of the Patients.J Cancer. 2019 May 12;10(9):2091-2101. doi: 10.7150/jca.28480. eCollection 2019.
• [1041] Long non-coding RNA TUG1 regulates the progression and metastasis of osteosarcoma cells via miR-140-5p/PFN2 axis.Eur Rev Med Pharmacol Sci. 2019 Nov;23(22):9781-9792. doi: 10.26355/eurrev_201911_19541.
• [1042] Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs-pRb2/p130 complexes.Oncogene. 2003 Jun 5;22(23):3518-29. doi: 10.1038/sj.onc.1206487.
• [1043] Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis.Gene. 2019 Aug 20;710:246-257. doi: 10.1016/j.gene.2019.06.005. Epub 2019 Jun 6.
• [1044] A Novel lncRNA MYOSLID/miR-1286/RAB13 Axis Plays a Critical Role in Osteosarcoma Progression.Cancer Manag Res. 2019 Dec 10;11:10345-10351. doi: 10.2147/CMAR.S231376. eCollection 2019.
• [1045] RRAS2 knockdown suppresses osteosarcoma progression by inactivating the MEK/ERK signaling pathway.Anticancer Drugs. 2019 Oct;30(9):933-939. doi: 10.1097/CAD.0000000000000799.
• [1046] SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance.Mol Cell. 2019 Oct 3;76(1):27-43.e11. doi: 10.1016/j.molcel.2019.07.010. Epub 2019 Aug 22.
• [1047] LncRNA-SRA1 Suppresses Osteosarcoma Cell Proliferation While Promoting Cell Apoptosis.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819841438. doi: 10.1177/1533033819841438.
• [1048] STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells.Ann Transl Med. 2019 Apr;7(7):127. doi: 10.21037/atm.2019.02.23.
• [1049] miR-1301/TRIAP1 Axis Participates in Epirubicin-Mediated Anti-Proliferation and Pro-Apoptosis in Osteosarcoma.Yonsei Med J. 2019 Sep;60(9):832-841. doi: 10.3349/ymj.2019.60.9.832.